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Summary 
In recent years, immunotherapy approaches for the treatment of cancer have been 
intensively investigated and substantial benefit observed in clinical trials has led to the 
marketing authorization of various immunotherapeutic drugs including monoclonal 
antibodies and cytokine-based therapies. Even though, several studies demonstrated 
effectivity of cancer immunotherapy, improvement is still required to address issues 
such as efficacy and safety. Development of suitable delivery systems might contribute 
to the improvement of immunotherapeutic approaches for cancer, whereby one strategy 
involves the application of viral vectors. For this purpose, viruses can be used in two 
ways: Either as replication-deficient viral vectors that solely deliver the therapeutic gene 
of interest or as replication-competent oncolytic viruses that directly kill tumor cells and 
are additionally engineered to encode immunomodulatory transgenes. The latter 
strategy was addressed in the first part of the thesis which aimed at combining the 
oncolytic activity of semireplication-competent vesicular stomatitis virus (srVSV) with 
the viral-mediated expression of immunotherapeutic transgenes in order to induce a 
long-lasting antitumor immune response. The second part of the thesis intended to 
generate and characterize replication-deficient, receptor-targeted adeno-associated 
viral (AAV) vectors for the tumor-specific delivery of immune checkpoint inhibitors.  
The srVSV system is based on two trans-complementing, propagation-deficient VSV 
vectors, VSVΔG and VSVΔL. Both vectors were armed with the immunostimulatory 
transgenes granulocyte-macrophage colony-stimulating factor (GM-CSF), FMS-like 
tyrosine kinase 3 ligand (Flt3L), B7 and the tumor-associated antigens Her2/neu as well 
as CTLA4-Her2/neu to enhance srVSV-mediated antitumor immune responses. After 
insertion of the immunotherapeutic transgenes into the VSVΔG as well as VSVΔL vector 
genomes, all recombinant vectors were successfully generated de novo and analyses 
confirmed srVSV-mediated transgene expression in vitro. As VSV is exquisitely sensitive 
to type I interferon (IFN)-induced antiviral responses, different murine tumor cell lines 
were analyzed for their IFN sensitivity to identify a suitable VSV-permissive syngeneic 
tumor mouse model for the preclinical studies. The murine colon cancer cell line MC38 
was identified as a potentially appropriate tumor model since MC38 cells were 
productively infectable even when pretreated with high doses of IFNα. First preclinical 
data showed the capability of transgene-armed as well as control srVSV to induce an 
antitumor immune response in the MC38 tumor model eventually leading to cure in 
some animals. However, the in vivo data showed only a marginally improved therapeutic 
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efficacy of transgene-armed versus control srVSV. Accordingly, more preclinical studies 
are required to clarify whether arming of srVSV with immunomodulatory payload 
indeed improves srVSV therapy efficacy.  
Monoclonal antibodies directed against immune checkpoints, such as programmed cell 
death protein-1 (PD-1) and its ligand PD-L1, have shown promising results for the 
treatment of certain cancer types eventually leading to the marketing authorization of 
several products. However, drawbacks of this therapy include lack of efficacy in some 
patients and treatment-related toxicity. Probably the systemic administration of these 
antibodies does not only promote the activation of immune responses in the tumor 
microenvironment but also in healthy tissue. Therefore, this project aimed at the specific 
delivery of immune checkpoint inhibitors precisely to sites of tumor growth. To this end, 
Her2/neu-targeted AAV (Her2-AAV) vectors were equipped with the coding sequence of 
PD-1- or PD-L1-specific inhibitors. In vitro analyses showed that the inhibitors were 
readily detectable in the supernatant of AAV-transduced tumor cells. Furthermore, AAV-
encoded αPD-1 as well as αPD-L1 specifically bound their target antigens. In vivo 
imaging analyses revealed that Her2-AAV successfully targeted tumor cells upon 
systemic injection into immunocompetent BALB/c mice bearing subcutaneously 
growing Her2/neu-positive RENCA tumors, while non-targeted AAV2 transduced mainly 
liver. Finally, in vivo delivery of AAV-encoded αPD-1 was assessed in the aforementioned 
mouse model. Mice injected with AAV2 showed the highest αPD-1 levels in the liver. In 
contrast, Her2-AAV successfully redirected the immune checkpoint inhibitor from liver 
to Her2/neu-positive tumor tissue upon systemic injection. In conclusion, this study is a 
proof of concept that tumor-targeted AAV vectors can be used for the delivery of 
immune checkpoint inhibitors to the site of tumor growth. It will pave the way for 
further investigations addressing toxicity and efficacy of vector-mediated compared to 
systemic immune checkpoint modulation.  
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Zusammenfassung 
Immuntherapeutische Ansätze stehen derzeit im Fokus der Forschung zur Behandlung 
von Krebserkrankungen und vielversprechende klinische Studien führten zur 
Markteinführung verschiedener Immuntherapeutika, einschließlich monoklonaler 
Antikörper und Zytokin-basierter Therapien. Um die Wirksamkeit und Sicherheit 
immuntherapeutischer Therapien zu verbessern, könnten virale Gentransfersysteme 
geeignete Instrumente darstellen. In diesem Zusammenhang ist der Einsatz von Viren 
auf zwei Arten denkbar: Entweder als replikationsdefiziente virale Vektoren, die 
ausschließlich für das therapeutische Gen kodieren oder als replikationskompetente 
onkolytische Viren, die nicht nur mit zusätzlichen immuntherapeutischen Genen 
ausgestattet sind, sondern Tumorzellen auch direkt lysieren können. Die letztgenannte 
Strategie wurde im ersten Teil dieser Arbeit verfolgt. Ziel war es die onkolytische 
Aktivität von semi-replikationskompetentem Virus der vesikulären Stomatitis (srVSV) 
mit der Expression von viral-kodierten immuntherapeutischen Transgenen zu 
kombinieren, um eine lang anhaltende antitumorale Immunantwort zu induzieren. Im 
zweiten Teil dieser Arbeit steht die Entwicklung von replikations-defizienten, 
zielgerichteten Adeno-assoziierten viralen (AAV) Vektoren für den tumorspezifischen 
Transfer von Immuncheckpoint-Inhibitoren im Fokus.  
Das srVSV-System basiert auf zwei sich in trans komplementierenden, propagations-
defizienten Vektoren, VSVΔG und VSVΔL. Zur Steigerung der antitumoralen Wirksamkeit 
wurden beide Vektoren mit den immuntherapeutischen Transgenen granulocyte-
macrophage colony-stimulating factor (GM-CSF), FMS-like tyrosine kinase 3 ligand 
(Flt3L), B7 und dem tumorassoziierten Antigen Her2/neu sowie CTLA4-Her2/neu 
ausgestattet. Nach erfolgter Insertion der Transgene in das Genom der VSV 
Deletionsmutanten wurden die rekombinanten Vektoren erfolgreich hergestellt und die 
Expression der von srVSV kodierten Transgene wurde in vitro nachgewiesen. Da VSV 
sensitiv gegenüber Typ I Interferon (IFN)-induzierten antiviralen Immunantworten ist, 
wurde zur Identifikation eines geeigneten Tumormodells für die präklinischen Studien, 
die Sensitivität verschiedener muriner Tumorzelllinien gegenüber IFNα untersucht. Die 
Darmkrebszelllinie MC38 wurde als potenziell geeignetes Tumormodell identifiziert, da 
sie auch nach Vorbehandlung mit hohen IFNα Konzentrationen noch infizierbar war. 
Erste präklinische Untersuchungen zeigten, dass sowohl srVSV, welches mit 
immunstimulierenden Transgenen armiert war, als auch nicht-armiertes srVSV eine 
antitumorale Immunantwort im MC38 Tumormodell induzieren konnten. Hierbei 
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zeigten die mit immunstimulatorischen Transgen-armierten srVSV lediglich eine 
geringfügige Steigerung der therapeutischen Wirksamkeit im Vergleich zu der nicht-
armierten srVSV-Kontrollgruppe. Daher sind weitere präklinische Studien notwendig, 
um endgültig zu klären, ob der Einbau der gewählten immuntherapeutischen Transgene 
die antitumorale Wirksamkeit von srVSV steigern kann.   
Monoklonale Antikörper, welche gegen Immuncheckpoints wie programmed cell death 
protein-1 (PD-1) oder seinen Liganden PD-L1 gerichtet sind, haben vielversprechende 
Behandlungsergebnisse bei fortgeschrittenen Krebserkrankungen erzielt, was zur 
Markteinführung verschiedener sogenannter Immuncheckpoint-Inhibitoren führte. 
Jedoch spricht nicht jeder Patient auf die Behandlung an und zudem können als 
Nebenwirkung schwerwiegende Autoimmunreaktionen auftreten. Vermutlich 
begünstigt die systemische Applikation der Antikörper nicht nur eine Stimulation des 
Immunsystems im Tumorgewebe, sondern auch in gesunden Organen. Daher wurden in 
dieser Arbeit zielgerichtete AAV-Vektoren für den tumorspezifischen Transfer von 
Immuncheckpoint-Inhibitoren entwickelt. Hierfür wurden AAV-Vektoren verwendet, die 
über die Bindung an den Rezeptor Her2/neu, welcher auf vielen Tumorentitäten 
hochreguliert wird, den Gentransfer vermitteln (Her2-AAV). Diese Vektoren wurden mit 
der kodierenden Sequenz für PD-1- oder PD-L1-spezifische Inhibitoren ausgestattet. In 
vitro Untersuchungen bestätigten die AAV-vermittelte Expression der 
Immuncheckpoint-Inhibitoren sowie deren spezifischen Anbindung an ihr Zielantigen 
PD-1 oder PD-L1. In vivo Imaging Analysen zeigten, dass Her2-AAV nach systemischer 
Applikation in immunkompetenten BALB/c Mäusen mit subkutan wachsenden 
HER2/neu-positiven RENCA Tumoren einen präzisen Gentransfer in das Tumorgewebe 
vermittelte, wohingegen ungerichtete AAV2-Vektoren einen Gentransfer in die Leber 
vermittelten. Zuletzt wurde die AAV-vermittelte Expression von αPD-1 in dem zuvor 
genannten Tumormodell untersucht. Die systemische Applikation von Her2-AAV führte 
zu erhöhten αPD-1 Werten im Tumor verglichen zu den Werten in der Leber. Im 
Gegensatz dazu wiesen die mit AAV2 behandelten Mäuse höhere αPD-1 Werte in der 
Leber auf. Zusammenfassend zeigt die vorliegende Arbeit, dass sich Her2-AAV für den 
tumor-gerichteten Transfer von Immuncheckpoint-Inhibitoren eignet. Die in dieser 
Arbeit entwickelten AAV-Vektoren liefern die Grundlage, auf der weiterführende 
Studien durchgeführt werden können, um letztendlich die Sicherheit und Wirksamkeit 
von Vektor-vermittelter mit systemischer Immuncheckpoint-Blockade vergleichen zu 
können.  
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1 Introduction  
1.1 Cancer immunotherapy 
Immunotherapy represents a promising treatment modality for different cancer types 
relying on harnessing the immune system to combat the malignancy. Already in 1909 
Paul Ehrlich hypothesized that the immune system is able to suppress tumor 
development (Ichim, 2005; Ehrlich, 1909). Later on the theory of immunosurveillance 
was postulated, a concept describing the ability of the immune system to recognize and 
destroy the vast majority of tumor cells during initial transformation (Zitvogel et al, 
2006; Thomas, 1982).  
The mechanisms required to induce a cellular antitumor immune response are 
comparable to host immune responses to infections. The immune system potentially 
recognizes tumor cells due to their expression of ‘neo-antigens’ arising through genetic 
alterations and epigenetic changes (Melero et al, 2014; Gubin et al, 2015; Alexandrov et 
al, 2013). These tumor antigens, being released by dying tumor cells for instance, are 
captured by antigen-presenting cells (APCs). Here, dendritic cells (DCs) are the key APCs 
that are responsible to stimulate antitumor immune responses (Mellman et al, 2011; 
Melief, 2008). Upon the encounter of the antigen in combination with a suitable 
maturation signal, DCs migrate to secondary lymphoid organs where they present the 
processed antigens to T cells in order to elicit a protective T cell response (Mellman et al, 
2011). In particular, cytotoxic CD8+ T cells that can directly lyse cancer cells and produce 
inflammatory cytokines, such as interferon γ (IFNγ), are assumed to be crucial for 
antitumor immunity. However, also helper CD4+ T cells are claimed to play an important 
role during antitumor immune responses as they stimulate the function of CD8+ T cells 
and also produce inflammatory cytokines (Pardoll, 2002; Toes et al, 1999). Finally, 
cancer-specific T cells migrate to the tumor site to directly mediate tumor cell killing by 
apoptosis (Mellman et al, 2011).  
However, cancer cells can acquire different strategies during carcinogenesis to evade 
immune recognition resulting from the selective pressure by the immune system. Cancer 
cells are capable to escape immunosurveillance by outgrowth of malignant cells with 
reduced antigenicity and immunogenicity (Beatty & Gladney, 2015). Loss of antigenicity 
of malignant cells can be induced by defects in antigen processing and presentation, for 
instance due to downregulation of major histocompatibility complex (MHC) molecules 
(So et al, 2005; Zitvogel et al, 2006). Upregulation of immunosuppressive molecules such 
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as programmed cell death ligand-1 (PD-L1) on the surface of tumor cells can further 
inhibit intratumoral T cell activity (Pardoll, 2012). Secretion of immunosuppressive 
cytokines such as transforming growth factor β (TGF-β) additionally reduces the 
immunogenicity of the malignancy by inhibiting cytotoxic T cells and DCs while 
stimulating differentiation of immunosuppressive regulatory T cells (Treg cells) (Thomas 
& Massagué, 2005; Melero et al, 2014; Beatty & Gladney, 2015; Sisirak et al, 2013; Gray 
et al, 1994; Chen et al, 2003). Another described mechanism for tumor cell immune 
escape is the recruitment of suppressive immune cells such as Treg cells and myeloid-
derived suppressor cells which orchestrate a tumor microenvironment provoking an 
inhibition of the antitumor immune response (Curiel et al, 2004; Viguier et al, 2004; 
Melero et al, 2014; Nagaraj & Gabrilovich, 2008; Srivastava et al, 2012).  
Different strategies have been developed to break cancer immune tolerance including 
non-specific stimulation of the immune system by cytokines, cancer vaccines, adoptive 
cell transfer therapy, monoclonal antibodies (mAbs) modulating immune checkpoint 
pathways and oncolytic viruses.  
1.1.1 Cytokines 
Cancer immunotherapeutic approaches started with cytokine therapies using IFNα and 
interleukin 2 (IL-2) being approved by the Food and Drug Administration (FDA) for 
tumor therapy in the 1990s (Jiang & Zhou, 2015; Lee & Margolin, 2011). Multiple 
mechanisms eliciting antitumor effects are described for IFNα including 
antiproliferative as well as antiangiogenic activities and the induction of MHC class I 
expression on tumor cells which enhances recognition by the immune system 
(Ferrantini et al, 2007). The mechanism underlying the antitumor effects of IL-2 is not 
fully understood but it is supposed to be based on its ability to induce activation and 
proliferation of T cells and natural killer (NK) cells among others (Skrombolas & 
Frelinger, 2014). However, even though cytokine therapy can induce durable complete 
tumor remissions in few cases, treatment is often associated with toxicities (Jiang & 
Zhou, 2015).  
1.1.2 Cancer vaccines 
Another approach in cancer immunotherapy are therapeutic cancer vaccines specifically 
stimulating the natural immune response against cancer to treat an existing malignancy 
and to induce a long-lasting antitumor immunity (Jiang & Zhou, 2015; Baxevanis et al, 
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2009). Most approaches rely on using tumor antigens, the so-called tumor-associated 
antigens (TAAs), which can be divided into shared and unique TAAs. Shared TAAs 
include cancer-testis antigens, differentiation antigens and antigens that are 
overexpressed on cancer cells. Unique TAAs arise through somatic point mutations 
induced by physical or chemical carcinogens (Tagliamonte et al, 2014). A commonly 
targeted shared TAA in cancer therapy is Her2/neu, a receptor tyrosine kinase which is 
overexpressed in various human malignancies such as breast, ovarian as well as gastric 
carcinomas and has been associated with poor prognosis (Slamon et al, 1989; Klapper et 
al, 2000; Roth et al, 2005). Tumor antigens for vaccination can be administered by viral 
vectors, peptides or recombinant proteins with an appropriate adjuvant, DNA or 
antigen-loaded DCs (Larocca & Schlom, 2011; van der Burg et al, 2006; Herrada et al, 
2012; Palucka & Banchereau, 2013). In 2010, sipuleucel-T, a DC-based cancer vaccine, 
was approved by the FDA for the treatment of advanced prostate cancer. Sipuleucel-T is 
a cellular product based on autologous peripheral blood mononuclear cells (PBMCs) that 
are incubated ex vivo with a fusion protein composed of the prostate-cancer antigen 
prostatic acid phosphatase (PAP) and the DC growth and differentiation factor 
granulocyte-macrophage colony-stimulating factor (GM-CSF). Matured antigen-loaded 
DCs are re-infused into the patient to elicit an antitumor immune response (Farkona et 
al, 2016). Clinical studies revealed a 4.1 month improvement in median survival of 
sipuleucel-T treated patients compared to the placebo group (Kantoff et al, 2010).  
1.1.3 Adoptive cell transfer 
Adoptive cell transfer (ACT) is another promising strategy in cancer immunotherapy 
utilizing antitumor properties of T cells to eliminate malignant cells. For autologous 
T cell therapy, tumor antigen-specific lymphocytes are isolated from the patient, 
selected, expanded ex vivo and re-infused into the patient (Farkona et al, 2016). ACT 
using autologous tumor infiltrating lymphocytes (TILs) showed promising clinical 
results. Treatment of lymphodepleted patients suffering from metastatic melanoma with 
autologous TILs in combination with IL-2 administration achieved a complete tumor 
regression in 22 % of the treated patients (Rosenberg et al, 2011). To further improve 
ACT, isolated peripheral blood T cells are used which are genetically engineered to 
express a T cell receptor (TCR) specific for a tumor antigen. This therapy is in principle 
applicable to patients whose tumor expresses the matching human leukocyte antigen 
(HLA) as well as the respective tumor antigen. Furthermore, the specificity of T cells can 
be engineered by chimeric antigen receptors (CARs). CARs are artificial receptors 
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composed of an extracellular domain enabling antigen recognition (usually a single-
chain variable fragment (scFv)) fused to an intracellular T cell activation domain (e.g. 
CD3ζ). CARs provide the advantage of an HLA-independent recognition of cell surface 
antigens leading to tumor cell destruction (Farkona et al, 2016; Rosenberg & Restifo, 
2015). Among the most advanced CARs in clinical trials are CD19-targeted CAR T cells 
for the treatment of B-cell malignancies (Oluwole & Davila, 2016). 
1.1.4 Immune checkpoint inhibitors 
One of the most promising approaches in cancer immunotherapy involves the blockade 
of immune checkpoints by mAbs. Among the most advanced immune checkpoint 
inhibitors are mAbs directed against the cytotoxic T-lymphocyte-associated antigen 
(CTLA-4), programmed cell death protein-1 (PD-1) and its ligand PD-L1. These immune 
checkpoints are crucial to maintain immunological homeostasis by regulating the 
activity of T cells but are also involved in tumor immune escape. The mechanisms of 
regulating T cell activation and inhibiting antitumor immune responses are different for 
CTLA-4 and PD-1/PD-L1 as described in the following section (Topalian et al, 2015).  
T cell activation is an antigen-dependent process that requires at least two signals to 
induce the differentiation and proliferation of naïve T cells into effector cells. Activation 
is initiated by the engagement of the TCR to antigenic peptides bound to MHC molecules 
on APCs (signal 1). For productive activation of T cells, additional co-stimulatory signals 
are needed. This T cell co-stimulation can be mediated by the binding of CD28 on the 
T cell surface to B7 proteins (e.g. B7-1 (CD80) and B7-2 (CD86)) on APCs (signal 2). 
However, this priming phase of T cell activation is modulated by the upregulation of 
CTLA-4 on activated T cells. CTLA-4 has a higher affinity for B7 proteins than CD28, 
thereby dampening T cell activity by outcompeting CD28 for binding to B7 molecules 
and consequently downregulates T cell responses (Chen, 2004; Sharma et al, 2011; 
Pardoll, 2012). Additionally, CTLA-4 is supposed to directly trigger inhibitory signals in 
T cells, to interfere with the ‘TCR Stop Signal’ required for stable conjugate formation 
between T cells and APCs and to induce the depletion of B7 proteins from the APCs by 
trans-endocytosis (Lee et al, 1998; Schneider et al, 2006; Qureshi et al, 2011). 
Furthermore, CTLA-4 is predominantly expressed on helper CD4+ T cells and plays a 
major role in enhancing the immunosuppressive function of Treg cells (Wing et al, 2008; 
Topalian et al, 2015).  
The level of T cell activation by co-stimulation with CD28 and co-inhibition with CTLA-4 
is regulated by the time point of surface expression and the strength of TCR signaling. 
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Naïve and resting T cells express high levels of CD28 but no CTLA-4 on the cell surface 
and thus co-stimulation dominates upon antigen recognition (Lindsten et al, 1993; 
Pardoll, 2012). However, surface expression of CTLA-4 is induced upon binding of the 
TCR to the MHC-presented antigen at levels depending on the strength of the TCR 
signaling and thus can result in an inhibition after antigen recognition (Egen & Allison, 
2002).  
T cell activity is additionally regulated in peripheral tissue by PD-1 that is expressed on 
antigen-experienced T cells. Expression of PD-L1 or PD-L2, the ligands of PD-1, is 
upregulated on tissue in response to inflammation. Binding of PD-1 to one of its ligands 
leads to the inhibition of T cell activity (Freeman et al, 2000; Latchman et al, 2001; 
Pardoll, 2012). Through this mechanism, PD-1 regulates the balance of T cell activity in 
the periphery at the time of an inflammatory response in order to limit autoimmunity 
(Pardoll, 2012).  
Recently, B7-1 was identified as a further interaction partner of PD-L1. B7-1 expressed 
on T cells binds PD-L1 with an affinity intermediate to that of B7-1 to CD28 and B7-1 to 
CTLA-4. This interaction also induces inhibitory signals in T cells (Butte et al, 2007). 
Furthermore, it was demonstrated that the PD-L1/B7-1 pathway is also required for the 
maintenance of peripheral T cell tolerance (Park et al, 2010).  
PD-1 and its ligand PD-L1 are expressed on a variety of different cell types. PD-1 is not 
only expressed on activated T cells but also on Treg cells, B cells, monocytes, NK cells and 
DCs. Its ligand PD-L1 is expressed on immune cells including activated T cells and DCs as 
well as on a wide range of non-hematopoietic tissue such as lung cells (Keir et al, 2008; 
Pardoll, 2012). However, PD-1 is also expressed on the majority of TILs, including Treg 
cells and CD8+ T cells, and PD-L1 is commonly upregulated on the cell surface of various 
solid tumor types (Ahmadzadeh et al, 2009; Thompson et al, 2007; Sfanos et al, 2009; 
Dong et al, 2002; Thompson et al, 2004; Ohigashi et al, 2005; Hino et al, 2010). Two 
different mechanisms are described for the upregulation of PD-1 ligands on tumor cells: 
intrinsic and adaptive immune resistance. The intrinsic immune resistance describes the 
upregulation due to constitutive oncogenic signaling (e.g. activation of AKT pathway). 
Adaptive immune resistance refers to the induction of PD-1 ligand expression on tumor 
cells in response to inflammatory signals. In particular, IFNγ, mainly produced by T cells 
attempting to elicit tumor-specific immune responses, is claimed to induce the 
upregulation of PD-1 ligands (Topalian et al, 2015).  
Accordingly, the PD-1/PD-L1 interaction is a major immune escape mechanism of 
cancer cells. Different tumor growth promoting mechanisms are described for the PD-
1/PD-L1 pathway. One described mechanism is the promotion of tumor cell survival by 
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delivering anti-apoptotic signals via PD-L1 into tumor cells (Azuma et al, 2008). 
Additionally, the PD-1/PD-L1 axis mediates tumor immune escape through the 
inhibition of signaling pathways in T cells required for differentiation, expansion and 
survival of T cells (Bardhan et al, 2016). Furthermore, permanent antigen exposure by 
cancer cells is supposed to mediate persistent expression of PD-1 on CD8+ TILs 
eventually inducing T cell exhaustion (Topalian et al, 2015; Ahmadzadeh et al, 2009). 
The findings that PD-L1 is upregulated on the vast majority of malignancies and PD-1 is 
expressed on TILs was the rationale to design antibodies to block the PD-1/PD-L1 
interaction in order to restore T cell activation and thereby prevent immune evasion of 
cancer cells. Blockade of the PD-1/PD-L1 axis is supposed to mainly provoke 
antitumoral effects within the tumor microenvironment since the ligands are 
overexpressed by tumor cells and TILs (Topalian et al, 2015). However, due to the 
expression of PD-L1 on APCs inhibition of the PD-1/PD-L1 interaction might also play a 
role in the secondary lymphoid tissue (Curiel et al, 2003). Antibody-mediated blockage 
of CTLA-4 is supposed to mediate antitumor immune responses by systemic T cell 
activation upon antigen encounter (Topalian et al, 2015). However, αCTLA-4 mAbs 
might also stimulate antitumor immune responses within the tumor microenvironment 
by directly depleting tumor-infiltrating Treg cells or by affecting their 
immunosuppressive functions (Peggs et al, 2009; Topalian et al, 2015; Simpson et al, 
2013). In conclusion, αCTLA-4, αPD-1 and αPD-L1 antibodies block different inhibitory 
interactions and thus induce the stimulation of antitumor immune responses by 
different ways (Figure 1).  
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Figure 1: Possible inhibitory interactions blocked by αCTLA-4, αPD-1 and αPD-L1 mAbs. αCTLA-4 mAbs block 
the binding of CTLA-4 to B7-1 and B7-2. αPD-1 mAbs block the interaction between PD-1 and PD-L1 as well as PD-L2. 
αPD-L1 mAbs inhibit the binding of PD-L1 to PD-1 and to B7-1. According to the information provided in (Topalian et 
al, 2015). 
Ipilimumab, an αCTLA-4 mAb, was one of the first immune checkpoint inhibitors that 
entered clinical trials and was approved in the US and EU in 2011 for the treatment of 
advanced melanoma (Topalian et al, 2015). A long-term follow up study for ipilimumab-
treated melanoma patients demonstrated a durable survival of about 20 % with 
observation periods lasting up to 10 years (Schadendorf et al, 2015). The success of 
αCTLA-4 mAbs paved the way for the clinical development of further immune 
checkpoint inhibitors including mAbs targeting PD-1 and PD-L1. In 2014, two PD-1 
specific mAbs, namely nivolumab and pembrolizumab, achieved marketing 
authorization by the FDA for therapy of advanced melanoma. Later on both PD-1 
blocking mAbs were also approved for the treatment of non-small cell lung cancer 
(NSCLC) and nivolumab additionally achieved marketing authorization for therapy of 
several cancer types including renal cell carcinoma (RCC) (Bardhan et al, 2016). 
Nivolumab and pembrolizumab demonstrated superior clinical benefit in melanoma 
patients compared to ipilimumab (Larkin et al, 2015; Robert et al, 2015b). Recently, also 
a PD-L1-specific mAb (avelumab) received marketing authorization in the US for the 
treatment of metastatic Merkel cell carcinoma (MCC) (Kim, 2017).  
While the clinical response in some patients with advanced cancer is impressive, there 
are also downsides including absence of response in a fraction of patients and toxicity 
induced by immune checkpoint modulation. Due to non-specific immunostimulation, 
these novel immunotherapeutics induce inflammation in tissues affecting multiple 
organs such as skin, gut, digestive tract, lung and liver. These so-called ‘immune-related 
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adverse events’ (irAE) include vitiligo, skin rash, colitis, pneumonitis as well as hepatitis 
and their severity can range from mild to fatal (Naidoo et al, 2016; Abdel-Wahab et al, 
2016). The irAEs are mainly managed with immunomodulatory medications such as 
steroids or immunosuppressive antibodies like tumor necrosis factor-alpha antagonists 
(infliximab) (Spain et al, 2016).  
1.1.5 Oncolytic immunotherapy 
Many of the aforementioned cancer immune escape mechanisms (chapter 1.1) result in 
a restricted ability of neoplastic cells to respond to viral infections compared to healthy 
cells (Lichty et al, 2014). In addition, malignant cells develop aberrant deregulated cell 
signaling pathways during carcinogenesis that also support productive viral infection. 
This includes the activation of the Ras signaling pathway and a deregulation of the type I 
IFN immune response (Kirn et al, 2001; Noser et al, 2007; Zhang et al, 2010). The 
parallels between the requirements for viral replication in mammalian cells and the 
mechanisms driving cancer cell growth have led to the development of oncolytic viruses 
(Lichty et al, 2014). Oncolytic viruses are a novel class of antitumor therapeutics that 
preferentially replicate and kill cancer cells while sparing normal tissue. They can be 
categorized into two groups: (i) viruses that have a natural preference to replicate in 
cancer cells (e.g. new castle disease virus, reovirus) and (ii) viruses that are engineered 
for cancer cell selectivity (e.g. herpes simplex virus, vaccinia virus) (Russell et al, 2012). 
Oncolytic viruses are especially promising anticancer agents as they promote antitumor 
responses through different mechanisms of action. First, oncolytic viruses cause tumor 
debulking due to viral infection and cell lysis, a process called oncolysis. Released viral 
particles infect neighboring tumor cells resulting in viral amplification and spread 
throughout the tumor tissue. However, this cycle is likely to be hampered by induced 
antiviral immune response mechanisms (Marchini et al, 2016). Second, some oncolytic 
viruses are described to trigger a tumor vasculature disruption and thereby elicit 
apoptosis or necrosis of uninfected tumor cells (Breitbach et al, 2013; Benencia et al, 
2005; Marchini et al, 2016). Furthermore, there is increasing evidence that oncolytic 
virotherapy induces a systemic antitumor immune response that is decisive for therapy 
efficacy. Thus, oncolytic virus-mediated cancer therapy is now referred more and more 
frequently as ‘oncolytic immunotherapy’ (Guo et al, 2017). In recent years, it was 
claimed that the induction of immunogenic cell death (ICD) by oncolytic virus-mediated 
cell killing is a key mechanism to promote a durable antitumor immune response. ICD 
describes modes of cell death like necroptosis, autophagic cell death and pyroptosis of 
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cancer cells that trigger the induction of immune responses. The oncolysis-induced 
inflammatory milieu in combination with the release and presentation of pathogen-
associated molecular patterns (PAMPs), danger-associated molecular patterns (DAMPs) 
and TAAs from the lysed tumor cells stimulate the recruitment and maturation of APCs, 
such as DCs (Guo et al, 2017; Marchini et al, 2016). DAMPs are endogenous molecules in 
the inside of a cell that are usually not recognized by the host immune system but 
initiate danger signaling after the release by dying cells (e.g. cell-surface exposure of 
calreticulin, release of heat-shock-proteins, secretion of ATP) (Galluzzi et al, 2017). 
Typical PAMPs in the context of oncolytic virotherapy include viral nucleic acids or viral 
proteins. Antigen-loaded DCs migrate to tumor draining lymph nodes promoting antigen 
presentation to immune cells. Ideally, antitumor immune responses are induced 
mediating killing of infected and uninfected tumor cells (Guo et al, 2017; Marchini et al, 
2016). 
Various transgenes have been incorporated into the genome of oncolytic viruses to 
improve their therapeutic efficacy and to further enhance the induction of an antitumor 
immunity. This includes the modification of oncolytic viruses to encode inflammatory 
cytokines or T cell co-stimulatory proteins (Lichty et al, 2014). The most advanced 
oncolytic virus in clinical development is Talimogene laherparepvec (T-Vec), which has 
been approved by the FDA in 2015 for the treatment of advanced metastatic melanoma 
(Farkona et al, 2016). T-Vec is an attenuated oncolytic herpes simplex virus-1 (HSV-1) 
that is engineered for tumor-selective replication, minimal pathogenicity and 
stimulation of a tumor-specific immune response (Hughes et al, 2014; Kaufman et al, 
2015; Liu et al, 2003). This is accomplished by deleting genes in the viral genome that 
are not essential for viral replication in cancer cells and by incorporating an 
immunostimulatory transgene. Removal of both copies of the ‘neurovirulence factor’ 
ICP34.5 required for viral immune evasion renders the virus tumor-selective and 
reduces its neurovirulence thereby attenuating viral pathogenicity (Chou et al, 1990; 
Sarinella et al, 2006; Liu et al, 2003; Hughes et al, 2014). Due to the deletion of the viral 
gene ICP47, that usually blocks antigen presentation in HSV-infected cells, the induction 
of T cell immunity is enhanced by improving antigen processing and presentation (York 
et al, 1994; Früh et al, 1995; Hughes et al, 2014; Liu et al, 2003). In addition, deletion of 
ICP47 leads to the early activation of the HSV promotor US11 thereby supporting viral 
growth (Mohr et al, 2001; Liu et al, 2003; Hughes et al, 2014). Additionally, T-Vec is 
engineered to express the immunomodulating cytokine GM-CSF to stimulate antitumor 
immune responses (Hughes et al, 2014). GM-CSF is described to play a critical role in the 
development and maturation of DCs, promotes the survival and activation of 
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macrophages, neutrophils as well as eosinophils and mobilizes myeloid populations 
from the bone marrow into blood (Hamilton, 2008). Thus, the rational to use GM-CSF in 
the context of oncolytic immunotherapy is to improve the recruitment of DCs into the 
tumor microenvironment resulting in an increased antigen presentation to T cells and 
thereby enhancing the induction of antitumor immune responses (Hughes et al, 2014).  
Another cytokine stimulating the maturation and proliferation of DCs that has been 
investigated in cancer immunotherapy is FMS-like tyrosine kinase 3 ligand (Flt3L) 
(Maraskovsky et al, 1996; Shurin et al, 1997). Treatment of different cancer types with 
either recombinant or viral-encoded Flt3L showed promising antitumor efficacy and the 
induction of an immunological memory (Chen et al, 1997; Wang et al, 2000; King et al, 
2008; Lynch et al, 1997).  
1.2 Vesicular stomatitis virus 
Vesicular stomatitis virus (VSV) is an enveloped, single-stranded RNA virus belonging to 
the family Rhabdoviridae. It is an arthropod-borne virus and natural hosts mainly 
include rodents, horse, cattle and swine. VSV can lead to an acute disease in livestocks 
that is characterized by vesicular lesions in the oral cavity, teats and feets that usually 
resolves within a few weeks without fatality. VSV is zoonotic but human infections are 
rare and are usually asymptomatic or only accompanied by mild-flu like symptoms in 
some individuals (Lichty et al, 2004). Only a single case of VSV-associated human 
encephalitis has been reported (Quiroz et al, 1988). The two predominant serotypes 
found in America are New Jersey and Indiana, whereas the New Jersey serotype is 
considered to be the agriculturally relevant pathogen. Oncolytic VSV agents are derived 
from the Indiana serotype (Lichty et al, 2004). 
1.2.1 VSV biology   
VSV is a membrane-enveloped virus having a bullet-shaped morphology with an 
approximate size of 185 x 75 nm (Ge et al, 2010; Hastie & Grdzelishvili, 2012). The 
virions contain a single-stranded RNA genome with negative polarity (ss(-)RNA) that 
exhibits a size of approximately 11,000 nucleotides. The genome encodes the five viral 
proteins nucleoprotein (N), phosphoprotein (P), matrix protein (M), glycoprotein (G) 
and large polymerase (L) (Figure 2).  
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Figure 2: Schematic representation of VSV virions and of their genome. The negative, single-stranded RNA 
genome encodes five viral proteins: Nucleoprotein (N), phosphoprotein (P), matrix protein (M), glycoprotein (G) and 
large polymerase (L). The viral proteins and a lipid envelope build up bullet-shaped VSV virions. According to the 
information provided in (Lichty et al, 2004).   
The N protein is tightly associated with the ss(-)RNA genome rendering the genome 
nuclease-resistant. Moreover, the ss(-)RNA-N protein complex constitutes the template 
for transcription as well as replication by the RNA-dependent RNA-polymerase (RdRP). 
The RdRP consists of the catalytically large subunit, the L protein, and the essential 
phosphoprotein cofactor, the P protein (Hastie & Grdzelishvili, 2012). The N-
encapsidated VSV genome together with the RdRP forms the ribonucleoprotein (RNP) 
complex. The M protein has multiple functions including virus assembly and budding. 
Additionally, it is an important virulence factor as it is involved in the induction of 
apoptosis and disruption of host antiviral mechanisms (Lichty et al, 2004). In particular, 
the M protein interrupts the host transcriptional machinery and blocks the mRNA 
export from the nucleus and thereby interferes with the expression of antiviral genes 
such as IFN (Black & Lyles, 1992; Petersen et al, 2000; Ahmed et al, 2003; Lichty et al, 
2004). The G protein binds to the cell surface via the ubiquitously expressed low density 
lipoprotein (LDL) receptor and mediates fusion of the viral and cellular membranes 
(Finkelshtein et al, 2013; Sun et al, 2010). The virus is internalized into the cell by actin- 
and clathrin-dependent endocytosis (Sun et al, 2005; Cureton et al, 2010). Acidification 
in the endosome (pH<6.2) triggers a conformational change in the G protein leading to 
the fusion of the viral envelope with the endosomal membrane finally causing the 
release of the infectious RNP complex into the cytoplasm (White et al, 1981; Sun et al, 
2010). The subsequent transcription and replication of the viral genome entirely occurs 
in the cytosol. Due to a single polymerase entry site on the 3’-end of the VSV genome 
transcription is obligatory sequential (Ball & White, 1976; Emerson, 1982). Highly 
conserved cis-acting elements within the intergenic regions provide start/stop signals 
required for transcriptional regulation (Barr et al, 2002; Rose, 1980; McGeoch, 1979). 
However, reinitation of transcription by the RdRP complex at each gene junction does 
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not always occur, resulting in 29-33 % fewer transcripts of downstream genes 
compared to the previous genes (Iverson & Rose, 1981). The resulting transcriptional 
gradient causes a decrease in mRNA and thus protein abundance from the 3’ to the 5’ 
located genes (Villarreal et al, 1976; Barr et al, 2002). Later on, the VSV genome is also 
replicated by the viral RdRP. During replication, full-length positive-sense VSV 
antigenomes are synthesized which in turn are used as template for the synthesis of the 
negative-sense VSV genomes. These genomes are either utilized as template for second 
transcription or packaged into progeny VSV virions (Barr et al, 2002).  
1.2.2 VSV – an oncolytic virus 
VSV is a promising oncolytic virus candidate showing impressive antitumor activity in a 
variety of animal models. It is under intense development due to several favorable 
characteristics including its cytoplasmic replication without the risk of host-cell-
transformation, its well-studied biology, a rapid replication cycle, a genome that is 
genetically stable as well as easily manipulable and its producibility to high virus yields. 
Furthermore, VSV primarily affects rodents and livestocks. Human infections are rare 
and are mainly limited to agricultural as well as laboratory workers. Thus, the 
occurrence of VSV-specific antibodies in the general human population is low. Due to the 
absence of preexisting immunity, neutralization of VSV during virotherapy treatment is 
reduced and further allows the systemic administration of VSV agents to treat also 
disseminated cancer (Hastie & Grdzelishvili, 2012). In addition, VSV exhibits inherent 
tumor selectivity due to its exquisitely sensitivity to type I IFN-induced antiviral 
responses (Stojdl et al, 2000; Stojdl et al, 2003; Liu et al, 2013). Many tumor cells 
acquired deregulated type I IFN signaling pathways during carcinogenesis. This includes 
the downregulation of genes associated with type I IFN responses such as the IFN 
receptor (IFNAR) or epigenetic silencing of IFN-responsive transcription factors (Zhang 
et al, 2010; Li & Tainsky, 2011). In addition, IFN signaling can be inhibited by Ras 
signaling pathways that are often activated in malignant cells (Noser et al, 2007).  
Different strategies have been investigated to further improve the efficacy of VSV 
therapeutics. This involves the combination of VSV therapy with chemical agents, 
radiotherapy or viral expression of suicide genes (Goel et al, 2007; Fernandez et al, 
2002; Hastie & Grdzelishvili, 2012). Additionally, numerous approaches have been 
developed to prevent premature clearance of VSV-based oncolytic viruses by the host 
immunity (Hastie & Grdzelishvili, 2012). This includes physical delivery methods to 
mask the virus from immune cells or engineering VSV to escape the host immune 
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response (Kottke et al, 2008; Muik et al, 2014). Since it is claimed that fully effective 
oncolytic virotherapy requires the activation of tumor-specific immune responses, VSV 
constructs have also been developed that encode for TAAs or cytokines (Hastie & 
Grdzelishvili, 2012; Pulido et al, 2012; Fernandez et al, 2002; Bergman et al, 2007).  
However, VSV exhibits inherent neurotoxicity which has hindered clinical development. 
VSV invasion of the central nervous system has been observed in rodent’s models after 
different application routes as well as in non-human primates finally leading to severe 
neurological diseases (Muik et al, 2012; Johnson et al, 2007; Bi et al, 1995; Shinozaki et 
al, 2005).  
1.2.2.1 Improving the safety of VSV 
Different strategies have been evaluated to improve the safety profile of VSV. One 
promising approach includes VSV-MΔ51 or VSV-M51R viruses exploiting the lack of IFN 
response in certain cancer types. The deletion or mutation of the methionine residue at 
position 51 prevents the matrix protein from blocking the nucleocytoplasmic transport 
of mRNA and from inhibiting host-cell gene expression. This enables the expression of 
antiviral genes such as IFN. Thereby, such VSV mutants retain their oncolytic activity in 
cancer cells defective for the IFN pathway while being attenuated in healthy tissue 
(Stojdl et al, 2003). A further strategy to exploit the defects in IFN signaling in cancer 
cells involves the development of recombinant VSV viruses engineered to encode IFN 
(e.g. VSV-IFNβ). The resultant virus protected non-malignant tissue from off-target 
toxicity while retaining oncolytic activity (Obuchi et al, 2003). Due to promising results 
in preclinical studies, VSV encoding IFNβ is currently evaluated in ongoing clinical trials 
(ClinicalTrials.gov identifier: NCT01628640, NCT02923466, NCT03120624). 
One of the key determinant of VSV neurovirulence is the VSV-G glycoprotein (Cooper et 
al, 2008; Clarke et al, 2007; Martinez et al, 2003). Thus, a further promising approach to 
improve the safety profile was the exchange of the VSV-G with the non-neurotropic 
envelope glycoprotein of the lymphocytic choriomeningitis virus WE strain (LCMV-GP). 
Tropism analysis showed that LCMV-GP pseudotyped single-cycle infectious VSV 
(VSVΔG-GP) showed enhanced infectivity of malignant glioma cells while sparing 
primary human and murine neurons in vitro and in vivo. Furthermore, immune cells 
(such as stimulated T cells and DCs) were less susceptible to VSVΔG-GP as compared to 
VSV-G complemented VSVΔG vectors (Muik et al, 2011). Pseudotyping replication-
competent VSV with LCMV-GP (rVSV(GP)) abrogates neurotoxicity while retaining 
potent antitumor activity. In addition, rVSV(GP) was proven to escape humoral 
immunity and resisted complement-mediated inactivation in normal human serum and 
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thus potentially allows repeated rVSV(GP) application without impaired therapeutic 
efficacy (Muik et al, 2014).  
A further approach to overcome the neurotoxicity of VSV was the development of a 
semireplication-competent VSV vector system (srVSV) which is based on two trans-
complementing, propagation-deficient VSV vectors (Figure 3) (Muik et al, 2012). 
 
Figure 3: Genome organization and mode of action of srVSV. srVSV is composed of two complementary VSV 
deletion mutants, namely VSVΔG and VSVΔL. In the genome of the VSVΔG vector the gene of the G protein was 
substituted with GFP and in the genome of the VSVΔL vector the gene encoding the L protein was substituted with 
DsRed. Both individual VSV deletion mutants are propagation-deficient alone. After co-infection with VSVΔG(GFP) 
together with VSVΔL(DsRed), they can co-replicate and co-propagate leading to viral spread. According to the 
information provided in (Muik et al, 2012).  
In particular, srVSV is composed of a VSVΔG vector lacking the G gene and a VSVΔL 
vector being deleted for the L gene. VSVΔG and VSVΔL cannot propagate alone and thus 
infectious progeny can only be produced in double infected cells. Consequently, co-
propagation is limited to foci of high vector concentrations such as the injection site and 
adjacent areas of the topically treated tumor reducing the risk of toxicity. srVSV was 
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shown to propagate without reversion to replication-competent virus, proved to be 
highly oncolytic in vitro and induced long-term tumor regression in a xenograft tumor 
mouse model. Treatment of tumor-bearing mice or direct intracranial administration in 
healthy mice was not associated with any side effects of neurotoxicity. It was also shown 
that srVSV exhibited a similar IFN-inducing capacity as VSV-M51R. Thus, next to its 
intrinsic mode of co-propagation resulting in limited viral spread, srVSV restriction to 
tumor tissue could additionally be caused by its effective induction of type I IFN (Muik et 
al, 2012).  
Further strategies to improve the safety of VSV include mutation in the VSV-G protein, 
adaption to cancer cells by serial passaging or insertion of targets for microRNA into the 
VSV genomes that are solely expressed in normal cells (Hastie & Grdzelishvili, 2012). 
1.3 Adeno-associated virus 
Adeno-associated viruses (AAV) are nonpathogenic, single-stranded DNA viruses 
belonging to the family Parvoviridae (Gonçalves, 2005). AAV is classified to the genus 
dependovirus as successful replication and production of AAV particles requires the co-
infection with a helper virus such as adenovirus or HSV (Casto et al, 1967; Buller et al, 
1981, Gonçalves, 2005). In the absence of a helper-virus the AAV genome preferentially 
integrates site-specifically into chromosome 19 of the host’s genome and persists in a 
latent form (Kotin et al, 1990; Samulski et al, 1991). The virus has an icosahedral capsid 
architecture with a diameter of approximately 22 nm and is formed by 60 subunits of 
the viral proteins (VP) VP1, VP2 and VP3 (Xie et al, 2002; Gonçalves, 2005).  
AAVs package a linear, single-stranded DNA genome of approximately 4.7 kb that can 
have negative or positive polarity (Samulski & Muzyczka, 2014; Srivastava et al, 1983). 
The genome consists of two open reading frames (ORF), rep and cap, that are flanked by 
inverted terminal repeats (ITR) serving as origin of replication and encapsidation signal 
(Samulski & Muzyczka, 2014; Senapathy et al, 1984; McLaughlin et al, 1988). The rep 
ORF encodes the four regulatory proteins Rep78, Rep68, Rep52 and Rep40 that are 
required for the regulation of gene expression, chromosomal integration, DNA 
replication, viral assembly and genome packaging (Im & Muzyczka, 1992; Im & 
Muzyczka, 1990; Smith & Kotin, 1998; Collaco et al, 2003; Pereira et al, 1997; Weitzman 
et al, 1994; King et al, 2001). The cap ORF encodes the structural proteins VP1, VP2 and 
VP3 (Samulski & Muzyczka, 2014). Recently, a third ORF within cap has been identified 
encoding the assembly-activating protein (AAP) that is required for capsid formation 
(Sonntag et al, 2010).  
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Various AAV serotypes have been isolated from human, non-human primates and other 
species such as horse. The different serotypes have a similar genome organization and 
size but differ in the amino acid composition of their capsid resulting in varying tissue 
tropisms. Further differences include their transduction efficiencies and prevalence of 
preexisting immunity. AAV serotype 2 (AAV2) is the best characterized as well as most 
abundant strain in the human population and was used by a vast majority of AAV gene 
transfer studies (Wu et al, 2006; Asokan et al, 2012). The primary receptor of AAV2 is 
heparin sulfate proteoglycan (HSPG), with residues R585 and R588 of AAV2 being 
primarily responsible for heparin sulfate binding (Summerford & Samulski, 1998; Kern 
et al, 2003; Opie et al, 2003). Recently, AAVR was identified as a further essential host 
receptor required for AAV infection and also other surface proteins including fibroblast 
growth factor, laminin receptor and integrin αVβ5 have been described as putative 
AAV2 co-receptors (Pillay et al, 2016; Qing et al, 1999; Akache et al, 2006; Summerford 
et al, 1999).   
1.3.1 AAV-based gene transfer vectors 
Over the past decade, AAV gained considerable interest as gene therapy vector due to 
some of its advantageous properties such as lack of pathogenicity, high stability, low 
immunogenicity, capability of transducing dividing and non-dividing cells and to 
establish a long-term transgene expression (Coura & Nardi, 2007). AAV vectors are 
investigated in numerous clinical studies addressing monogenetic diseases such as 
hemophilia B, retinal diseases or muscular dystrophy. In 2012, the AAV vector Glybera® 
was the first gene therapy medicinal product that achieved marketing authorization in 
the western nation. The AAV1-based vector delivers the human lipoprotein lipase (LPL) 
gene to muscle cells following intramuscular injection into patients suffering from a rare 
genetic disease in lipid metabolism. Further clinical trials utilize AAV vectors to treat 
also other diseases such as Parkinson’s disease or heart failure (Kotterman et al, 2015). 
For gene therapeutic applications, recombinant AAV vectors are generated by 
incorporating a gene of interest into the viral genome. For this, the rep and cap ORFs are 
deleted from the AAV genome and replaced by the transgene that is now flanked by the 
ITRs, the only cis-acting elements required for DNA encapsidation (hereafter designated 
as ‘transfer vector’). The rep and cap genes as well as the adenoviral helper functions are 
provided in trans on separate plasmids during vector production. After transfection of 
these plasmids into producer cell lines, rAAV vectors carrying the desired transgene are 
purified (Gonçalves, 2005). Due to the construction of rAAV vectors that do not encode 
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Rep proteins and lack the integration efficiency element (IEE), both required for site-
specific integration, the transferred transgene primarily persists episomally (Philpott et 
al, 2002; Daya & Berns, 2008).  
One of the rate-limiting steps during AAV transduction is the conversion of the single-
stranded into double-stranded DNA genome which is required prior to transgene 
expression. To avoid the delayed start of gene expression after transduction, this step 
can be circumvented by using self-complementary AAV vectors (scAAV). Such scAAVs 
contain an AAV genome with a deleted terminal resolution site sequence from one ITR 
preventing the Rep-mediated DNA nick and thus leading to the generation of self-
complementary, double-stranded AAV genomes. Even though scAAV vectors lost about 
half of their coding capacity, they showed increased transduction efficiency relative to 
single-stranded AAV (ssAAV) in various animal models (McCarty, 2008).  
1.3.2 Surface engineering of AAV vectors  
Different strategies have been developed to enable effective AAV-mediated gene transfer 
to specific tissues or relevant cell types to increase efficiency and safety of gene therapy 
applications, especially after systemic vector administration. One approach includes the 
control of gene expression using cell type-specific promotors and microRNA target 
sequences (Nettelbeck et al, 2000; Gentner & Naldini, 2012). However, these vector 
particles can still enter non-target cells which potentially reduce the efficiency of gene 
transfer.  
A further approach is based on capsid engineering either by directed evolution efforts or 
rational design. Directed evolution approaches use AAV libraries that are created by 
modification of the cap genes. This includes (i) the usage of libraries carrying a mutation 
in the cap ORF introduced by error-prone PCR, (ii) capsid shuffling which is based on 
fragmenting the capsid DNA sequences of different serotypes that is followed by random 
assembly of the sequences and (iii) random peptide sequences that are genetically 
introduced into the AAV capsid. The capsid libraries are put under selective pressure in 
vitro or in a suitable animal model to isolate an AAV vector with the desired properties. 
Finally, the capsid modifications of the selected AAV variants are identified enabling the 
development of the corresponding vector. Thereby, AAV vectors can be identified that 
enter the cell type of choice and allow intracellular processing of AAVs (Kotterman & 
Schaffer, 2014; Büning et al, 2015).   
Rational design approaches rely on the identification of cell surface receptors that are 
expressed on the relevant cell type (Buchholz et al, 2015). Recently, successful 
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redirection of the AAV2 receptor usage has been achieved by incorporating designed 
ankyrin repeat proteins (DARPin) as high-affinity ligands into the AAV capsid. The 
concept is based on ablating natural receptor binding of AAV2 to HSPG by introducing 
two point mutations into the VP proteins (R585A, R588A). Next, genetic fusion of a 
DARPin to the N-terminus of the VP2 protein enabled the binding to the cell surface 
receptor of choice (Münch et al, 2013) (Figure 4). 
 
Figure 4: Rational engineering of receptor-targeted AAV. Generation of receptor-targeted AAV vectors involves 
two steps. First, natural receptor binding to HSPG is ablated by introducing two point mutations into the capsid 
proteins (indicated in orange). Second, a DARPin specific for a cell surface receptor of choice is fused to the capsid 
proteins on genetic level enabling the transduction of receptor-positive cells. According to the information provided in 
(Buchholz et al, 2015).  
Among these receptor-targeted AAV vectors is a tumor-specific vector displaying a 
Her2/neu-specific DARPin on the capsid surface (Her2-AAV). Her2-AAV enabled specific 
gene transfer into subcutaneous and disseminated Her2/neu-positive tumor cells in a 
xenograft tumor mouse model, while non-targeted AAV2 retained in the liver (Münch et 
al, 2013; Münch et al, 2015). In addition, application of Her2-AAV equipped with the 
suicide gene thymidine kinase from HSV was sufficient to control tumor growth and to 
substantially prolong survival in a therapeutic xenograft mouse model. In contrast, non-
targeted AAV2 showed decreased survival compared to untreated animals due to liver 
toxicity (Münch et al, 2013). The system was proven to be highly flexible, since the 
incorporation of further DARPins, specific for CD4 or epithelial cell adhesion molecule 
(EpCAM), also enabled selective transduction of target cells even if they were highly 
underrepresented (Münch et al, 2015). 
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1.4 Objectives 
Aim of this study was the generation and characterization of two different types of viral 
gene transfer systems for applications in cancer immunotherapy. The first project aimed 
at the development of srVSV as a novel vector system for oncolytic immunotherapy. 
Combining the oncolytic activity of srVSV with the expression of immunotherapeutic 
transgenes was assumed to interfere with tumor immune escape mechanisms leading to 
a long-lasting antitumor immunity. Tumor cells acquired a variety of mechanisms to 
evade the immune response in order to favor cancer progression including reduced 
numbers as well as functionally impaired DCs, low TAA presentation due to 
downregulation of MHC molecules and secretion of factors suppressing the activity of 
cytotoxic T cells (Melzer et al, 2017; Zou, 2005). Thus, srVSV should be armed with the 
cytokines GM-CSF or Flt3L to stimulate the generation and recruitment of DCs into the 
tumor microenvironment. Furthermore, srVSV should be equipped with the coding 
sequence of the TAA Her2/neu or of a fusion protein comprised of CTLA-4 and 
Her2/neu in order to directly deliver the respective TAA to B7-expressing APCs. 
Additionally, srVSV should be armed with the T cell co-immunostimulatory molecule B7. 
To this end, the different immunostimulatory transgenes (GM-CSF, Flt3L, B7) and TAAs 
(Her2/neu, CTLA-4-Her2/neu) had to be cloned into the genome of VSVΔG and VSVΔL 
vectors. The different binary srVSV systems had to be generated de novo and analyzed 
for their capacity to mediate transgene expression. In order to investigate the 
antitumoral efficacy of the generated srVSV systems in vivo, a suitable tumor mouse 
model should be identified. For this purpose, different murine tumor cell lines had to be 
analyzed in regard to their sensitivity to type I IFN-induced antiviral responses. Finally, 
antitumoral efficacy of srVSV armed with immunotherapeutic transgenes had to be 
evaluated in a subcutaneous tumor mouse model.  
The second part of the thesis aimed at developing receptor-targeted AAV vectors for 
tumor-specific delivery of immune checkpoint inhibitors. While immune checkpoint 
blockade is promising, this therapy is associated with a number of irAEs. These toxicities 
are fostered by the systemic administration of these antibodies which do not only lead 
to the activation of the immune response at sites of tumor lesions but also in healthy 
tissue. Thus, the aim of this study was the specific delivery of αPD-1 and αPD-L1 
precisely to sites of tumor growth. As potential vehicle for the delivery of the immune 
checkpoint inhibitors tumor-targeted AAV vectors should be investigated. In particular, 
Her2/neu-specific AAV vectors should be used as gene transfer system, as they had been 
well characterized for their specificity in vitro as well as for their targeting capacity in 
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immunodeficient tumor-bearing mice (Münch et al, 2013; Münch et al, 2015). To this 
end, the ORF of PD-1- and PD-L1-specific molecules had to be incorporated into AAV 
transfer vectors. Generated AAV vector particles had to be characterized regarding their 
genomic titers, packaging efficiency and transgene expression. For quantification and 
detection of AAV-encoded αPD-1 and αPD-L1 in cell culture supernatants as well as in 
mice organs an ELISA had to be developed. Since the immune system is mandatory for 
immune checkpoint modulation, a suitable syngeneic tumor mouse model for the 
investigation of tumor-targeted delivery of immune checkpoint inhibitors by AAV 
vectors had to be identified and Her2-AAV tumor targeting had to be investigated in 
immunocompetent mice. Finally, the capability of Her2-AAV to mediate tumor-targeted 
delivery of immune checkpoint inhibitors in vivo should be assessed.  
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2 Material and Methods 
2.1 Material 
Consumables used for cell culture, molecular biology, protein biochemistry and animal 
work were obtained from Braun, TPP, BD Bioscience, Greiner Bio-One, GE Healthcare, 
Biozym, Nerbe, Biotix, Thermo Fisher Scientific, Merck Millipore, Micronic, Beckman 
Coulter, Bio-Rad, BD Microfine, Fujifilm, Sarstedt, VWR and MP Biomedical. Chemicals 
were generally obtained from Biozym, Carl Roth, Sigma-Aldrich, Applichem, VWR or 
Medienküche of the Paul-Ehrlich-Institut and more details of commonly used reagents 
are given in Table 1.  
2.1.1 Reagents, chemicals, recombinant proteins and cytokines 
Table 1: Reagents, chemicals, recombinant proteins and cytokines 
Name Supplier 
1-StepTM Ultra TMB substrate Thermo Fisher Scientific 
2-log DNA ladder New England Biolabs 
Ampicillin Roche 
Concanavalin A (ConA) from canavalia ensiformis  
(Jack bean) 
Sigma-Aldrich 
D-Luciferin Perkin Elmer 
Dulbecco’s Modified Eagle Medium (DMEM) Biowest 
Fetal calf serum (FCS) Biochrom 
FuGENE® HD Transfection Reagent  Promega 
Geneticin® life technologies 
Ionomycin  Sigma-Aldrich 
Kanamycin  Sigma-Aldrich 
LipofectamineTM LTX Reagent with PLUSTM Reagent Invitrogen 
Midori Green DNA, Direct loading dye Nippon Genetics 
Mouse IFNα Miltenyi Biotec 
Mouse IFNγ Miltenyi Biotec 
OptiMEM® (1x) + GlutaMAXTM life technologies 
PageBlueTM Protein Staining Solution  Thermo Fisher Scientific 
PageRulerTM Plus Prestained Protein Ladder Thermo Fisher Scientific 
Panexin NTA  PanBiotech 
Passive Lysis Buffer Promega 
PBS (w/o Mg2+/Ca2+) Lonza, Paul-Ehrlich-Institut 
PBS(w/o Mg2+/Ca2+)/EDTA (1 mM), pH 7.1 Paul-Ehrlich-Institut 
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Penicillin/Streptomycin (PenStrep) Paul-Ehrlich-Institut 
Phorbol 12-myristate 13-acetate (PMA) Sigma-Aldrich 
Pierce BCA Protein Assay Kit Thermo Fisher Scientific 
PierceTM ECL Western Blotting substrate Thermo Fisher Scientific 
Protease inhibitor cocktail, complete ULTRA Tablets Roche 
Puromycin life technologies 
Quick StartTM Bradford 1x dye Bio-Rad 
Quick StartTM BSA Standard Set Bio-Rad 
Recombinant PD-1 Life technologies 
Recombinant PD-L1 Life technologies 
Rec-Protein A-Sepharose® 4B Conjugate Invitrogen 
RPMI 1640 medium Biowest 
VP-SFM life technologies 
2.1.2 Commercially available kits 
Table 2: Kits 
Name Supplier 
AAV2 Titration ELISA Progen 
DNeasy® Blood & Tissue Kit Qiagen 
eBioscienceTM Fixable Viability Dye eFluorTM 450 Thermo Fisher Scientific 
Flt3 Ligand Human ELISA Kit Abcam 
GeneJET Gel Extraction Kit Thermo Fisher Scientific 
GeneJET Plasmid Miniprep Kit Thermo Fisher Scientific 
JETSTAR 2.0 Plasmid Maxiprep Kit Genomed 
JETSTAR 2.0 Plasmid Midiprep Kit Genomed 
Mouse GM-CSF ELISA Kit Thermo Fisher Scientific 
Mouse IFN gamma ELISPOT Ready-Set-Go!®-Kit eBioscience 
NucleoBond® Xtra Midi  Macherey-Nagel 
Rapid DNA Ligation Kit Thermo Fisher Scientific  
SensiFASTTM Probe No-ROX Kit Bioline 
WST-1 Cell Proliferation Assay Kit Takara Clontech 
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2.1.3 Enzymes 
Table 3: Enzymes 
Name Supplier 
Antarctic Phosphatase New England Biolabs 
Benzonase® Nuclease Sigma-Aldrich 
KOD Hot Start DNA Polymerase Merck Millipore 
Restriction endonucleases New England Biolabs 
Trypsin 2.5 %  Paul-Ehrlich-Institut 
2.1.4 Buffers 
Table 4: Buffer composition 
Name Composition 
AAV lysis buffer 
50 mM Tris-HCl 
150 mM NaCl 
H2O 
pH 8.5 
ELISA blocking buffer 
5 % (v/v) FCS (filtered through 0.45 µm) 
0.05 % (v/v) Tween 
PBS 
ELISA washing buffer 
0.05 % (v/v) Tween  
PBS 
FACS fix 
1 % formaldehyde  
PBS 
FACS washing buffer 
2 % (v/v) FCS  
0.1 % (v/v) NaN3 
PBS  
Freezing medium 
90 % (v/v) FCS  
10 % (v/v) DMSO 
PBS M/K 
2.5 mM KCl 
1 mM MgCl2  
PBS 
PEI 18 mM polyethylenimine in H2O 
Protein A collection buffer 
1 M Tris  
PBS  
pH 8.8 
Protein A elution buffer 
100 mM glycine  
PBS 
pH 2.7 
Protein A storage buffer 
0.1 % (v/v) NaN3 
PBS 
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Red Blood Cell Lysis Buffer 
(provided by Medienküche Paul-Ehrlich-
Institut) 
155 mM NH4Cl 
10 mM Tris  
H2O 
pH 7.5 
SDS loading dye (4x) 
250 mM Tris/HCl (pH 6.8) 
4 % (w/v) SDS 
20 % (v/v) glycerol 
20 mg/l bromphenolblue 
10 % β-Mercaptoethanol  
H2O 
SDS running buffer 
(10x buffer provided by Medienküche Paul-
Ehrlich-Institut) 
25 mM Tris 
192 mM glycine 
1 % (w/v) SDS 
H2O 
TAE buffer 
(20x TAE buffer provided by Medienküche 
Paul-Ehrlich-Institut) 
40 mM Tris 
20 mM acetic acid 
1 mM EDTA 
H2O 
TBS-T 
(10x TBS buffer provided by Medienküche 
Paul-Ehrlich-Institut) 
50 mM Tris 
150 mM NaCl 
0.1 % (v/v) Tween 
H2O 
pH 7.4 
Western blot transfer buffer 
48 mM Tris 
39 mM glycine 
20 % (v/v) methanol  
H2O 
2.1.5 Antibodies 
Table 5: Antibodies 
Antibody Application & Dilution Supplier 
α-Myc-tag (Myc.A7) mouse WBa (1:1,000) abcam 
α-His-PE (GG11-8F3.5.1.) mouse FCb (1:50-1:100) Miltenyi Biotec 
α-human-CD86-FITC 
(FM95)  
mouse FC (1:50-1:100) Miltenyi Biotec 
α-human-CD80-PE (2D10) mouse FC (1:50-1:100) Miltenyi Biotec 
α-human IgG (Fc specific), 
HRP-coupled  
goat 
WB (1:10,000)  
ELISA (1:10,000) 
Sigma-Aldrich 
α-mouse-CD28-PE  (37.51) hamster FC (1:50-1:100) Miltenyi Biotec 
F(ab')2 α-human IgG-FITC goat  FC (1:100) 
Biozol (Southern 
Biotech) 
α-murine GM-CSF rabbit WB (1:500) Peprotech 
  Material and Methods 
 
25 
 
α-human Flt3L rabbit WB (1:500) Peprotech 
α-HA-tag (16B12) mouse 
WB (1:1,000) 
ELISA (1:200) 
abcam 
α-HA-Biotin (3F10) rat ELISA (1:500) Roche 
α-mouse-PD-L1-PE (MIH5) rat FC (1:300) eBioscience 
α-mouse-PD-1-PE (HA2-
7B1) 
rat FC (1:10-1:100) Miltenyi Biotec 
α-rabbit, HRP-conjugated goat WB (1:2,000) Dako 
α-mouse, HRP-conjugated rabbit WB (1:2,000) Dako 
Rat IgG2b, isotype control  FC (1:10) Miltenyi Biotec 
FcR blocking reagent, 
mouse  
- FC (1:10) Miltenyi Biotec 
a WB: Western blot, b FC: flow cytometry 
2.1.6 Oligonucleotides 
All oligonucleotides were synthesized by the company Sigma-Aldrich or Eurofins MWG 
Operon. 
Table 6: Primer 
Name Oligonucleotides (5’ 3’) 
ΔL_GMCSF_for CGATGGATCCATGTGGCTGCAGAATTTACTTTTCCTG 
ΔL_GMCSF_rev CAGTGCGGCCGCTCATTTTTGGACTGGTTTTTTGCATTCAAAG 
ΔG_Flt3L_for ATTCGATCCCGGGATGACAGTGCTGGCTCCTGCATG 
ΔG_Flt3L_rev TATTGCGGCCGCTCAGGATGTC 
ΔL_TAA_for CGATGGATCCATGGAGACAGACACACTCCTGCTATGG 
ΔG_TAA_for ATTCGATCCCGGGATGGAGACAGACACACTCCTGCTATGG 
ΔL/ΔG_TAA_rev CAGTGCGGCCGCTCAATGATGATGATGATGATGGTC 
ΔL_B7_for GAGCGATAGATCTATGGCTTGCAATTGTCAGTTG 
ΔG_B7_for GAGCGATACCGGTATGGCTTGCAATTGTCAGTTG 
ΔL/ΔG_B7_rev ATTAGCGGCCGCTTATTTACCCGGGGACAGGG 
pB7_for CGGCTTAATTAAATGGCTTGCAATTGTCAG 
pB7_rev CGATGCTAGCCTTACCTGTCTTGCTATCAGGAG 
pIRES-G_for GGCGCGACATGTATGAAGTGCCTTTTGTACTTAG 
pIRES-G_rev CCGCGGAATTCTTACTTTCCAAGTCGGTTCATC 
scAAV-αPD-1/αPD-L1_for TGCCACCATGGAGACAGACAC 
scAAV-αPD-1/αPD-L1_rev ATATGGGCGGCCGCTTCAATTCAGATCTTCTTCTGAGATG 
Fc-only_for ATATAGGCCCAGCCGGCCGTCGACGAGGCCAAATCTTG 
Fc-only_rev GCATGCGGCCGCTTCAATTCAGATC 
ITR2_for GGAACCCCTAGTGATGGAGTT 
ITR2_rev CGGCCTCAGTGAGCGA 
ITR2_probe 6FAM-CACTCCCTCTCTGCGCGCTCG-TAMRA 
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2.1.7 Plasmids 
Table 7: Plasmids 
Name Description Source 
pGM-CSF cDNA encoding GM-CSF 
O. Ebert, TU München, 
München 
pEX-A-sFlt3L 
cDNA encoding human Flt3L; on 
the 5’ and 3’ prime ends 
restrictions sites BamHI and NotI 
were included 
Eurofins MWG operon 
pCR-B7IG 
Plasmid containing the B7-1-IgG 
cassette 
S.D. Rabkin, 
Massachusetts General 
Hospital, MA, USA 
phuFc-endoglin 
cDNA of endoglin fused to human 
IgG1-Fc 
G. Braun, Paul-Ehrlich-
Institut, Langen 
phuFc-B7-1 
Plasmid with B7-1-IgG cassette 
used as template for cloning of VSV 
vectors 
This thesis 
(3.1.1) 
pSecTag2B-Her2/neu 
Plasmid encoding Her2/neu or 
CTLA-4-Her2/neu 
W. Wels, Georg-Speyer-
Haus, Frankfurt pSecTag2B-CTLA-4-
Her2/neu 
pVSVΔG(GM-CSF)a 
G deletion mutant of the VSV 
genome encoding GM-CSF, Flt3L, 
B7, Her2, C-Her2 
This thesis  
(3.1.1) 
pVSVΔG(Flt3L)a 
pVSVΔG(B7)a 
pVSVΔG(Her2)a 
pVSVΔG(C-Her2)a 
pVSVΔL(GM-CSF)a 
L deletion mutant of the VSV 
genome encoding GM-CSF, Flt3L, 
B7, Her2, C-Her2 
This thesis 
(3.1.1) 
pVSVΔL(Flt3L)a 
pVSVΔL(B7)a 
pVSVΔL(Her2)a 
pVSVΔL(C-Her2)a 
pVSVΔL(DsRed)a 
L deletion mutant of the VSV 
genome encoding the fluorescent 
protein DsRed 
A. Muik, Georg-Speyer- 
Haus, Frankfurt  
(Muik et al, 2012) 
pVSV(GP)a 
VSV-WT genome encoding LCMV-
GP instead of VSV-G 
A. Muik, Georg-Speyer-
Haus, Frankfurt 
pBSII-G-ΔL-HDVR 
Cloning vector: DsRed is flanked by 
the G-L intergenic regions and a 
part of the G-gene of VSV as well as 
the L-HDV (Hepatitis Delta Virus) 
ribozyme region  
A. Muik, Georg-Speyer-
Haus, Frankfurt 
(Muik et al, 2012) 
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pBSII-M-ΔG-L 
Cloning vector: LCMV-GP  is 
flanked by the M-G intergenic 
regions and a part of the M gene as 
well as G-L intergenic region of 
VSV 
A. Muik, Georg-Speyer-
Haus, Frankfurt 
pBSIIΔL-GM-CSF Cloning vector: transgene (GM-
CSF, Flt3L, B7, Her2 or C-Her2) is 
flanked by the G-L intergenic 
regions and a part of the G-gene of 
VSV as well as the L-HDV 
(Hepatitis Delta Virus) ribozyme 
region 
This thesis 
(3.1.1) 
pBSIIΔL-Flt3L 
pBSIIΔL-B7 
pBSIIΔL-Her2 
pBSIIΔL-C-Her2 
pBSIIΔG-GM-CSF 
Cloning vector: GM-CSF is flanked 
by the M-G intergenic regions and 
a part of the M gene as well as G-L 
intergenic region of VSV 
This thesis 
(3.1.1) 
pIRES-N Helper plasmids required for VSV 
rescue: based on pBS II (+) 
plasmids containing ECMV IRES 
and the VSV viral proteins N, P, L 
under the control of a T7 promotor 
M. J. Schnell, Thomas 
Jefferson University, PA, 
USA 
pIRES-P 
pIRES-L 
pIRES-G 
Helper plasmid required for 
VSVΔG rescue: based on pBS II (+) 
plasmid containing ECMV IRES and 
the VSV viral protein G under the 
control of a T7 promotor 
This thesis 
(3.1.2) 
pS-GluRD-IP-W 
Bicistronic HIV-1 transfer vector 
encoding the murine glutamate 
receptor subunit D and an IRES-
driven puromycin resistance gene 
under control of the SFFV 
promotor; used as backbone for 
cloning of pS-mPD1-IP-W and pS-
CD28-IP-W 
R. Bender, Paul-Ehrlich-
Institut, Langen 
pmCD28_BamHI_SpeI 
cDNA encoding mouse CD28; on 
the 5’ and 3’ prime ends 
restrictions sites BamHI and SpeI 
were included 
InvitrogenTM GeneArtTM 
pS-CD28-IP-W 
Bicistronic HIV-1 transfer vector 
encoding mouse CD28 and an 
IRES-driven puromycin resistance 
gene under control of the SFFV 
promotor 
This thesis 
(3.1.3) 
Cloned by D. Beckmann 
as part of a supervised 
student internship 
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pCG-sa-PD-1 Expression plasmid encoding αPD-
1 (scFv derived from the clone J43) 
or αPD-L1 (scFv derived from the 
clone YW243.55.S70) under the  
control of a CMV promotor 
G. Ungerechts, NCTb, 
Heidelberg pCG-sa-PD-L1 
pXX6-80 
Adenoviral helper plasmid 
encoding the adenoviral genes VA 
RNA, E2A and E4 
H.Büning, ZMMKc, 
Cologne 
pRC 
Encodes the AAV2 rep and cap 
proteins 
H.Büning, ZMMK, 
Cologne 
pRC-VP2KO-HSPGmut 
Encodes the AAV2 rep proteins 
and capsid proteins VP1and VP3, 
VP2 start codon is mutated, capsid 
proteins contain the point 
mutations R585A and R588A 
H.Büning, ZMMK, 
Cologne 
pHer2/neuD9.29-HisXa-
VP2KO 
Encodes the His-tagged DARPin-
9.29 fused to the N-terminus of the 
AAV2 VP2 protein (start codon 
mutated) containing the point 
mutations R585A and R588A 
under the control of a CMV 
promotor 
R. Münch, Paul-Ehrlich-
Institut, Langen 
(Münch et al, 2015) 
pscαPD-1-SFFV 
scAAV transfer vector encoding 
αPD-1 under the control of the 
SFFV promotor; BGH polyA 
This thesis 
(3.2.1) 
pscαPD-L1-SFFV 
scAAV transfer vector encoding 
αPD-L1 under the control of the 
SFFV promotor, BGH-polyA  
This thesis 
(3.2.1) 
pscIgG-Fc-SFFV 
scAAV transfer vector encoding 
IgG-Fc under the control of the 
SFFV promotor, BGH-polyA 
This thesis 
(3.2.1) 
pscGFP-SFFV_2.0 
scAAV transfer vector encoding 
GFP under the control of the SFFV 
promotor; BGH-polyA 
T. Abel, Paul-Ehrlich-
Institut, Langen 
pscGFP-SFFV 
scAAV transfer vector encoding 
GFP under the control of the SFFV 
promotor, SV40-polyA 
R. Münch, Paul-Ehrlich-
Institut, Langen          
(Münch et al, 2013) 
pscluc-SFFV 
scAAV transfer vector encoding 
luciferase under the control of the 
SFFV promotor, SV40-polyA  
R. Münch, Paul-Ehrlich-
Institut, Langen          
(Münch et al, 2013) 
pmPD1_BamHI_SpeI 
cDNA encoding mouse PD-1; on 
the 5’ and 3’ prime ends 
restrictions sites BamHI and SpeI 
were included 
InvitrogenTM GeneArtTM 
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pS-mPD1-IP-W 
Bicistronic HIV-1 transfer vector 
encoding mouse PD-1 and an IRES-
driven puromycin resistance gene 
under control of the SFFV 
promotor 
This thesis 
(3.2.6) 
pMDG-2 Encodes the glycoprotein of VSV 
D. Trono, École 
Polytechnique Fédérale 
De Lausanne, 
Switzerland 
pCMVΔR8.91 HIV-1 packaging plasmid 
U. Blömer, University 
Hospital Kiel   
(Zufferey et al, 1998) 
pCG1 
Empty expression plasmid for 
mock control 
R. Cattaneo, Mayo Clinic, 
USA 
aAll used pVSV as well as pVSVΔG/pVSVΔL genomes are originally derived from pVSV-XN2 that consists of a pBS SK(+) 
backbone containing the full-length cDNA genome of VSV, Indiana serotype, under the control of a T7 promotor; bNCT: 
Nationales Centrum für Tumorerkrankungen; cZMMK: Zentrum für Molekulare Medizin 
2.1.8 Bacterial & eukaryotic cells 
Medium used for the cultivation of bacterial or eukaryotic cells are described in detail in 
chapter 2.2.2 or 2.4.1, respectively.  
Table 8: Bacterial & eukaryotic cells 
Name Description 
4T1 Mouse mammary carcinoma cell line; ATCC®, CRL-2539TM 
B16-F10 Mouse melanoma cell line; ATCC®, CRL-6475TM 
BHK-21 
Baby hamster kidney cells, derived from a Syrian gold hamster; 
ATCC®, CCL-10TM 
BHK21-GP 
BHK-21 cells genetically engineered to express the glycoprotein 
of LCMV; provided by G. Zimmer, Institute of Virology and 
Immunoprophylaxis, Switzerland 
E. coli (Top10) 
Highly transformable laboratory strain of Escherichia coli 
(Invitrogen) 
E0771 
Mouse metastatic breast cancer model, provided by M. 
Mühlebach, Paul-Ehrlich-Institut, Langen 
HEK293-NPeGFPL 
HEK-293 cells stably expressing VSV-N, -P and -L protein (clone 
206); provided by A. Pattnaik, University of Nebraska, Lincoln, 
USA (Panda et al, 2010) 
HEK-293T 
Human fetal kidney epithelial cells, transformed to express the 
adenoviral SV40 T antigen; ATCC®, CRL-11268TM  
HT1080 Human fibrosarcoma cell line; ATCC®, CCL-121TM 
HT1080-CD28 
Human fibrosarcoma cell line genetically engineered to express 
mouse CD28; generated in this thesis by D. Beckmann as part of a 
supervised student internship (3.1.3) 
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HT1080-PD-1 
Human fibrosarcoma cell line genetically engineered to express 
mouse PD-1; generated in this thesis (3.2.6) 
MC38 
Mouse colon adenocarcinoma cell line; provided by H. Abken, 
ZMMK, Cologne  
MC38-ek-Her2/neu 
MC38 cells stably expressing the ectodomain of human Her2/neu 
displayed on the transmembrane domain of the platelet-derived 
growth factor receptor (PDGFR); provided by M. Mühlebach/V. 
Scheuplein, Paul-Ehrlich-Institut, Langen 
Molt 4.8 Human T cell leukemia cell line  
Raji Human B lymphoblast cell line; ATCC®, CCL-86TM 
RENCA-Her2/neu 
Mouse renal carcinoma cells (RENCA cells), stably expressing β-
galactosidase and human Her2/neu; provided by W. Wels, Georg-
Speyer-Haus, Frankfurt (Maurer-Gebhard et al, 1998) 
2.1.9 Viruses 
All viruses not listed in Table 9 were generated during this thesis and are described in 
more detail in the results part.   
Table 9: Viruses 
Virus Description Source 
MVA-T7pol 
Modified vaccinia virus Ankara (MVA) 
expressing T7 RNA polymerase; highly 
attenuated and host range restricted strain 
(Sutter et al, 1995) 
A. Muik, Georg-Speyer-
Haus, Frankfurt 
rVSV(GFP) 
Replication-competent VSV Indiana coding 
for GFP as reporter 
A. Muik, Georg-Speyer-
Haus, Frankfurt 
VSVΔG(GFP) 
Propagation-defective VSVΔG vector 
coding for GFP as reporter instead of VSV-
G 
G. Zimmer, Institute of 
Virology and 
Immunoprophylaxis, 
Switzerland 
VSVΔL(DsRed) 
Propagation-defective VSVΔL vector 
coding for DsRed as reporter instead of 
VSV-L 
A. Muik, Georg-Speyer-
Haus, Frankfurt 
(Muik et al, 2012) 
2.2 Molecular biology 
2.2.1 Transformation of chemically competent bacteria 
For the amplification of plasmid DNA, chemically competent E. coli (Top10) was used. 
Bacteria (100 µl) were thawed on ice and after adding of approximately 50 ng plasmid 
DNA or 5 µl ligation reaction mix, bacteria were incubated on ice for 30 min. 
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Subsequently, a heat shock at 42°C for 45 s was performed and bacteria were 
immediately cooled on ice. After the addition of 100 µl SOC medium (2 % (w/v) 
tryptone, 0.5 % (w/v) yeast extract, 8.6 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 20 mM 
glucose in H2O, pH 7.0; provided by Medienküche Paul-Ehrlich-Institut), bacteria were 
incubated at 37°C, 600 rpm for 30 – 60 min in a thermomixer (Eppendorf). Bacteria 
suspension was plated on Luria-Bertani (LB) agar plates containing the corresponding 
antibiotic (4 % (w/v) LB-Agar, 100 mg/l ampicillin or kanamycin; provided by 
Medienküche Paul-Ehrlich-Institut) and either cultivated overnight at 37°C, overnight at 
30°C or for three days at 25°C in a bacteria incubator (Innova 4200, New Brunswick 
Scientific). 
For retransformation of purified plasmid DNA, around 50 ng plasmid DNA were added 
to thawed E. coli (Top10) cells and incubated for 5 min at 37°C in a thermomixer 
(Eppendorf). Subsequently, bacteria suspension was applied on LB agar plates 
containing the corresponding antibiotic and either incubated overnight at 37°C, 
overnight at 30°C or for three days at 25°C in a bacteria incubator (Innova 4200, New 
Brunswick Scientific).  
2.2.2 Plasmid preparation 
Preparation of plasmid DNA from transformed and cultured bacteria was performed 
using GeneJET Plasmid Miniprep Kit (Thermo Fisher Scientific), JETSTAR 2.0 Plasmid 
Midiprep Kit (Genomed) or JETSTAR 2.0 Plasmid Maxiprep Kit (Genomed) according to 
the manufacturer’s instructions. Accordingly, 5 ml, 50 ml or 250 ml LB medium (1 % 
(w/v) tryptone, 0.5 % (w/v) yeast extract, 1 % (w/v) NaCl in H2O, pH 7.0; provided by 
Medienküche Paul-Ehrlich-Institut) supplemented with the corresponding antibiotic 
(100 mg/l ampicillin or 35 mg/l kanamycin) were inoculated with a single bacteria 
clone and incubated with constant shaking (180 rpm) either over night at 37°C, 
overnight at 30°C or for three days at 25°C in a bacteria incubator (Innova 4200, New 
Brunswick Scientific). Alternatively, NucleBond® Xtra Midi Kit (Macherey-Nagel) was 
used and bacterial cells were grown in 200 ml LB-Medium supplemented with the 
appropriate antibiotics. Bacteria were harvested by centrifugation at 4,566 xg for 10 min 
(Multifuge 3S-R, Heraeus) (Miniprep, Midiprep) or at 6,000 rpm for 15 min (Sorvall® RC 
26 plus, Rotor: Sorvall® SLA-1500) (Maxiprep) and the resulting pellet was used for 
plasmid DNA purification. The extracted DNA was eluted or resuspended in Tris-EDTA 
buffer (TE-buffer) and concentration of extracted DNA was determined photometrically 
(NanoDropTM 2000c, Thermo Fisher Scientifc). Purified plasmid DNA was analyzed by 
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restriction endonuclease digestion (2.2.3) and subsequent agarose gel electrophoresis 
(2.2.4).  
2.2.3 Restriction of DNA 
Analytical and preparative DNA digestions were performed using restriction 
endonucleases from New England Biolabs according to the manufacturer’s instructions. 
Generally, for analytical DNA digestions 1 µg DNA was mixed with 3-5 U of the 
corresponding enzyme and incubated under the recommended buffer conditions and 
temperature (standard 37°C) for around 2-4 h in a thermomixer (Eppendorf). 
Preparative DNA digestions were performed using 3-5 µg DNA mixed with 10-20 U 
enzyme as well as with the recommended buffer and incubated for 4-16 h at the 
recommended temperature in a thermomixer (Eppendorf). Restriction samples were 
analyzed by agarose gel electrophoresis (2.2.4) and if required, respective DNA 
fragments were further purified by GeneJET Gel Extraction Kit (Thermo Fisher 
Scientific).  
2.2.4 Agarose gel electrophoresis 
Analytical and preparative plasmid DNA digestions were analyzed by agarose gel 
electrophoresis that separates DNA fragments according to their size. Generally, 1 % 
(w/v) DNA agarose gels were used for analyses. For the preparation of the agarose gels, 
the required amount of agarose powder was dissolved in TAE buffer by heating in a 
microwave prior to casting the solution into a tray for polymerization. For visualization 
of DNA, either ethidium bromide or Midori Green was used. When using ethidium 
bromide, 50 µg/ml were added to the liquid agarose gel solution and DNA samples were 
mixed with 6x DNA loading buffer (New England Biolabs) prior to loading into the gel 
pockets of the polymerized agarose gel. When using the Midori Green technology, DNA 
samples were mixed with Midori Green Direct Loading dye (Nippon Genetics) according 
to the manufacturer’s instructions prior to loading into the gel pockets. Electrophoresis 
was performed at 70-120 V in a Wide Mini-Sub® Cell GT chamber (Bio-Rad) and as 
reference the 2-log DNA ladder (New England Biolabs) was used. Separated DNA 
fragments were analyzed under ultraviolet light for ethidium bromide or blue/green 
LED light for Midori Green in a gel documentation imager (Intas). 
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If required, gel pieces containing DNA fragments with the desired size were excised from 
agarose gels and purified using the GeneJET Gel Extraction Kit (Thermo Fisher 
Scientific) according to manufacturer’s instructions. 
2.2.5 Dephosphorylation and ligation of DNA 
In case linearized backbone DNA with two compatible ends was used for ligation, re-
ligation was prevented by dephosphorylation of the 5’-ends using the antarctic 
phosphatase (New England Biolabs). For this, approximately 300 ng linearized 
backbone DNA was mixed with 5 U antarctic phosphatase, 3 µl of the corresponding 
antarctic phosphatase buffer and the reaction mix was filled up to 30 µl with H2O. The 
reaction was incubated for 30 min at 37°C followed by 5 min enzyme inactivation at 
65°C.  
DNA ligation was performed using the Rapid DNA Ligation Kit (Thermo Fisher Scientific) 
according to the manufacturer’s protocol. Briefly, 50 ng of linearized backbone DNA and 
a three-fold molar excess of insert DNA were mixed with 4 µl rapid ligation buffer, 5 U 
T4 ligase and with H2O to a final volume of 20 µl. The ligation sample was mixed, 
incubated for at least 5 min at 22°C and 5 µl were used for transformation (2.2.1).  
2.2.6 Polymerase chain reaction 
Polymerase chain reaction (PCR) was used for the specific amplification of DNA 
sequences using specific oligonucleotide primers (Table 6). When required for cloning, 
DNA primers additionally contained the desired endonuclease restriction sites. A typical 
PCR reaction consists of a series of temperature changes allowing the initial 
denaturation of DNA, the annealing of the primers to the complementary DNA strand 
and finally the DNA elongation by the DNA polymerase. Annealing temperatures and 
elongation times were adjusted to the primer pair (Table 6) and the DNA length. 
Amplification of DNA sequences for cloning was performed using the KOD Hot Start DNA 
Polymerase (Merck Millipore) according to the manufacturer’s instructions. The 
reaction mix was prepared as followings:  
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Table 10: Standard reaction set up for PCR 
Template DNA 10 ng 
10x Buffer for KOD Hot Start DNA polymerase 5 µl 
MgSO4 1.5 mM 
dNTPs 0.2 mM 
Sense (5’) Primer 0.3 µM 
Antisense (3’) Primer 0.3 µM 
KOD Hot Start DNA Polymerase 0.02 U/µl 
H2O Add to 50 µl 
 
The PCR reaction was performed according to the manufacturer’s instructions using a 
PCR thermal cycler (Bio-Rad). The steps 2-4 were repeated 20-40 times:  
Table 11: Cycling conditions 
Step Temperature Time 
Polymerase activation 95°C 2 min 
Denature 95°C 20 s 
Annealing Lowest Primer Tma 10 s 
Extension 70°C 10-25 s/kbb 
a melting temperature of primer 
b depending on PCR product length (<500 bp: 10 s/kb; 500-1,000 bp: 15 s/kb; 1,000-3,000 bp: 20 s/kb; >3,000 bp: 
25 s/kb) 
 
PCR products were analyzed by agarose gel electrophoresis (2.2.4) and purified using 
the GeneJET Gel Extraction Kit (Thermo Fisher Scientific) according to manufacturer’s 
instructions. 
2.2.7 DNA sequencing 
Plasmid DNA was either sequenced by Eurofins MWG Operon or GATC Biotech. Samples 
were prepared according to the guidelines of the company and standard or customized 
primer sets were used for sequencing. For sequencing by Eurofins MWG Operon about 
50-100 ng/µl plasmid DNA diluted in a total volume of 15 µl H2O were used. For 
sequencing by GATC Biotech 80-100 ng/µl plasmid DNA were combined with 5 µM 
primer in a total volume of 10 µl H2O. Sequencing results were analyzed by the software 
ContigExpress in the Vector NTI Suite (Invitrogen).  
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2.2.8 Quantitative polymerase chain reaction 
Genomic titers of AAV vector preparations were determined by TaqMan®-based 
quantitative PCR (qPCR) using ITR-specific primers. The DNA isolation from AAV vector 
particles as well as the determination of the genomic titers by qPCR were routinely 
performed by the technical assistant Manuela Gallet. 
DNA isolated from AAV vectors were used as template. For this, 10 µl iodixanol density 
gradient purified vector was mixed with 190 µl PBS. Subsequently, DNA was purified 
using the DNeasy® Blood and Tissue Kit (Qiagen) according to the manual for the 
isolation of genomic DNA from cultured cells.   
To determine AAV genomic titers, the SensiFASTTM Probe No-ROX Kit (Bioline) was used 
according to manufacturer’s instructions. Briefly, 10 µl template DNA (isolated from 
AAV)/standard/control, 0.2 µM ITR2_for, 0.68 µM ITR2_rev and 0.2 µM ITR2_probe 
were mixed with the SensiFASTTM Probe No-ROX mix and the solution was filled up with 
H2O to a final volume of 25 µl. A ten-fold serial dilution of the linearized AAV transfer 
vector plasmid pscGFP-SFFV was used as standard and pure H20 served as negative 
control. Eventually, the qPCR was performed on a LightCycler® 480 Real-Time PCR 
System (Roche) applying the below described cycling conditions:  
Table 12: Cycling conditions of qPCR 
 Polymerase activation 95°C 15 min 4.4 °C/s 
x40 cycles 
 Denaturation 95°C 15 s 4.4 °C/s 
Annealing and extension 60°C 72 s 2.2 °C/s 
 Cooling 40°C 30 s 1.5°C/s 
 
2.3 Protein biochemical methods 
2.3.1 Determination of protein concentrations 
Concentrations of purified proteins were determined by the Quick StartTM Bradford 1x 
dye reagent (BioRad) according to the manufacturer’s instructions. Briefly, 5 µl of 
sample or protein standard (Quick StartTM BSA Standard Set, Bio-Rad) were mixed with 
250 µl Bradford reagent in a flat bottom microplate well. After incubation for about 
5 min at room temperature, the absorbance was measured between 580 – 610 nm on a 
microplate reader (EMax® Plus, Molecular Devices). The corresponding buffer solution 
  Material and Methods 
 
36 
 
was used as blank and the protein concentrations of the unknown samples were 
calculated with the help of a standard curve.  
Protein concentrations of organ lysates were determined using the Pierce BCA Protein 
Assay Kit (Thermo Fisher Scientific) according to the manufacturer’s instructions. 
Accordingly, 25 µl of sample or protein standard (Quick StartTM BSA Standard Set, Bio-
Rad) were pipetted into a flat bottom microplate well and mixed with 200 µl BCA 
working reagent (50:1 of A:B). The plate was covered with foil and incubated at 37°C for 
30 min. After the samples were cooled down to room temperature, the absorbance was 
measured between 540 – 590 nm on a microplate reader (EMax® Plus, Molecular 
Devices). The corresponding buffer solution was used as blank and the protein 
concentrations of the unknown samples were calculated with the help of a standard 
curve.  
2.3.2 SDS-polyacrylamide gel electrophoresis 
The sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) allows the 
separation of proteins according to their molecular weight. Purified proteins or cell 
culture supernatants of infected or transduced cells were mixed with the appropriate 
amount of SDS-loading dye (4x) and boiled at 95°C for 10 min in a thermoblock (FALC). 
Depending on the molecular weight of the analyzed proteins, samples were either 
loaded on 10 % (separation of large proteins) or on 12 % (separation of smaller 
proteins) SDS polyacrylamide gels (Table 13).  
Table 13: Composition of resolving and stacking gel. 
 Resolving Gel Stacking Gel 
 10 % 12 % 5 % 
30% acrylamide solution (Rotiphorese® Gel 30)  2.5 ml 3 ml 0.83 ml 
1 M Tris, pH 8.8 2.93 ml 2.93 ml - 
1 M Tris, pH 6.8 - - 0.63 ml 
50 % glycerine 0.65 ml 0.65 ml  
10 % SDS 85 µl 85 µl 50 µl 
H2O 1.34 ml 0.83 ml 3.5 ml 
TEMED 6.25 µl 6.25 µl 6.25 µl 
20 % APS 20 µl 20 µl 20 µl 
  
The PageRulerTM Plus Prestained Protein Ladder (Thermo Fisher Scientific) served as 
protein standard. Samples were separated using Mini-Protean® 3 cell chamber (Bio-
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Rad) filled with SDS running buffer. Separation was carried out at 70 V until samples 
entered the resolving gel and thereafter at 120 V until the desired protein separation 
was achieved. Afterwards SDS polyacrylamide gels were either subjected to Coomassie 
staining (2.3.3) or Western blot analysis (2.3.4). 
2.3.3 Coomassie staining of SDS-PAGE 
After SDS-PAGE, proteins in the gels were visualized by the PageBlueTM Protein Staining 
Solution (Thermo Fisher Scientific). For this purpose, the SDS polyacrylamide gel was 
first washed for 10 min with 10 % acetic acid for fixation. Then, the gels were washed 
twice with H2O for 10 min and stained with the PageBlueTM Protein Staining Solution 
(Thermo Fisher Scientific) for at least 2 h at room temperature while shaking. Finally, 
the gels were destained by several wash steps with H2O until the protein bands became 
visible.  
2.3.4 Western blot analysis 
After separation by SDS-PAGE, proteins were transferred to a nitrocellulose membrane 
and analyzed by immunostaining. Whatman filter papers (GE Healthcare), the 
nitrocellulose membrane (Amersham Protran 0.2 µm nitrocelluose blotting membrane, 
GE Healthcare) and the SDS polyacrylamide gel were soaked in transfer buffer and 
layered into the Trans-Blot® SD semi-dry transfer cell (Bio-Rad). Generally, proteins 
were blotted to the membrane using 180 mA at max. 20 V for 60 – 90 min for one gel. 
After blotting, the membrane was blocked with an appropriate blocking buffer (Table 
14) on an orbital shaker for at least 1 h at room temperature. Thereafter, membranes 
were incubated with primary antibody diluted in blocking buffer (Table 14) over night 
at 4°C at constant shaking. Then, the membranes were washed five times with TBS-T. If 
the primary antibody was not labeled with the horseradish peroxidase (HRP), 
membranes were incubated with the respective secondary antibody conjugated to HRP 
on an orbital shaker for at least 1 h at room temperature and thereafter, were again 
washed five times with TBS-T. Proteins were detected with PierceTM ECL Plus Western 
blotting substrate (Thermo Fisher Scientific) according to manufacturer’s instructions 
and luminescence was detected using Super RX x-ray films (Fujifilm) and a x-ray film 
developer (Curix 60, AGFA).  
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Table 14: Antibodies and corresponding blocking buffer used for Western blot analysis. 
 Antibody Dilution Blocking puffer 
p
ri
m
ar
y 
an
ti
b
od
ie
s 
α-Myc-tag (Myc.A7) mouse 1:1,000 5 % (v/v) horse serum in TBS-T 
α-human IgG, 
HRP-conjugated 
goat 1:10,000 2 % (w/v) milk powder in TBS-T 
α-human Flt3L rabbit 1:500 5 % (w/v) milk powder in TBS-T 
α-murine GM-CSF rabbit 1:500 5 % (w/v) milk powder in TBS-T 
α-HA-tag (16B12) mouse 1:1,000 5 % (v/v) horse serum in TBS-T 
se
co
n
d
ar
y 
an
ti
b
od
ie
s α-rabbit, 
HRP-conjugated 
goat 1:2,000 
Same blocking buffer as used for the 
primary antibody 
α-mouse, 
HRP-conjugated 
rabbit 1:2,000 
Same blocking buffer as used for the 
primary antibody 
 
2.3.5 Enzyme-linked immunosorbent assay  
Enzyme-linked immunosorbent assays (ELISA) were used for the quantification of GM-
CSF and Flt3L in cell culture supernatants of srVSV-infected cells, for the quantification 
of intact AAV capsids in vector preparations and for the quantification of immune 
checkpoint inhibitors in the cell culture supernatants of AAV-transduced cells as well as 
in organ lysates.  
For quantification of GM-CSF in cell culture supernatants, the Mouse GM-CSF Elisa Kit 
(Thermo Fisher Scientific) and for the quantification of Flt3L in cell culture supernatant 
the Flt3 Ligand Human ELISA Kit (abcam) were used according to the manufacturer’s 
instructions. Cell culture supernatants of cells infected with srVSV(GFP/DsRed) were 
used as blank.  
For quantification of intact AAV capsids, the AAV2 Titration ELISA (Progen) was used 
according to the manufacturer’s instructions. The dilution buffer was used as blank.  
2.3.5.1 Immune checkpoint inhibitor ELISA: Approach 1 
Adapted according to Engeland et al. (Engeland et al, 2014). 96-well immunoplates 
(Nunc MaxiSorpTM, Thermo Fisher Scientific) were coated with 200 ng recombinant 
PD-1 or PD-L1 (Life Technologies) in a total volume of 100 µl PBS for 2 h at room 
temperature. Thereafter, the plates were washed twice with 200 µl PBS and then, 
blocked with 200 µl ELISA blocking buffer for 2-3 h at room temperature. After 
incubation, plates were washed three times with 200 µl PBS. Sample dilutions were 
prepared using PBS as diluent and 100 µl of each sample were added per well. The 
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plates were covered with foil and incubated overnight at 4°C. On the next day, the plates 
were washed five times with 300 µl ELISA washing buffer and subsequently, were 
incubated with 100 µl of biotin-conjugated anti-HA-tag antibody (clone 3F10; Roche) 
diluted 1:500 in ELISA blocking buffer. The plates were incubated for 1 h at room 
temperature. After the plates were washed five times with 300 µl ELISA washing buffer, 
100 µl HRP-streptavidin (Jackson Immuno Research, Dianova) diluted 1:500 in blocking 
buffer were added per well and incubated for 1 h at room temperature. During all 
incubation steps by now, the plates were slowly shaken on an orbital shaker. Finally, 
plates were washed again five times with 300 µl ELISA washing buffer and 100 µl 1-
StepTM Ultra TMB substrate (Thermo Fisher Scientific) were added. After 20 min of 
incubation, the reaction was stopped by adding 100 µl 1 N H2SO4 and absorbance was 
measured at 450 nm within 30 min using a microplate reader (EMax® Plus, Molecular 
Devices). 
2.3.5.2 Immune checkpoint inhibitor ELISA: Approach 2 
96-well immunoplates (Nunc MaxiSorpTM, Thermo Fisher Scientific) were coated with 
250 ng α-HA-tag antibody (clone 16B12; abcam) in a total volume of 50 µl PBS for 2-3 h 
at room temperature. Thereafter, the plates were washed twice with 200 µl PBS and 
then, blocked with 200 µl ELISA blocking buffer for 2-3 h at room temperature. After 
incubation, plates were washed three times with 200 µl PBS. Unless otherwise stated, 
serial sample dilutions were prepared using PBS as diluent and 100 µl sample was 
applied per well. The plates were covered with foil and incubated overnight at 4°C. On 
the next day, plates were washed five times with 300 µl ELISA washing buffer and 100 µl 
of α-human-IgG conjugated with HRP (Sigma-Aldrich) diluted 1:10,000 in ELISA 
blocking buffer were added per well. After 3 h of incubation, the plates were again 
washed five times with 300 µl ELISA washing buffer. During all aforementioned 
incubation steps, plates were slowly shaken on an orbital shaker. Finally, 100 µl 1-
StepTM Ultra TMB substrate (Thermo Fisher Scientific) were added per well and 
reactions were stopped with 100 µl 1 N H2SO4 after the desired color had been 
developed. Within 30 min absorbance was measured at 450 nm using a microplate 
reader (EMax® Plus, Molecular Devices). 
The respective blank was subtracted prior quantification. For the mice samples the 
organ lysates of PBS-treated mice were used as blank. Protein concentrations were 
calculated using αPD-1 and αPD-L1 protein standards (2.4.4, 2.3.6).   
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2.3.6 Protein affinity tag purification from cell culture supernatant  
Recombinant αPD-1 and αPD-L1 were purified out of cell culture supernatants of 
transfected HEK-293T cells by Protein A affinity purification. For this purpose, 20 ml 
sterile-filtered cell culture supernatant (2.4.4) were mixed with 10 µl Protein A beads 
(rec-Protein A-Sepharose® 4B Conjugate, Invitrogen) and the solution was incubated 
overnight at 4°C on a roller bottle shaker. After equilibration of an empty gravity-flow 
Econo-Pac® chromatography column (Bio-Rad) with 10 column volumes (CV) of PBS, 
protein-bound Protein A beads were loaded and washed with 20 CV of PBS. Proteins 
were eluted by incubation of the beads with 5 ml acidic elution buffer (pH 2.7) and the 
protein was collected in 1 ml fractions. The acidic pH was neutralized by elution into 
500 µl (1/10 of elution volume) collection puffer. Protein A beads were regenerated by 
adding 10 CV of PBS and stored in storage buffer at 4°C. All purification steps were 
performed at 4°C and with ice cold buffer. 
Purified proteins were concentrated via Amicon® Ultra centrifugal filter devices (Merck 
Millipore). Amicons were equilibrated with 0.1 % Pluronic® in PBS, the elution fractions 
of the Protein A purification were supplemented with Pluronic® to a final concentration 
of 0.001 % (v/v) and were concentrated with 4,000 xg at 4°C (Multifuge 3S-R, Heraeus). 
Then, the concentrated protein solution was washed several times with PBS to exchange 
the buffer. For long-term storage at -80°C, protein solution was supplemented with 
protease inhibitor cocktail (Roche) and 5 % (v/v) glycerol. The protein concentration 
was determined via Bradford Assay (2.3.1).  
2.4 Cell culture and virological methods 
2.4.1 Cultivation of eukaryotic cell lines 
Cells were cultured in the appropriate culture medium in a cell culture incubator at 
37°C, 5 % CO2 and 90 % humidity (Hereaus BBD 6220, Thermo Fisher Scientific). HEK-
293T, BHK-21, MC38, B16-F10, E0771 and HT1080 cells were cultivated in Dulbecco’s 
Modified Eagles Medium (DMEM) supplemented with 10 % fetal calf serum (FCS) and 
2 mM L-glutamine (thereafter abbreviated with DMEMcomplete). HEK-293NPeGFPL cells 
were grown in DMEMcomplete supplemented with 2 mg/ml Geneticin® and MC38-ek-
Her2/neu cells were grown in DMEMcomplete supplemented with 0.75 mg/ml Geneticin®. 
BHK21-GP, HT1080-CD28 and HT1080-PD-1 cells were cultivated in DMEMcomplete 
supplemented with 10 µg/ml puromycin. Raji, Molt 4.8 and 4T1 cells were cultivated in 
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Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10 % FCS 
and 2 mM L-glutamine (abbreviated with RPMIcomplete). RENCA-Her2/neu cells were 
grown in RPMIcomplete either supplemented with 0.48 mg/ml Geneticin® or with 
0.48 mg/ml Geneticin® and 0.25 mg/ml Zeocin.  
Cells were passaged twice a week under sterile conditions using a laminar flow cabinet 
(SterilGARD® III Advance, The Baker Company). For this, the medium was aspirated 
from adherent cells, cells were washed with PBS and then detached with 0.25 % trypsin 
solution (PBS/1 mM EDTA). Fresh medium was added, cells were resuspended and an 
appropriate fraction of detached cells were seeded into a new cell culture flask with 
fresh medium. Suspension cells were passaged by resuspending the cells and then an 
appropriate fraction of cells were directly transferred into a new cell culture flask with 
fresh medium. Morphology and growth characteristics of the cells were monitored by 
microscopy (AxiovertTM 25, Carl Zeiss). Furthermore, cell lines were checked for 
mycoplasma contamination by PCR on a regular basis.  
2.4.2 Freezing and thawing of cells 
After the cells were detached and resuspended in an appropriate amount of medium 
(2.4.1), they were pelleted at 140 xg for 4 min at 4°C (HeraeusTM MultifugeTM X3R, 
Thermo Fisher Scientific). The pellet was resuspended in ice cold freezing medium, 
aliquoted into cryotubes and frozen at -80°C using a Mr.FrostyTM Freezing Container 
(Nalgene). On the next day, cells were transferred to the gas phase of a liquid nitrogen 
tank and stored at -155°C. 
Frozen cells were thawed in a water bath at 37°C. Immediately, thawed cells were 
transferred into pre-warmed medium in a new cell culture flask. On the next day, cell 
culture medium was exchanged. 
2.4.3 Transfection of BHK-21 cells  
For transfection, 1x106 BHK-21 cells were seeded in DMEMcomplete culture medium per 
well of a 6-well plate. On the next day, cells were transfected using LipofectamineTM LTX 
Reagent with PLUSTM Reagent (Invitrogen). For this, 5 µg DNA (pSecTag2B-Her2/neu, 
pSecTag2B-CTLA-4-Her2/neu, phuFc-B7-1 or pCG1) were combined with 250 µl 
OptiMEM® and 5 µl PLUSTM reagent. Furthermore, 10 µl LipofectamineTM LTX Reagent 
were combined with 250 µl OptiMEM®. Both solutions were mixed by inverting the 
tubes and incubated for 5 min at room temperature. Subsequently, solutions were 
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combined and mixed again by inverting the tube. The transfection mix was incubated for 
20 min at room temperature. During the incubation step, cells were washed three times 
with PBS. After incubation, the transfection mix was added to the cells and incubated for 
5 min at 37°C. Then, 1.5 ml DMEMcomplete was added. On the next day, cells were washed 
three times with PBS and 2 ml serum-free VP-SFM medium was added. VP-SFM was 
used instead of DMEMcomplete medium to avoid the detection of ‘FCS clouds’ in the 
Western blot analysis. Two days after transfection, cell culture supernatants were 
harvested, filtrated through a 0.45 µm pore size filter (Minisart® Syringe Filters, 
Sartorius) and stored at -80°C until needed for analysis.  
2.4.4 Production of recombinant αPD-1 and αPD-L1 
For the production of recombinant αPD-1 and αPD-L1, both proteins were transiently 
expressed in HEK-293T cells. For transfection, 1.8x107 HEK-293T cells were seeded in a 
T175 cell culture flask. On the next day, the cell culture medium was exchanged with 
12 ml DMEM supplemented with 15 % FCS and 2 mM L-glutamine. Then, 35 µg DNA 
(pCG-sa-PD-1 or pCG-sa-PD-L1) and 140 µl PEI were each diluted with 2.3 ml DMEM 
without additives (DMEMw/o) and vortexed. Both solutions were combined, vortexed 
thoroughly and incubated for 20 min at room temperature. After incubation, the 
PEI/DNA mix was added to the cells and about 5 to 7 h later, the medium was replaced 
with DMEM supplemented with 5 % Panexin and 2 mM L-glutamine medium. In the 
following three days after transfection, cell culture supernatants were collected. For this, 
cell culture supernatants were harvested, filtrated through a 0.45 µm pore size filter 
(Minisart® Syringe Filters, Sartorius) and supplemented with sodium acid to a final 
concentration of 0.01 % (v/v). Supernatants were stored at 4°C until used for protein 
affinity tag purification (2.3.6).  
2.4.5 VSV rescue 
A reverse genetic system was used for the de novo generation of VSV vectors from cDNA 
(Whelan et al, 1995; Lawson et al, 1995). On the day prior to transfection, 1x106 BHK-21 
cells were seeded per well of a 6-well plate. Then, the cells were washed with PBS, 
infected with MVA-T7pol at a multiplicity of infection (MOI) of about 0.5 in 200 µl 
DMEMcomplete for 1 h at room temperature and every 10 min plate was mildly rocked. 
Meanwhile, the transfection mix was prepared as follows:  
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Table 15: Transfection mix for VSV rescue 
 Rescue of VSVΔG Rescue of VSVΔL 
OptiMEM® 100 µl 100 µl 
pVSVΔG or pVSVΔL to be rescued 2 µg 2 µg 
pIRES-N 1 µg 1 µg 
pIRES-P 0.8 µg 0.8 µg 
pIRES-L 0.4 µg 0.4 µg 
pIRES-G 0.25 µg - 
FuGENE® HD 18 µl 18 µl 
Plasmid amounts and transfection reagents were calculated for the transfection of one well of a 6-well plate (culture 
area 9.6 cm2) 
The transfection mix was mixed gently by inverting the tube several times and incubated 
for 20 min at room temperature. The MVA-T7pol inoculum was removed from the cells, 
the cells were washed with PBS and 2 ml DMEM supplemented with 5 % FCS and 2 mM 
L-glutamine were added per well. Subsequently, the transfection mix was added drop-
wise and the cells were incubated at 37°C in a cell culture incubator. Three days after 
transfection, the supernatant was collected and filtered through 0.2 µm pore size filter 
(Minisart® Syringe Filters, Sartorius) to remove MVA-T7pol virions as well as cell debris. 
Subsequently, the supernatant was added to BHK21-GP cells (1x106 cells/well of a 6-
well plate) for the rescue of VSVΔG vectors or to HEK-293NPeGFPL cells (2x106 
cells/well of a 6-well plate) for the rescue of VSVΔL vectors. After three days, cells were 
inspected for cytopathic effects, the supernatants of wells exhibiting cytopathic-effect-
positive cells were filtered through 0.2 µm pore size filters (Minisart® Syringe Filters, 
Sartorius) and subsequently stored at -80°C until plaque purification.  
2.4.6 Plaque purification of VSV and preparation of virus stocks  
After successful VSV rescue, a clonal vector population was generated by plaque 
purification. Additionally, any possible remaining MVA-T7pol contaminations were 
removed by this purification step. For the plaque purification of VSVΔG vectors, BHK21-
GP cells and for the plaque purification of VSVΔL vectors, HEK-293NPeGFPL cells were 
used. Cells were seeded either in 6-well or 12-well plates with a cell number leading to 
confluent cell monolayers on the day of infection (generally one day prior to infection: 
3x105 BHK21-GP cells/well of a 6-well plate; 8x105–1.5x106 HEK-293NPeGFPL 
cells/well of a 12-well plate). Cells were infected with different dilutions of rescued VSV 
vectors and incubated for 1 h at 37°C. Meanwhile, 1.8 % plaque agarose was melt and 
combined 1:1 with pre-warmed DMEMcomplete medium. After incubation, the inoculum 
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was removed and the cells were washed with pure DMEMcomplete medium or PBS. The 
melted DMEM/plaque agarose mixture was added carefully to the cells (1 ml/well for 
12-well plate; 2 ml/well for 6-well plate) and allowed to gel. After an incubation time of 
one to two days at 37°C, single plaques were microscopically visible. Eventually, a single 
plaque was isolated with a pipette tip and used to inoculate fresh BHK21-GP or HEK-
293NPeGFPL cells seeded in a 6-well plate. Infected cells were incubated for one up to 
two days at 37°C until cytopathic effects were fully visible. Then, cell culture 
supernatants were harvested, filtrated through a 0.45 µm pore size filter (Minisart® 
Syringe Filters, Sartorius), aliquoted and stored at -80°C.  
Plaque-purified VSV vectors were titrated (2.4.7) and used for the large-scale production 
of ‘P2’ VSV vector stocks. Generally, for amplification of VSVΔG vectors 6x106 BHK21-GP 
cells and for amplification of VSVΔL vectors 1.5x107 HEK-293NPeGFPL cells were 
seeded in a T75 cell culture flask one day prior to infection. Cells were infected with a 
low MOI ranging between 0.01 and 0.03 in 8 ml DMEMcomplete medium and were 
incubated for one up to two days at 37°C until cytopathic effects were visible. 
Eventually, cell culture supernatants were filtrated through 0.45 µm pore size filter 
(Minisart® Syringe Filters, Sartorius), aliquoted and stored at -80°C. After the TCID50 of 
the VSV stocks were determined, they were subjected to co-plaque purification.   
In order to generate srVSV vector preparations that are composed of VSVΔL and VSVΔG 
vectors a co-plaque purification was performed. For this, 1.5x105 BHK-21 or 4x105 BHK-
21 cells were seeded in a well of a 12-well plate or a 6-well plate, respectively. The next 
day, cells were co-infected with serial dilutions of VSVΔG and VSVΔL vectors (generally 
MOI ranged between 0.0001 and 0.1). Cells were overlaid with plaque agarose and a 
single clone was picked as described before for the plaque purification of VSV vectors. 
Eventually, a single clone was isolated and amplified on fresh BHK-21 cells seeded in a 
6-well plate. Cells were incubated for at least one day at 37°C until cytopathic effects 
were microscopically visible. Subsequently, cell culture supernatants were collected, 
filtrated through 0.45 µm pore size filters (Minisart® Syringe Filters, Sartorius), 
aliquoted and stored at -80°C.  
Plaque-purified srVSV preparations were titrated (2.4.7) and used for the large-scale 
production of ‘P2’ vector stocks. Generally, 6x106 cells were seeded in a T75 cell culture 
flask one day prior to infection and were infected with plaque-purified srVSV at a low 
MOI ranging between 0.01 and 0.03 in 8 ml DMEMcomplete. When cytopathic effects were 
visible, generally on the next day, cell culture supernatants were collected, filtrated 
through 0.45 µm pore size filter (Minisart® Syringe Filters, Sartorius), aliquoted and 
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stored at -80°C. Generated srVSV stocks were subjected to virus titer determination 
(2.4.7).  
2.4.7 Determination of the 50 % tissue culture infective dose 
Viral titers of VSV vectors and of srVSV preparations were determined using the 50 % 
tissue culture infective dose (TCID50) method according to Kärber (Kärber, 1931). For 
titration of VSVΔG vectors, 5x103 BHK21-GP cells, of VSVΔL vectors 1x104 HEK-
293NPeGFPL cells and of srVSV 5x103 BHK-21 cells were seeded per well of a 96-well 
plate. On the next day, a 10-fold serial dilution of the respective vector stock was 
prepared using DMEMcomplete medium as diluent. Dilutions used for titration ranged 
between 10-2–10-9. Finally, 20 µl of each dilution was added to the cells in eight 
replicates. After three days of incubation at 37°C, the titration was analyzed by 
microscopy. Infection was detected by cytopathic effects or expression of marker 
proteins such as GFP or DsRed. Finally, the titer was calculated according to following 
equation:  
/	 =  ∗ 10
((. 
x: extrapolation factor arising from the volume of virus dilution used per well 
A: value of the last dilution step where all eight wells showed cytopathic effects 
B: summation of the proportion of positive wells including both the last 100 % up to the first 0 % 
infectious dilution 
2.4.8 Infection 
For infection, 106 cells were seeded per well of a 6-well plate and generally cells were 
infected with virus at a MOI of 0.1. On the next day, cell culture supernatant was 
harvested, filtrated through 0.45 µm pore size filters (Minisart® Syringe Filters, 
Sartorius) and stored at 4°C or -80°C until used for ELISA (2.3.5), Western blot (2.3.4) or 
flow cytometry analysis (2.4.13). If required, medium was replaced with serum free VP-
SFM medium in order to prevent the detection of ‘FCS clouds’ in the Western blot 
analysis.  
Expression of the marker proteins DsRed and GFP was analyzed by microcopy using the 
fluorescence microscope Axiovert200 (Carl Zeiss). Pictures were taken with the 
fluorescence microscope Axiovert200, the AxioCam HRc (Carl Zeiss) and the software 
AxioVision 4.8 (Carl Zeiss). 
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2.4.9 Cell viability assay 
Cell viability was analyzed using the WST-1 cell proliferation assay kit (Takara 
Clontech). Mouse cancer cell lines (4x103 cells/well) were seeded into 96-well plates 
and stimulated with different concentrations of mouse IFNα for 24 h. Two days after 
infection, cell viability was analyzed by WST-1 assay. For this, 10 µl WST-1 substrate 
was added per well and incubated for 4 h at 37°C. Eventually, absorption was measured 
between 420-480 nm using a multiplate reader. Pure medium served as blank and cell 
viability was normalized to uninfected control cells that were stimulated with the same 
IFNα concentrations. The type I IFN sensitivity assay was adapted according to Liu et al. 
(Liu et al, 2013).   
2.4.10 AAV vector production and concentration 
AAV vectors were generated by an adenovirus-helper free, four plasmid transfection 
system using PEI as transfection reagent (Xiao et al, 1998; Münch et al, 2013). The AAV 
transfer vector plasmid (pscGFP-SFFV, pscluc-SFFV, pscαPD-1-SFFV, pscαPD-L1-SFFV or 
pscIgG-Fc-SFFV), pRC and pXX6-80 were co-transfected into HEK-293T cells in a ratio of 
1:1:3 for the production of AAV2 vectors. For the production of Her2-AAV vectors, the 
AAV transfer vector plasmid, pRC-VP2KO-HSPGmut, pHer2/neuD9.29-HisXa-VP2KO and 
pXX6-80 were co-transfected in a ratio of 1:1:1:3 into HEK-293T cells. 
One day prior to transfection, 1.8-2x107 HEK-293T cells were seeded in a 15 cm cell 
culture dish. On the next day, medium was replaced with 14 ml DMEM supplemented 
with 15 % FCS and 2 mM L-glutamine. Subsequently, the transfection mix was prepared 
as follows:  
Table 16: Transfection mix for AAV production 
 AAV2 Her2-AAV 
DMEMw/o 1,958.4 µl 1,958.4 µl 
AAV transfer vector 5.91 µg 4.93 µg 
pXX6-80 17.74 µg 14.78 µg 
pRC 5.91 µg - 
pRC-VP2KO-HSPGmut - 4.93 µg 
pHer2/neuD9.29-HisXa-VP2KO - 4.93 µg 
Plasmid amounts are calculated for the transfection of one 15 cm cell culture dish (culture area 148 cm2) 
Additionally, 118 µl PEI solution was mixed with 1,958.4 µl DMEMw/o. Each solution was 
mixed shortly by vortexing. Subsequently, both solutions were combined and again 
vortexed thoroughly. After an incubation of 20 min at room temperature, the 
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transfection mix was added to the cells. On the next morning, the medium was 
exchanged with fresh DMEMcomplete medium.  
Two days after transfection, cells were scraped off the cell culture dish and pelleted for 
7 min at 218 xg, 4°C (MultifugeTM 3-S-R, Hereaus). The supernatant was discarded and 
the pellet was resuspended in 500 µl AAV lysis buffer per 15 cm cell culture dish. 
Subsequently, the lysate was subjected to three freeze/thaw cycles in liquid nitrogen 
and a 37°C water bath. After benzonase digestion (50 U/ml) for 30 min at 37°C (rocking 
every 10 min), cell debris were pelleted for 20 min at 3,700 xg and 4°C (MultifugeTM 3-S-
R, Hereaus). Vector particle containing supernatant was diluted in PBS M/K and 
transferred to Quick-Seal® Ultra-ClearTM ultracentrifugation tubes (1x3½ in.) (Beckman 
Coulter). For purification by density gradient centrifugation, the supernatant was under 
layered with 9 ml 15 %, 6 ml 25 %, 5 ml 40 % and up to 7.5 ml 60 % iodixanol solution 
(Table 17).  
Table 17: Composition of iodixanol solutions 
 15% iodixanol 25% iodixanol 40% iodixanol 60% iodixanol 
PBS (10x) 1 ml 0.8 ml 0.8 ml - 
MgCl2 (1 M) 10 µl 8 µl 8 µl 8 µl 
KCl (1 M) 25 µl 20 µl 20 µl 20 µl 
NaCl (5 M) 2 ml - - - 
Phenolred (0.5%) 15 µl 12 µl - 12 µl 
H2O  4.45 ml 3.8 ml 1.8 ml - 
OptiPrepTM (60%) 2.5 ml 3.3 ml 5.33 ml 8 ml 
 
The gradient was centrifuged for 2 h in a 70 Ti rotor (Beckman-Coulter) at 63,000 rpm 
and 4°C (OptimaTML-70k, Beckman Coulter) and AAV vector particles were recovered 
from the 40 % iodixanol fraction, aliquoted and stored at -80°C. 
2.4.11 Transduction 
In order to analyze AAV-mediated transgene expression, 8x103 or 8-9x104 RENCA-
Her2/neu cells were seeded per well of a 96-well plate or of a 12-well plate, 
respectively. On the next day, cells were transduced with AAV2 or Her2-AAV at genome 
containing particles per cell (GOI) ranging between 450,000 and 500,000. The next day, 
the medium was exchanged with fresh RPMIcomplete medium. For Western blot analysis, 
cells were washed three times with PBS and serum-free VP-SFM medium instead of 
RPMIcomplete medium was added to the cells in order to avoid the detection of ‘FCS 
clouds’. Four days after transduction, cell culture supernatants were harvested and 
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centrifuged to remove cell debris. Cleared supernatants were stored either at 4°C 
or -80°C until used for Western blot (2.3.4), ELISA (2.3.5.1; 2.3.5.2) or flow cytometry 
analysis (2.4.13). 
2.4.12 Generation of stably transgenic cell lines 
Cell lines stably expressing a transgene were generated by transduction with lentiviral 
vectors (LV) encoding the transgene and an IRES-driven puromycin resistance gene.  
LVs pseudotyped with the VSV glycoprotein were generated in a 6-well scale format. For 
this, 1.8x106 HEK-293T cells were seeded per well of a 6-well plate and on the following 
day were transfected with PEI as transfection reagent. For this, 3.4 µg pMDG-2, 6.3 µg 
pCMVΔR8.91 and 0.96 µg LV transfer vector plasmid (pS-CD28-IP-W; pS-mPD1-IP-W) 
were combined with 130 µl DMEMw/o. Additionally, 8 µl PEI solution was combined with 
120 µl DMEMw/o. Each solution was mixed by vortexing. Then, both solutions were 
combined, mixed again by vortexing and incubated for 20 min at room temperature. 
Meanwhile, medium of the cells were replaced with 1 ml DMEM supplemented with 
15 % FCS and 2 mM L-glutamine. After incubation, the transfection mix was added to the 
cells. On the next morning, medium was replaced with 2 ml fresh DMEMcomplete. Two 
days after transfection, vector particle containing supernatant was collected, filtrated 
through 0.45 µm pore size filter (Minisart® Syringe Filters, Sartorius) and used for the 
transduction of HT1080 cells. For this, 5-6x104 HT1080 cells were seeded per well of a 
12-well plate and transduced with different volumes of LV containing supernatant (25 µl 
up to 500 µl). Three days after transduction, transduced cells were selected by the 
addition of puromycin (10 µg/ml) and cultures were expanded to establish a stably 
transgenic cell line.  
2.4.13 Flow cytometry 
Flow cytometry analyses were used to examine cell surface expression of proteins and 
to investigate specific binding of srVSV- or AAV-encoded transgenes. 
To investigate cell surface expression of stably transgenic cell lines, adherent cells were 
detached (2.4.1), resuspended and subjected to antibody staining. For this, 5x104–1x105 
cells per sample were washed twice with 500 µl FACS washing buffer (314 xg, 4 min, 
4°C) (HereausTM MultifugeTM X3R, Thermo Fisher Scientific) and stained with 
fluorophore-labelled primary antibody (Table 5). Subsequently, cells were washed again 
twice and fixed with 200 µl FACS fix.  
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To investigate binding of srVSV- or AAV-encoded proteins to their target, 5x104–1x105 
cells were washed twice as described above and were then incubated with 400–600 µl 
cell culture supernatant or with 4-5 µg recombinant protein for 30-60 min at 4°C. 
Subsequently, cells were pelleted, the supernatant was discarded and cells were washed 
twice as described above. Then, binding was detected with an appropriate fluorophore-
labelled secondary antibody. Eventually, cells were washed again twice and were finally 
fixed with 200 µl FACS fix.  
For flow cytometry analyses of mouse splenocytes, 3x105 stimulated cells (2.5.5) were 
subjected to the analysis. After washing the cells twice with 500 µl PBS (314 xg, 5 min, 
4°C) (HereausTM MultifugeTM X3R, Thermo Fisher Scientific), a live/dead staining using 
eBioscienceTM Fixable Viability Dye eFluorTM 450 (Thermo Fisher Scientific) according to 
the manufacturer’s instructions was performed in order to exclude dead cells from the 
analysis. Prior to antibody staining, FcR blocking reagent was added to the cell 
suspensions and incubated for 10 min at 4°C. Eventually, cell surface staining or binding 
assay was performed as described above.   
Flow cytometry measurements were performed using MACSQuant® analyzer 10 
(Miltenyi Biotec) and data were analyzed with FCS ExpressTM software (DeNovo 
SoftwareTM). 
2.4.14 ELISpot  
Tumor-specific immune cells isolated from spleens of cured mice 14 days after tumor re-
challenge were analyzed by enzyme-linked immune spot assay (ELISpot) using the 
Mouse IFN gamma ELISPOT Ready-Set-Go!®-Kit (eBioscience). First, 96-well 
MultiScreen® filter plates with hydrophobic high protein binding immobilon®-P PVDF 
membrane (MultiScreen®-IP, Merck Millipore) were activated with 50 µl 70 % ethanol 
per well. After adding 200 µl H2O per well, the fluid was discarded and the plate was 
washed again twice with 200 µl H2O followed by a single washing step with 200 µl PBS. 
Further assay procedures were performed according to the manufacturer’s instructions. 
Following splenocyte isolation (2.5.5), 5x105 splenocytes were resuspended in 100 µl 
RPMI supplemented with 10 % FCS, 2 mM L-glutamine and 1 % PenStrep (RPMI+PenStrep) 
and added per well of a 96-well round bottom plate. Then, splenocytes were mixed with 
100 µl stimulants or controls that were also diluted in RPMI+PenStrep medium. Cells were 
either stimulated with γ-irradiated (60 Gy) MC38 tumor cells (two cell counts tested: 
5x104 and 1x105) or with MC38 tumor cell lysates (two cell counts tested: 8x104 or 
2.5x105). For the preparation of the MC38 tumor cell lysates, MC38 cells were detached 
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with PBS supplemented with 1 mM EDTA, resuspended in RPMI+PenStrep medium and 
lysed via five freeze/thaw cycles using liquid nitrogen and a 55°C water bath. Cell debris 
were pelleted and supernatant was used for ELISpot assay. Stimulation of splenocytes 
with 10 µg/ml ConA served as positive control and plain medium as negative control. 
The mixtures of stimulants and splenocytes were transferred to the blocked 
MultiScreen®-IP filter plates and incubated for 36 h in a cell culture incubator at 37°C, 
5 % CO2 and 90 % humidity. IFNγ-secreting cells were detected according to 
manufacturer’s instructions and the counts were documented with an ELISpot Reader 
(Eli.Scan; software ELI. Analyse; A.EL.VIS).   
2.5 Experimental mouse work 
2.5.1 Injection of tumor cells 
Tumor cell lines were cultured and detached as described in 2.4.1. Then, cells were 
pooled, pelleted at 314 xg, 4°C for 5 min (HereausTM MultifugeTM X3R, Thermo Fisher 
Scientific) and washed with PBS. Cells were counted and resuspended in the desired 
amount of PBS. Mice were anesthetized with 2-3 % isoflurane using an anesthetic 
machine with an isoflurane vaporizer and an oxygen concentrator (indulab-vet). Prior to 
tumor implantation, aliquoted cell suspensions were briefly vortexed and 100 µl tumor 
cell suspension was subcutaneously injected using a 23 or 29 gauge needle into one 
flank of the mouse. 2x106 MC38 cells in 100 µl PBS were injected per C57BL/6 mouse 
(provided by the animal facility of the Paul-Ehrlich-Institut or purchased from Harlan 
Nederland). 5x106 RENCA-Her2/neu cells in 100 µl PBS were injected per BALB/c 
mouse (Charles River) or NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse (provided by the 
animal facility of the Paul-Ehrlich-Institut). The tumor growth was monitored by digital 
caliper measurements and tumor size was calculated according to the volume of an 
ellipsoid by the following equation:  
 	  !"#$ = 0.4 ∗ 	 &'ℎ !"$ ∗ ()*+ℎ !"$, 
2.5.2 Injection of vector particles 
When MC38 tumors reached a specified volume, they were intratumorally injected with 
50 µl srVSV using a 30 gauge needle. For injection, mice were anesthetized with 2-3 % 
isoflurane using an anesthetic machine with an isoflurane vaporizer and an oxygen 
concentrator (indulab-vet). 
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For intravenous injection, mice were prewarmed under a heat-lamp in order to dilate 
the veins and transferred to a mouse–restrainer. 200 µl AAV vector particles were 
injected into one of the lateral tail veins using a 29 gauge needle.  
2.5.3 Blood sampling 
Mice were anesthetized with 2-3 % isoflurane using an anesthetic machine with an 
isoflurane vaporizer and an oxygen concentrator (indulab-vet) and blood was collected 
by retro-orbital bleeding using thin glass capillaries. Blood was transferred into EDTA-
coated tubes (Microvette® CB 300 K2E, Sarstedt) and serum was recovered by 
centrifugation at 2,000 xg for 5 min. Eventually, serum was aliquoted and stored 
at -80°C until analysis.  
2.5.4 In vivo Imaging 
AAV-mediated luciferase expression in living mice was analyzed by in vivo imaging using 
the IVIS® Imaging System 200 (Caliper Life Science) as described previously (Münch et 
al, 2013). For this purpose, mice were injected intraperitoneally with 150 mg D-
Luciferin (Perkin Elmer) per kg body weight using a 29 gauge needle. About five minutes 
later, mice were anesthetized with 2-3 % isoflurane using a XGI-8 Gas Anesthesia system 
(Caliper Life Sciences). Finally, imaging data were recorded 10 to 20 min post substrate 
injection and data analyses were performed using the Living Image 4.3 software (Caliper 
Life Science).  
2.5.5 Isolation and cultivation of splenocytes from mice 
Prior to removal of the spleen, mice were sacrificed by cervical dislocation under 
isoflurane anesthesia. The spleen was explanted, placed onto a 70 µm cell strainer (BD 
Bioscience) and pushed through the strainer using the plunger end of a syringe. The 
strainer was washed with RPMI+PenStrep medium and cells were pelleted for 5 min at 
314 xg and 4°C (HereausTM MultifugeTM X3R, Thermo Fisher Scientific). Erythrocytes 
were lysed by incubation of the cells in 5 ml red blood cell lysis buffer for 2 min at room 
temperature. After adding 5 ml RPMI+PenStrep medium, cells were pelleted as described 
above, the supernatant was discarded and cells were resuspended in 5 ml RPMI+PenStrep. 
Cells were filtered again through a 70 µm cell strainer (BD Bioscience), counted and 
either cultivated or used for ELISpot analysis (2.4.14).  
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For cultivation, 5x105 splenoctyes were seeded per well of a round-bottom 96-well plate 
and cells were cultivated in RPMI+PenStrep supplemented with 10 ng/ml PMA and 
500 ng/ml ionomycin (del Rio et al, 2005). Two days after stimulation, cells were used 
for flow cytometry analysis (2.4.13). 
2.5.6 Preparation of mouse organ lysates 
In order to detect in vivo delivered immune checkpoint inhibitors by AAV vectors, organ 
lysates were prepared. For this, mice were sacrificed by cervical dislocation under 
isoflurane anesthesia, organs were explanted, snap frozen in liquid nitrogen and stored 
at -80°C. For preparation of organ lysates, organs were thawed on ice, cut in small pieces 
and transferred into lysing matrix D tubes (MP Biomedicals). Passive lysis buffer 
(Promega) supplemented with protease-inhibitor cocktail (Roche) was applied to the 
tubes (generally: 2 µl buffer per 1 mg tumor; 1.25 µl buffer per 1 mg liver) and organs 
were homogenized using a Fast-Prep-24® instrument (MP Biomedicals) equipped with a 
cooling rotor. Thereafter, cell homogenates were incubated for further 15 min at room 
temperature. Cell homogenates were transferred to fresh tubes and cell debris were 
removed by two centrifugation steps (1. centrifugation: 16,200 xg, 4°C, 20 min; 2. 
centrifugation: 16,200 xg, 4°C, 10 min) (Biofuge Fresco, Heraeus). Supernatant was 
aliquoted and stored at -80°C until used for analysis.  
Samples were thawed on ice prior to ELISA and centrifuged again (16,200 xg, 4°C, 
10 min) (Biofuge Fresco, Heraeus) to remove remaining precipitates. Protein 
concentrations of the organ lysates were determined by BCA assay (2.3.1). 
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3 Results 
This thesis describes the generation and characterization of oncolytic srVSV and 
receptor-targeted AAV vectors as gene transfer systems for applications in cancer 
immunotherapy. In the first part of the thesis srVSV encoding different 
immunotherapeutic transgenes was developed as a novel vector system for oncolytic 
immunotherapy. This approach aimed at combining immunostimulatory transgene 
expression with srVSV-mediated oncolysis to induce a long-lasting antitumor immunity. 
After demonstrating functionality of the de novo generated srVSV encoding APC-
recruiting cytokines, TAA or B7 T cell co-immunostimulators, their therapeutic efficacy 
was investigated in a subcutaneous tumor mouse model.  
The second part of this thesis describes the development of receptor-targeted AAV 
vectors for tumor-specific delivery of immune checkpoint inhibitors. Her2/neu-targeted 
AAV vectors were generated encoding the immune checkpoint inhibitors αPD-1 or αPD-
L1. In vitro analyses revealed that the vectors were able to mediate expression of 
functional inhibitors upon transduction of cancer cell lines. Furthermore, Her2-AAV 
vectors successfully redirected immune checkpoint inhibitors from liver to Her2/neu-
positive tumor tissue upon systemic injection into tumor-bearing mice.  
3.1 Development of semireplication-competent VSV as a novel vector system for 
oncolytic immunotherapy 
This project aimed at the development of srVSV as a novel vector system for oncolytic 
immunotherapy by combining the oncolytic activity of srVSV with its ability to 
accommodate multiple transgenes. To this end, srVSV was engineered to express 
different immunostimulatory transgenes and its therapeutic efficacy was investigated in 
a subcutaneous tumor mouse model.  
3.1.1 Incorporation of immunotherapeutic transgenes into VSV vector genomes 
With the aim of inducing a durable antitumor immune response by srVSV, different 
immunostimulatory transgenes were incorporated into the VSV vector genomes. First, 
the APC-recruiting cytokines GM-CSF as well as Flt3L were investigated in this study as 
potential transgenes to improve antitumor immune responses (Figure 5A). The coding 
sequence of mouse GM-CSF was cloned into the genomes of the VSV deletion mutants 
VSVΔG and VSVΔL (Figure 5B). Due to the described cross-reactivity of mouse and 
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human Flt3L, the cDNA encoding the soluble form of human FlT3L (Isoform 2 P49771-2 
found at UniProt database) was cloned into the VSV vector genomes (Maraskovsky et al, 
1996; Brasel et al, 1996) (Figure 5B).  
A further promising approach to break cancer immune tolerance is the induction or 
maintenance of T cell activation in the tumor microenvironment. In this context, B7 
family members, being crucial for T cell activation and tolerance, have been described to 
be effective in tumor immunotherapy (Zang & Allison, 2007; Capece et al, 2012). Thus, in 
a further approach srVSV was armed with B7, a protein required for T cell co-
stimulation. The utilized construct was composed of the extracellular domain of mouse 
B7-1 (B7-11-245 according to isoform 1 Q00609-1 found at UniProt database) fused to the 
Fc portion of human IgG1 (IgG-Fc) (hereafter abbreviated with B7) (Figure 5A). In order 
to generate the respective fusion construct, the extracellular domain of mouse B7-1 was 
amplified from pCR-B7IG using the primer pair pB7_for and pB7_rev and was cloned via 
the restriction sites PacI/NheI into phuFc-endoglin, thereby replacing the endoglin 
coding sequence with that for the extracellular domain of mouse B7-1. The resulting 
plasmid phuFc-B7-1 was used as template for cloning the coding sequence of B7 into the 
two different VSV vector genomes VSVΔG and VSVΔL (Figure 5B).  
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Figure 5: Schematic representation of the incorporated immunotherapeutic transgenes and the resulting VSV 
vector genomes. (A) The immunostimulatory transgenes GM-CSF, Flt3L, B7, Her2 and C-Her2 were cloned into the in 
(B) indicated positions of the VSVΔG and VSVΔL vector genomes. Conserved intergenic regions between the viral 
genes were left unchanged during cloning. IgGκ leader sequence and small epitope tags (Myc, His6) are indicated. The 
amino acid position of B7-1 refers to the accession number Q00609-1, of Her2/neu to P04626-1 and of CTLA-4 to 
P16410 found at UniProt database. Furthermore, VSVΔG vector genome encoding the reporter protein GFP and the 
VSVΔL vector genome encoding the reporter protein DsRed are shown. CH: constant region of the heavy chain 
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Besides direct recruitment of immune cells and stimulation of antitumoral T cell 
responses, the equipment of oncolytic viruses with TAAs is another feasible strategy to 
enhance immune stimulation (Pulido et al, 2012; Vigil et al, 2008; Diaz et al, 2007). As a 
consequence, srVSV was armed with TAAs as a third strategy to enhance antitumor 
immunity. First, VSV vector genomes were cloned encoding the N-terminal part of 
human Her2/neu (Her2/neu21-243 according to isoform 1 P04626-1 found at UniProt 
database) (hereafter abbreviated with Her2) (Figure 5B). This part of Her2/neu 
contains the immunodominant peptide epitope TYLPTNASL which is described to be 
efficiently presented by mouse MHC class I molecules (Nagata et al, 1997). In addition, 
the construct encodes an N-terminal IgGκ leader sequence for secretion and C-terminal 
His6- and Myc-tags (Figure 5A). In order to facilitate targeted delivery of tumor antigens 
to APCs, constructs had been generated that are composed of the extracellular domain of 
human CTLA-4 (CTLA-436-161 according to isoform 1 P16410 found at UniProt database) 
fused to Her2 (hereafter abbreviated with C-Her2) (Sloots et al, 2008; Rohrbach et al, 
2005) (Figure 5A). In this approach, CTLA-4 acts as binding domain for B7 proteins on 
APCs and thereby facilities antigen uptake (Sloots et al, 2008; Rohrbach et al, 2005). 
Furthermore, using human CTLA-4 is feasible for studies in murine tumor models since 
it has been described to interact functionally with mouse B7 proteins (Rohrbach et al, 
2005; Freeman et al, 1993). Hence, the ORF of C-Her2 was also cloned into the VSVΔG 
and VSVΔL vector genomes (Figure 5B).  
The cloning strategies are summarized in Table 18. For cloning it was necessary to 
ensure that the intergenic regions between the viral genes are kept unchanged as they 
provide essential cis-acting elements required for viral transcription (Schnell et al, 
1996). If no suitable single cutting sites were present in the intergenic regions, the 
transgene was initially cloned into a pBluescriptII (pBSII) cloning vector, either pBSII-G-
ΔL-HDVR for cloning of pVSVΔL or pBSII-M-ΔG-L for cloning of pVSVΔG. These cloning 
vectors had been designed in a way that the inserted gene is framed by the respective 
VSV gene junctions. Furthermore, unique cutting sites had been inserted into the cloning 
vector to enable easy cloning of the gene into the VSV vector genome. After cloning, the 
inserts of the generated plasmids were sequenced in order to confirm the absence of 
mutations and subsequently used for the de novo generation of replication-deficient 
VSVΔG and VSVΔL vectors.  
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Table 18: Cloning strategies to generate VSV vector genomes encoding different immunotherapeutic transgenes 
Cloned construct Template 
Cloning of the  transgene into cloning vector pBluescriptII (pBSII) Cloning of the transgene into VSV vector genome 
Primera Restriction sitesb Backbonec Primera Restriction sitesb Backbonec 
pVSVΔL(GM-CSF) 
pGM-CSF 
ΔL_GMCSF_for/ΔL_GMCSF_rev BamHI/NotI pBSII-G-ΔL-HDVRd  -  KpnI/SpeI of pBSIIΔL-GM-CSFg pVSVΔL(DsRed) 
pVSVΔG(GM-CSF) ΔL_GMCSF_for/ΔL_GMCSF_rev  BamHI/NotI pBSII-M-ΔG-Le  -  MluI/HpaI of pBSIIΔG-GM-CSFh pVSV(GP) 
pVSVΔL(Flt3L) pEX-A-
sFlt3L 
 -  BamHI/NotI pBSII-G-ΔL-HDVRd  -  KpnI/SpeI of pBSIIΔL-Flt3Lg pVSVΔL(DsRed) 
pVSVΔG(Flt3L)  -  -  - ΔG_Flt3L_for/ΔG_Flt3L_rev XmaI/NotI of PCR product pVSV(GP) 
pVSVΔL(B7) 
phuFc-B7-1 
ΔL_B7_for/ΔL/ΔG_B7_rev  BglII/NotIf pBSII-G-ΔL-HDVRd  -  KpnI/SpeI of pBSIIΔL-B7g pVSVΔL(DsRed) 
pVSVΔG(B7)  -  -  - ΔG_B7_for/ΔL/ΔG_B7_rev  AgeI/NotI of PCR producti pVSV(GP) 
pVSVΔL(Her2) pSecTag2B-
Her2/neu 
ΔL_TAA_for/ΔL/ΔG_TAA_rev BamHI/NotI pBSII-G-ΔL-HDVRd  - NheI/SpeI of pBSIIΔL-Her2g pVSVΔL(DsRed) 
pVSVΔG(Her2)  -  -  - ΔG_TAA_for/ΔL/ΔG_TAA_rev XmaI/NotI of PCR product pVSV(GP) 
pVSVΔL(C-Her2) pSecTag2B- 
CTLA-4-
Her2/neu 
ΔL_TAA_for/ΔL/ΔG_TAA_rev BamHI/NotI pBSII-G-ΔL-HDVRd  - NheI/SpeI of pBSIIΔL-C-Her2g pVSVΔL(DsRed) 
pVSVΔG(C-Her2)  -  -  - ΔG_TAA_for/ΔL/ΔG_TAA_rev XmaINotI of PCR product pVSV(GP) 
a primer pair used for the amplification of the insert (= immunotherapeutic transgene), b restriction sites used for the digestion of the the PCR product/plasmid, c unless otherwise 
noted backbone is digested with the same restriction enzymes as stated in column “restriction sites”, d pBSII-G-ΔL-HDVR cloning vector: inserted transgene is flanked by the G-L 
intergenic regions and a part of the G-gene as well as the L-HDV (Hepatitis Delta Virus) ribozyme region, e pBSII-M-ΔG-L cloning vector: inserted transgene is flanked by the M-G 
intergenic regions and a part of the M-gene as well as the G-L intergenic region , f PCR product was digested with BglII/NotI and cloned into pBSII-G-ΔL-HDVR digested with 
BamHI/NotI, g pBSII-G-ΔL-HDVR cloning vector with incorporated transgene, h pBSII-M-ΔG-L cloning vector with incorporated transgene, i PCR product was digested with AgeI/NotI 
and cloned into pVSV(GP) digested with XmaI/NotI 
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3.1.2 De novo generation of srVSV   
A reverse genetic system was used for the de novo generation of VSVΔG and VSVΔL 
vectors from cDNA (Whelan et al, 1995; Lawson et al, 1995) (Figure 6). For this, BHK-21 
cells were transfected with the full length antigenomic cDNA of the respective VSV 
vector variant (Figure 5B: pVSVΔG or pVSVΔL) encoding for one of the described 
immunotherapeutic transgenes. Using the antigenomic cDNA for viral rescue is 
important to avoid hybridization of the viral genomic RNA and transcribed N, P and L 
mRNAs supplied from the helper plasmids (Lawson et al, 1995; Schnell et al, 1994). The 
nucleocapsid protein, the phosphoprotein as well as the RNA-dependent RNA-
polymerase required for the initiation of viral replication were provided by co-
transfection with the helper plasmids pIRES-N, pIRES-P and pIRES-L (Lawson et al, 
1995). The rescue of VSVΔG vectors required an additional helper plasmid encoding the 
glycoprotein of VSV-G (Boritz et al, 1999). The helper plasmid pIRES-G was cloned by 
amplifying the coding sequence of VSV-G from the cDNA of the VSV genome using the 
primer pair pIRES-G_for and pIRES-G_rev. Next, the PCR product was digested with 
PcI/EcoRI and inserted into the NcoI/EcoRI digested pIRES-P plasmid, thereby replacing 
the sequence of the P-gene with the G-gene. Since all plasmids are under the control of a 
bacteriophage T7 RNA promotor, BHK-21 cells were infected with recombinant 
modified vaccinia virus expressing T7 RNA polymerase prior to transfection. 
Propagation-defective VSV vectors were recovered from the cell culture supernatants 
three days post transfection. The recovered VSV vectors were amplified by passaging 
supernatants on cells complementing the deleted VSV protein. For propagation of 
VSVΔG vectors, BHK-21 cells were used that had been engineered to express the 
glycoprotein of LCMV (BHK21-GP). For amplification of VSVΔL vectors, modified 
HEK293 cells expressing the VSV-N, VSV-P and VSV-L proteins were utilized (HEK293-
NPeGFPL).  
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Figure 6: Viral rescue of recombinant VSV deletion mutants. Helper plasmids encoding VSV-N, -P and -L protein 
(pIRES-N, pIRES-P, pIRES-L) as well as the full-length antigenomic cDNA of the respective VSV genome (pVSVΔG or 
pVSVΔL) were co-transfected into BHK-21 cells. The rescue of VSVΔG vectors required an additional helper plasmid 
encoding the glycoprotein of VSV (pIRES-G). All plasmids are driven by a bacteriophage T7 promotor. The T7 RNA 
polymerase was provided by infection of BHK-21 cells with modified vaccinia virus Ankara coding for the T7 
polymerase (MVA-T7pol). The shown table summarizes the in this thesis de novo generated VSVΔG as well as VSVΔL 
vectors.  
Following rescue, the recovered VSVΔG and VSVΔL vectors were analyzed for their 
ability to trans-complement and co-propagate after co-infection with their respective 
complementing VSV vector. For this, BHK-21 cells were co-infected with 
VSVΔG(transgene) and VSVΔL(DsRed) or with VSVΔL(transgene) and VSVΔG(GFP). 
‘Transgene’ refers to the different immunostimulatory transgenes GM-CSF, Flt3L, B7, 
Her2 or C-Her2. As control, cells were co-infected with VSV vectors deleted for the same 
VSV protein: VSVΔG(transgene) and VSVΔG(GFP) or with VSVΔL(transgene) and 
VSVΔL(DsRed). On the following day, cell culture supernatants were transferred to 
freshly seeded BHK-21 cells and another day later cells were analyzed for cytopathic 
effects as well as for the expression of the fluorescent proteins by microscopy. An 
example for the fluorescence microscopy is shown in Figure 7. The analyses showed that 
the VSVΔG as well as VSVΔL vectors did only generate progeny virions in cell cultures 
when the respective deleted viral gene was provided by the complementing VSV vector 
(Figure 7). 
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Figure 7: Trans-complementation of VSVΔG(GM-CSF) and VSVΔL(GM-CSF). BHK-21 cells were co-infected with 
VSVΔG(GM-CSF) and VSVΔL(GM-CSF) together with VSVΔG(GFP) or VSVΔL(DsRed). On the following day, 
supernatants were transferred to freshly seeded BHK-21 cells. One hour later, the cells were washed and fresh 
medium was added. On the next day, cells were analyzed by fluorescence microscopy. VSV vector variants encoding 
GM-CSF are shown as representative example. (Scale bar: 200 µm) 
When trans-complementation of the recovered VSV vector variants was observed, as 
exemplarily shown for VSVΔG(GM-CSF) and VSVΔL(GM-CSF), the recovered vector 
preparations were subjected to plaque purification in order to purify a clonal vector 
population arising from a ‘single’ VSV vector. For plaque purifications as well as for the 
subsequent amplifications and titrations BHK21-GP and HEK293-NPeGFPL cells were 
used for VSVΔG and for VSVΔL vectors, respectively (Figure 8). After amplification of the 
plaque-purified vector stocks, the titers were determined as TCID50/ml.  
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Figure 8: Generation of clonal VSVΔG and VSVΔL vectors. Plaque purifications were performed by infection of cells 
with serial dilutions of VSVΔG or VSVΔL vectors. The cells were overlaid with 0.9 % agarose solution to limit viral 
spread. A clonal vector population was purified by isolating an individual plaque. Subsequently, VSV vectors were 
amplified and titers determined. For this, BHK21-GP or HEK293-NPeGFPL cells were infected with ten-fold serial 
dilutions of the respective VSV vector variant. Three days later cells were analyzed for cytopathic effects by 
microscopy and titers were determined as TCID50/ml. Titers of the newly generated VSV vector variants are 
summarized in Table 19.  
Table 19: TCID50/ml of VSV vectors after single plaque purification 
  VSVΔG VSVΔL 
GFP 5x105 - 
DsRed - 1.6x107 
GM-CSF 1.6x105 3.8x106 
Flt3L 3.8x105 6.7x106 
B7 5x106 6.7x106 
Her2 1.2x105 3.7x107 
C-Her2 1.6x105 2.8x107 
 
Titrations revealed that the titers for VSVΔG vectors were approximately one up to two 
log levels lower compared to VSVΔL vector preparations (Table 19). The average titer 
for VSVΔG vector preparations was around 1.1x106  ± 1.9x106 TCID50/ml (n=6, 
mean ± SD) and for VSVΔL around 1.6x107 ± 1.3x107 TCID50/ml (n=6, mean ± SD). 
However, the observed differences can presumably be explained by the different cell 
lines used for vector amplification and titration. Overall, all VSV vector variants 
encoding the different immunostimulatory transgenes were successfully rescued. 
In order to generate srVSV stocks, a plaque purification was performed after co-infection 
of BHK-21 cells with VSVΔG and VSVΔL vectors (Figure 9A). Single clones were 
amplified and subsequently titrated on BHK-21 cells. The resulting srVSV preparations 
were either composed of a VSVΔG(transgene) vector together with a VSVΔL(DsRed) 
vector (mixture of those two vector types is further referred to as 
srVSV(transgene/DsRed)) or of a VSVΔG(GFP) vector together with a VSVΔL(transgene) 
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vector (mixture of those two vector types is further referred to as 
srVSV(GFP/transgene)) (Figure 9B). Generated srVSV preparations are summarized in 
Figure 9C. 
 
Figure 9: Generation and titration of srVSV. (A) srVSV stocks were generated by co-infection of BHK-21 cells with 
serial dilutions of VSVΔG together with VSVΔL vectors. On the following day, a single plaque was isolated and 
amplified on BHK-21 cells. Subsequently, titers were determined as TCID50/ml. (B) Schematic drawing of the 
generated srVSV variants. For srVSV(transgene/DsRed), the immunotherapeutic transgene replaces the G-gene in the 
VSV vector genome and for srVSV(GFP/transgene), the immunotherapeutic transgene replaces the L-gene. 
‘Transgene’ refers to the immunotherapeutic transgenes GM-CSF, Flt3L, B7, Her2 or C-Her2. (C) Summary of the 
generated srVSV variants. (D) TCID50/ml of the generated srVSV preparations. For titration, BHK-21 cells were 
infected with ten-fold serial dilutions of srVSV. Three days later cells were analyzed for cytopathic effects by 
microscopy and titers were determined as TCID50/ml. (n=2, means ± SD) 
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The titers of the different srVSV vector preparations were quite similar among the 
different transgenes having an average value of 4.2x107 ± 2.3x107 TCID50/ml (n=11, 
mean ± SD) (Figure 9D). Thus, different srVSV vectors encoding either GM-CSF, Flt3L, 
B7, Her2 or C-Her2 were available for further studies.  
3.1.3 Analyzing srVSV-mediated expression of immunostimulatory proteins 
The previous chapter described the successful de novo generation of srVSV encoding 
various immunotherapeutic transgenes. Next, it was analyzed whether the newly 
generated srVSVs mediate transgene expression. For this, cells were infected with srVSV 
and on the next day cell culture supernatants were collected and subjected to ELISA, 
Western blot or flow cytometry analyses in order to confirm the presence of the srVSV-
encoded immunotherapeutic proteins.  
 
In order to assess the transgene expression of the APC-recruiting cytokine Flt3L, the 
murine melanoma cell line B16-F10, the murine renal cancer cell line RENCA-Her2/neu 
and BHK-21 cells were infected with srVSV(Flt3L/DsRed) or srVSV(GFP/Flt3L). To 
analyze the transgene expression of GM-CSF, B16-F10 and RENCA-Her2/neu cells were 
infected with srVSV(GM-CSF/DsRed) or srVSV(GFP/GM-CSF). On the next day, cell 
culture supernatants were analyzed by ELISA.  
 
Figure 10: srVSV-mediated expression of Flt3L and GM-CSF. (A) BHK-21, RENCA-Her2/neu and B16-F10 cells 
were infected with srVSV(Flt3L/DsRed) or srVSV(GFP/Flt3L) (MOI 0.1). On the following day, cell culture 
supernatants were collected for the quantification of srVSV-encoded Flt3L by ELISA. (n=3, means ± SD) (B) RENCA-
Her2/neu and B16-F10 cells were infected with srVSV(GM-CSF/DsRed) or srVSV(GFP/GM-CSF) (MOI 0.1). On the next 
day, the amount of srVSV-encoded GM-CSF was quantified in cell culture supernatants by ELISA. (n=3, means ± SD) 
The analyses revealed srVSV-mediated expression of GM-CSF and Flt3L on various cell 
lines for all srVSV constructs tested (Figure 10). The amount of detected Flt3L and GM-
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CSF was higher in cell culture supernatants of infected B16-F10 compared to RENCA-
Her2/neu tumor cells. In cell culture supernatants of srVSV(Flt3L/DsRed)-infected cells 
an average amount of 182 ± 10 ng/ml (n=3, mean ± SD) were detected for RENCA-
Her2/neu cells, 937 ± 42 ng/ml (n=3, mean ± SD) for B16-F10 cells and 740 ± 149 ng/ml 
(n=3, mean ± SD) for BHK-21 cells (Figure 10A). The amount of Flt3L in cell culture 
supernatants of srVSV(GFP/Flt3L)-infected cells was in average 2.8 ± 0.7 ng/ml (n=3, 
mean ± SD) for RENCA-Her2/neu cells, 21 ± 2.6 ng/ml (n=3, mean ± SD) for B16-F10 
cells and 10 ± 0.4 ng/ml (n=3, mean ± SD) for BHK-21 cells. In cell culture supernatants 
of srVSV(GM-CSF/DsRed)-infected cells concentrations of 300 ± 18 ng/ml (n=3, 
mean ± SD) were measured for RENCA-Her2/neu cells and 556 ± 10 ng/ml (n=3, 
mean ± SD) for B16-F10 cells (Figure 10B). The amount of GM-CSF in cell culture 
supernatants of srVSV(GFP/GM-CSF)-infected cells was in average 53 ± 5.6 ng/ml (n=3, 
mean ± SD) for RENCA-Her2/neu cells and 200 ± 30 ng/ml (n=3, mean ± SD) for B16-
F10 cells. Taken together, the results revealed higher levels of transgene expressions for 
the constructs having the cytokine-gene inserted into the G-position than for those 
having the cytokine reading frame inserted into the L-position of the VSV vector 
genome.  
Transgene expression of Her2 and C-Her2 was analyzed in cell culture supernatants of 
srVSV-infected BHK-21 cells by Western blot analysis using a Myc-tag-specific antibody. 
Cell culture supernatants of BHK-21 cells that had been transfected with expression 
plasmids encoding the same Her2 or C-Her2 protein as the srVSV variant served as 
positive control. Western blot analysis revealed specific bands for Her2 at the expected 
size between 36 and 55 kDa for srVSV(Her2/DsRed) as well as srVSV(GFP/Her2) 
(Figure 11A). Moreover, the analysis showed the expression of the fusion protein C-Her2 
for both srVSV variants.  
Functionality of srVSV-encoded C-Her2 was assessed by flow cytometry using the Raji 
B cell lymphoma cell line constitutively expressing the B7 molecules B7-1 (CD80) and 
B7-2 (CD86) (Figure 11B). For the analysis, Raji cells were incubated with cell culture 
supernatants of BHK-21 cells that had been infected with srVSV(C-Her2/DsRed) or 
srVSV(GFP/C-Her2). B7-negative Molt4.8 cells as well as cell culture supernatants of 
BHK-21 cells that had been infected with srVSV encoding Her2 served as negative 
controls. Binding to cell surface was detected using a fluorophore-labeled His-tag-
specific antibody. The analysis revealed specific binding of C-Her2 to Raji cells whereas 
no binding was detectable for the negative controls (Figure 11C).  
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Figure 11: srVSV-mediated expression of Her2 and C-Her2. (A) BHK-21 cells were infected with 
srVSV(Her2/DsRed), srVSV(C-Her2/DsRed), srVSV(GFP/Her2), srVSV(GFP/C-Her2) and srVSV(GFP/DsRed) (MOI 
0.1). On the following day, cell culture supernatants were collected and examined for C-Her2 or Her2 by Western blot 
analysis using a Myc-tag-specific antibody. As positive control, cell culture supernatants of BHK-21 cells that had been 
transfected with the expression plasmids pSecTag2B-Her2/neu (pHer2) or pSecTag2B-CTLA-4-Her2/neu (pC-Her2) 
were included to the analysis. (B) Surface expression of CD80 (B7-1) and CD86 (B7-2) on Raji cells was analyzed using 
PE-labelled CD80- and FITC-labelled CD86-specific antibodies and flow cytometry (αCD86 clone: FM95; αCD80 clone: 
2D10). (C) Specific binding of C-Her2 to B7 molecules was analyzed by incubating Raji cells (black empty curve) with 
400 µl cell culture supernatants of BHK-21 cells that had been infected with srVSV(C-Her2/DsRed) or srVSV(GFP/C-
Her2) (MOI 0.1). As control, Raji cells were incubated with cell culture supernatants of srVSV(Her2/DsRed)- or 
srVSV(GFP/Her2)-infected BHK-21 cells. In addition, cell culture supernatants were incubated with B7-negative 
Molt4.8 cells (grey filled curve). Binding to cell surface was assessed by flow cytometry measurements using a PE-
labelled His-tag-specific antibody.  
Next, srVSV-mediated expression of B7 was assessed. Transgene expression in cell 
culture supernatants of BHK-21 cells that had been infected with srVSV(B7/DsRed) or 
srVSV(GFP/B7) was confirmed by Western blot analysis using a Fc-specific antibody 
(Figure 12A). The detected band at ~95 kDa corresponded to B7 and the additional 
band at the size between 28 and 36 kDa presumably represents a cleaved Fc-part. As 
already observed for the previously described transgenes GM-CSF as well as Flt3L, 
Western blot analysis also indicated a higher level of transgene expression for B7 when 
the gene was inserted into the G-position in the VSV vector genome.  
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Figure 12: srVSV-mediated expression of B7. (A) BHK-21 cells were infected with srVSV(B7/DsRed) or 
srVSV(GFP/B7) (MOI 0.1). As negative control, cells were infected with srVSV(GFP/DsRed). On the next day, 
supernatants were collected and analyzed by Western blot using a Fc-specific antibody. Cell culture supernatant of 
BHK-21 cells that had been transfected with the expression plasmid phuFc-B7-1 encoding B7 (pB7) was used as 
positive control. Cell culture supernatant of BHK-21 cells that had been transfected with an empty plasmid (pCG1) 
served as further negative control. (B) CD28 expressing HT1080 cells were generated by transduction with VSV-G 
pseudotyped lentiviral vectors encoding mouse CD28 and puromycin resistance. Subsequently, transduced cells were 
selected by addition of puromycin to the cell culture medium. Surface expression of CD28 was analyzed by flow 
cytometry using a PE-labelled CD28-specific antibody (clone: 37.51). (C) Parental HT1080 (grey filled curve) and 
HT1080-CD28 (black empty curve) were incubated with 600 µl cell culture supernatant of BHK-21 cells that had been 
infected with srVSV(B7/DsRed) or srVSV(GFP/B7) (MOI 0.1). As control, cells were incubated with supernatant of 
srVSV(GFP/DsRed)-infected BHK-21 cells. Binding to cell surface was detected by a FITC-labelled Fc-specific antibody 
followed by flow cytometry analysis. Peaks were normalized to number of events.  
To investigate functionality of srVSV-encoded B7, HT1080 cells stably expressing CD28 
were generated. For this, the cDNA sequence of mouse CD28 (NCBI NM_007642.4) was 
cloned into a lentiviral transfer vector plasmid via the restriction sites BamHI/SpeI 
resulting in pS-CD28-IP-W. In this construct, the ORF for CD28 and for the puromycin 
antibiotic resistance are linked by an internal ribosomal entry site (IRES) allowing the 
expression of both genes from a single mRNA. The transfer vector plasmid was packaged 
into VSV-G pseudotyped lentiviral vectors and the resulting vectors were used for the 
transduction of HT1080 cells. Successfully transduced cells were selected using the 
antibiotic puromycin. Surface expression of CD28 on the newly generated HT1080-CD28 
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cells was confirmed by staining the cells with a fluorophore-labelled CD28-specific 
antibody and flow cytometry analysis (Figure 12B).  
Specific binding of srVSV-encoded B7 to CD28 was investigated by incubating HT1080-
CD28 or parental HT1080 cells with cell culture supernatants of srVSV-infected BHK-21 
cells. Cell culture supernatant of cells that had been infected with srVSV(GFP/DsRed) 
was used as control. Subsequently, cells were stained with a fluorophore-labeled Fc-
specific antibody and analyzed by flow cytometry. Analysis confirmed specific binding of 
srVSV-encoded B7 to CD28-positive HT1080 cells and no binding was detected for the 
negative controls (Figure 12C). Furthermore, a higher mean fluorescence intensity was 
observed for srVSV(B7/DsRed) as compared to srVSV(GFP/B7) indicating again a higher 
level of transgene expression for constructs that had incorporated the transgene into the 
G-position of the VSV vector genome compared to the L-position. 
In summary, the data demonstrate that the generated srVSV variants mediated 
transgene expression of the different immunostimulatory proteins. Furthermore, the 
analysis revealed a higher level of transgene expression of the constructs having the 
transgene inserted into the G-position than for those having the transgene inserted into 
the L-position of the VSV vector genome. 
3.1.4 Sensitivity of murine tumor cell lines to the antiviral effects of type I IFN 
In order to investigate antitumor efficacy of the srVSV systems in vivo, a suitable VSV-
permissive syngeneic tumor mouse model had to be identified. VSV is exquisitely 
sensitive to type I IFN-induced antiviral responses. Hence, defective IFN pathways in 
cancer cells are described to be the key determinant of VSV oncoselectivity (Stojdl et al, 
2000; Stojdl et al, 2003; Liu et al, 2013; Hastie & Grdzelishvili, 2012). However, not all 
cancer cells have a deregulated IFN response and thus resist to VSV infection (Liu et al, 
2013; Dold et al, 2016). Therefore, five different murine cancer cell lines were analyzed 
concerning their IFN sensitivity. 
The breast cancer cell line 4T1, the renal cancer cell line RENCA-Her2/neu, the 
melanoma cell line B16-F10, the colon cancer cell line MC38 or the breast cancer cell line 
E0771 were pretreated for 24 h with different concentrations of IFNα and subsequently 
infected either with replication-competent rVSV(GFP) or srVSV(GFP/DsRed). Two days 
later, the different cancer cell lines were analyzed by fluorescence microscopy revealing 
different sensitivity to the antiviral effects of IFNα (Figure 13). The analysis showed that 
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4T1 and B16-F10 cells were productively infected with VSV up to a concentration of 
1 U/ml IFNα. At a concentration of 10 U/ml IFNα only single infected cells were 
observable but no viral spread. RENCA-Her2/neu cells showed the highest IFN 
sensitivity as these cells were only infectable with VSV up to a concentration of 0.1 U/ml 
IFNα. In contrast, MC38 and E0771 cells were infectable even when pretreated with the 
highest tested IFNα dose of 1000 U/ml. However, at high concentrations of IFNα 
fluorescence microscopy indicated less infected cells for MC38 and E0771 as compared 
to cells that were not pretreated with IFNα. The same was observed for cells that were 
infected with srVSV (not shown).  
 
 
Figure 13: Susceptibility of IFNα-stimulated murine cancer cell lines to VSV infection. (A) 4T1, RENCA-
Her2/neu, B16-F10 and (B) MC38, E0771 cells were pretreated with the indicated concentrations of mouse IFNα for 
24 h prior to rVSV(GFP) infection. Two days post infection cells were analyzed by fluorescence microscopy. (Scale bar: 
200 µm) 
To further examine the relative sensitivity of the cancer cell lines to protection by IFNα, 
the cell viability was examined by WST-1 assay. Results obtained from the fluorescence 
microscopy analyses were mainly confirmed by the WST-1 assay. RENCA-Her2/neu cells 
were exquisitely sensitive to the antiviral effects of IFNα (Figure 14). Only 1 U/ml IFNα 
was sufficient to protect all RENCA-Her2/neu cells from rVSV- as well as srVSV-
mediated oncolysis. 10 U/ml IFNα was sufficient to protect 4T1 and B16-F10 cells from 
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VSV-mediated cell killing. In contrast to the other examined cancer cell lines, 30-40 % of 
E0771 cells were still viable even if the cells were not pretreated with IFNα. Moreover, 
pretreatment with IFNα influenced the susceptibility of E0771 cells to VSV infection. 
Thus, albeit E0771 cells were infectable by VSV, even at high IFNα concentrations, the 
susceptibility to VSV-mediated cell killing seemed to be restricted or decelerated 
compared to the other tested cancer cell lines. MC38 cells showed the best susceptibility 
to VSV-mediated oncolysis and cells pretreated with IFNα up to a dose of 10 U/ml were 
not protected from VSV-mediated oncolysis. However, incubation with higher doses of 
IFNα still revealed cell viability of about 30 % for srVSV- and about 60 % for VSV-treated 
MC38 cells. Thus, even though MC38 cells retained highly susceptible to VSV infection at 
high concentrations of IFNα, none of the tested cancer lines were proven to be 
completely unresponsive to type I IFN-induced antiviral responses. Overall, the 
fluorescence microscopy analyses and the WST-1 assay showed the same antiviral 
effects of IFNα against both tested VSV systems, the replication-competent rVSV and the 
semireplication competent srVSV.  
 
Figure 14: VSV-mediated oncolysis of murine cancer cell lines after pretreatment with IFNα. Murine cancer cell 
lines were pretreated with the indicated concentrations of mouse IFNα for 24 h prior to rVSV(GFP) or 
srVSV(GFP/DsRed) infection. Cell viability was measured two days post infection by WST-1 assay and is presented as 
percentage to the uninfected control. (n=3, means ± SD) 
In order to investigate the antitumor effects of srVSV encoding the TAA Her2, the usage 
of a Her2/neu-positive tumor model is mandatory. However, the previous experiment 
showed that RENCA-Her2/neu cells are quite sensitive to the antiviral effects of IFNα. 
Thus, this cancer cell line is not a suitable tumor model to investigate the therapeutic 
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efficacy of srVSV in vivo. As MC38 cells showed the best susceptible to VSV oncolysis 
after pretreatment with IFNα, this cancer cell line was considered to be a potential 
tumor model. Therefore, MC38 cells genetically engineered to express the ectodomain of 
Her2/neu (MC38-ek-Her2/neu) were also analyzed in regard to their sensitivity to IFNα. 
For this, MC38 and MC38-ek-Her2/neu cells were pretreated with different 
concentrations of IFNα for 24 h and subsequently infected with srVSV(GFP/DsRed) or 
rVSV(GFP).  
 
Figure 15: Different susceptibility of MC38 and MC38-ek-Her2/neu cells to VSV infection after pretreatment 
with IFNα. MC38 and MC38-ek-Her2/neu cells were pretreated with the indicated concentrations of IFNα for 24 h. 
(A) 24 h and (B) 48 h post infection with rVSV(GFP) cells were analyzed by fluorescence microscopy. hpi: hours post 
infection. (Scale bar: 200 µm)  
Surprisingly, fluorescence microscopy analysis 24 h post infection indicated a different 
sensitivity of MC38 and MC38-ek-Her2/neu cells to the antiviral effects of IFNα (Figure 
15). As expected, MC38 cells were infectable up to a concentration of 1000 U/ml IFNα. In 
contrast, MC38-ek-Her2/neu cells showed an infection only up to an IFNα dose of 
10 U/ml and no infected cells were observable at higher IFNα concentrations. Two days 
after infection, MC38-ek-Her2/neu cells showed single infected cells at 100 U/ml and 
1000 U/ml but no viral spread. These observations were confirmed by measuring the 
cell viability by WST-1 assay. In contrast to MC38 cells, MC38-ek-Her2/neu cells showed 
no VSV-induced cell killing at high IFNα doses of 100 U/ml and 1000 U/ml (Figure 16).  
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Figure 16: VSV-mediated cell killing of MC38 and MC38-ek-Her2/neu cells after IFNα treatment. MC38 and 
MC38-ek-Her2/neu cells were pretreated for 24 h with the indicated concentrations of mouse IFNα prior to 
rVSV(GFP) or to srVSV(GFP/DsRed) infection. Cell viability was measured two days after infection by WST-1 assay 
and is presented as percentage to the uninfected control. (n=3, means ± SD) 
These results revealed a slightly increased sensitivity of MC38-ek-Her2/neu cells to the 
antiviral effects of IFNα as compared to parental MC38 cells. During the generation of 
the transgenic MC38-ek-Her2/neu cell line, probably a single clone had been selected 
exhibiting a higher IFN sensitivity compared to parental MC38 cells. It cannot be 
excluded that the integration of the gene encoding ek-Her2/neu into the genome upon 
transduction with the lentiviral vector altered the characteristics of the generated cell 
line.  
 
Overall, most of the tested mouse cancer cell lines were quite sensitive to the antiviral 
effects of IFNα indicating that the IFN-signaling seems to be at least partially intact in 
these cells. The parental murine colon cancer cell line MC38 showed the best 
susceptibility to VSV infection post IFNα incubation and thus was considered to be a 
suitable tumor model to investigate the therapeutic efficacy of srVSV in vivo.  
3.1.5 Generation and characterization of srVSV for the in vivo studies 
So far, srVSVs encoding a single immunotherapeutic transgene together with a 
fluorescent protein were generated and it could be shown that srVSV can be engineered 
to express cytokines or TAAs. However, srVSV is an especially promising platform for 
the use in cancer immunotherapy as it is a suitable system to easily deliver two 
therapeutic transgenes, one transgene incorporated into the VSVΔG and one into the 
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VSVΔL vector genome. To take advantage of this property, srVSV encoding two different 
immunotherapeutic transgenes were generated for the in vivo studies. However, the 
previously tested mouse cancer cell lines expressing the TAA Her2/neu were quite 
sensitive to the antiviral effects of IFNα. Thus, no tumor mouse model could be identified 
so far that is suitable to investigate the antitumoral efficacy of srVSV encoding Her2 or 
C-Her2 in vivo. As a consequence, it was initially focused on srVSV delivering the APC-
recruiting cytokines GM-CSF and Flt3L as well as the T cell co-immunostimulator B7.  
 
To this end, srVSV encoding GM-CSF and B7 (srVSV(GM-CSF/B7)) and srVSV encoding 
Flt3L and B7(srVSV(Flt3L/B7)) were generated as described in chapter 3.1.2 (Figure 
17). Titers of the generated srVSV preparations were in the expected range of 
2.2x107 ± 8.5x106 TCID50/ml (mean ± SD, n=2) for srVSV(GM-CSF/B7) and 
3.9x107 ± 1.56x107 TCID50/ml (mean ± SD, n=2) for srVSV(Flt3L/B7).  
 
 
Figure 17: Schematic representation of srVSV(GM-CSF/B7) and srVSV(Flt3L/B7). srVSV(GM-CSF/B7) is 
composed of VSVΔG(GM-CSF) and VSVΔL(B7) and srVSV(Flt3L/B7) is composed of VSVΔG(Flt3L) and VSVΔL(B7).  
To confirm functionality of the newly generated srVSV stocks, transgene expression was 
analyzed in cell culture supernatants of srVSV-infected MC38 cells. The expression of the 
APC-recruiting cytokines GM-CSF and Flt3L was investigated by Western blot using GM-
CSF or Flt3L-specific antibodies. As control, cell culture supernatants of cells infected 
with srVSV(GM-CSF/DsRed) or srVSV(Flt3L/DsRed), whose expression was already 
confirmed by ELISA (Figure 10), were also subjected to the Western blot analysis. As 
additional control, not only supernatants of infected MC38 cells but also of infected BHK-
21 cells were analyzed. 
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Figure 18: Expression of GM-CSF and Flt3L by srVSV-infected MC38 cells. MC38 cells were infected with the 
indicated srVSV variants. On the following day, cell culture supernatants were collected and analyzed by Western blot 
using a (A) GM-CSF- or (B) Flt3L-specific antibody. As control, cell culture supernatants of srVSV-infected BHK-21 
cells were used.   
Western blot analyses proved the expression of the APC-recruiting cytokines GM-CSF 
and Flt3L by srVSV-infected MC38 cells (Figure 18). The same specific bands were 
identified in cell culture supernatants of infected MC38 and BHK-21 cells. However, 
analysis revealed next to a strong band at ~19 kDa two further distinct bands for GM-
CSF in the Western blot analysis (Figure 18A). The different molecular weights observed 
for GM-CSF are also described in the literature and originates from varying degrees of 
glycosylation (Miyajima et al, 1986). GM-CSF is a monomeric protein composed of 141 
amino acids having two potential N-linked and two potential O-linked glycosylation sites 
(according UniProt database P01587 and ‘NetNGlyc’ predictor). Thus, the apparent 
molecular mass of the protein varies from around ~16 kDa for unglycosylated GM-CSF 
to ~19 kDa and ~24 kDa for glycosylated GM-CSF.  
Analysis of supernatants collected from cells infected with srVSV encoding Flt3L 
identified two specific bands at a size of ~20 kDa and ~25 kDa confirming the 
expression of the cytokine (Figure 18B). As already described for GM-CSF, also two 
predicted N-linked glycosylation sites exist for Flt3L (according UniProt database 
P49771 and ‘NetNGlyc’ predictor) presumably explaining the detection of two bands 
instead of one single band. Also in literature it is described that purified, recombinant 
Flt3L exhibited two specific bands in Western blot analysis (Zhang et al, 2005).   
Next, srVSV(GM-CSF/B7) and srVSV(Flt3L/B7) were characterized with respect to their 
capacity to express functional B7 after infection of MC38 cells. First, supernatants of 
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infected cells were examined for transgene expression by Western blot analysis using a 
Fc-specific antibody. A specific band at the expected size of ~95 kDa was detectable 
confirming the presence of B7 in cell culture supernatants of srVSV-infected MC38 cells 
(Figure 19A).  
 
Figure 19: Expression of B7 by srVSV-infected MC38 cells. (A) MC38 cells were infected with srVSV(Flt3L/B7), 
srVSV(GM-CSF/B7) or srVSV(GFP/DsRed) (MOI 0.1). On the next day, cell culture supernatants were collected and 
analyzed by Western blot using a Fc-specific antibody. (B) Parental HT1080 (grey filled curve) and HT1080-CD28 
cells (empty black curve) were incubated with 600 µl cell culture supernatant of MC38 cells that had been infected 
with srVSV(GFP/B7), srVSV(Flt3L/B7) or srVSV(GM-CSF/B7) (MOI 0.1). As control, cells were incubated with 
supernatants of srVSV(GFP/DsRed)-infected MC38 cells. Binding to cell surface was detected by FITC-labelled Fc-
specific antibody followed by flow cytometry analysis. Peaks were normalized to number of events. 
Functionality of srVSV(GM-CSF/B7)- and srVSV(Flt3L/B7)-encoded B7 after infection of 
MC38 cells were investigated by specific binding to CD28-positive HT1080 cells as 
described previously (chapter 3.1.3). As positive control, cell culture supernatant of 
MC38 cells infected with the previously characterized srVSV(GFP/B7) was used. The 
flow cytometry analysis showed specific binding of B7 to CD28-positive HT1080 cells 
demonstrating the expression of functional B7 by srVSV-infected MC38 cells (Figure 
19B). 
 
Taken together, the obtained results demonstrate the successful generation of 
srVSV(GM-CSF/B7) and srVSV(Flt3L/B7). Generated srVSV productions yielded high 
titers and transgene expression was proven in cell culture supernatants of infected 
MC38 cells. 
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3.1.6 Analyzing therapeutic efficacy of srVSV equipped with immunotherapeutic 
transgenes in vivo 
The previous chapters showed the identification of a VSV-permissive mouse cancer cell 
line and the successful generation as well as characterization of srVSV encoding 
different immunotherapeutic transgenes. Next, it was analyzed whether the generated 
srVSVs encoding immunotherapeutic transgenes exhibit a superior antitumoral effect as 
compared to srVSV(GFP/DsRed). For this, MC38 cells were subcutaneously transplanted 
into C57BL/6 mice and tumor growth was monitored until the tumors reached an 
average volume of about 0.1 cm3. Subsequently, animals were injected intratumorally 
with srVSV(GFP/DsRed), srVSV(GM-CSF/B7) or srVSV(Flt3L/B7).  
The analysis revealed complete tumor regression for two out of four mice treated with 
srVSV(Flt3L/B7) and for one out of three mice treated with srVSV(GM-CSF/B7) (Figure 
20A). However, also one mouse injected with srVSV(GFP/DsRed) revealed complete 
tumor regression. All mock-treated mice showed progressing tumor growth. Altogether, 
tumor response to therapy treatment was dichotomous, with some mice responding and 
some mice not responding within a cohort. Remarkably, all mice showing complete 
tumor regression were female. In contrast, only one male mouse showed a delayed 
tumor growth in the srVSV(GFP/DsRed) cohort, whereas the tumors of the other male 
mice showed progressing growth. This difference in treatment response might be 
explained by the growth inhibition of MC38 cells by female sex steroids, such as estrone 
and progesterone (Motylewska & Melen-Mucha, 2009). Thus, possibly hormones 
supported the antitumor effects in female mice. 
Comparing the tumor volumes on day 15, the last day when all mice were alive, revealed 
no differences between the different srVSV treatment groups (Figure 20B). However, an 
easier comparison of the tumor growth can be achieved by calculating the area under 
the curve (AUC). The obtained AUC value reflects the entire tumor growth curve through 
a single number and considers the total observation period from srVSV injection until 
the mouse had to be sacrificed (Duan et al, 2012). The analysis indicated an improved 
therapeutic efficacy of srVSV(GM-CSF/B7) or srVSV(Flt3L/B7) as compared to 
srVSV(GFP/DsRed) (Figure 20C). Survival analysis revealed a clear benefit of srVSV-
treated mice in comparison to the mock cohort (Figure 20D). Furthermore, srVSV 
equipped with immunostimulatory transgenes indicated a modest increase in overall 
survival as compared to srVSV(GFP/DsRed) (Figure 20D). 
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Figure 20: Therapeutic efficacy of srVSV in a subcutaneous syngeneic tumor mouse model. C57BL/6 mice were 
subcutaneously transplanted with 2x106 MC38 tumor cells. Once the tumors had reached an average size of 0.1 cm3, 
animals were assigned to four different treatment groups with each having the same mean tumor volume. Mice were 
subjected to intratumoral injections of 1x106 TCID50 with srVSV(GFP/DsRed) (n=4),  srVSV(GM-CSF/B7) (n=3) or 
srVSV(Flt3L/B7) (n=4) (5 injections: 6, 8, 11, 13 and 15 days post tumor implantation). Control animals were injected 
with the same volume PBS (Mock). (A) Tumor growth curves of individual mice are shown. Curves of female mice are 
displayed as continuous lines and curves of male mice are displayed as dashed lines. (B) Distribution of tumor 
volumes of each group on day 15 post tumor implantation. Dots represent tumor volume of each mouse. (means ± SD) 
(C) Group comparison was performed by calculating the AUC for each animal normalized to the day when the 
respective mouse was sacrificed. (means ± SD) (D) Kaplan-Meyer survival analysis. AUC: area under the curve 
3.1.6.1 Induction of an antitumor immune response 
Next, it was tested whether cured mice conferred protective antitumor immunity 
against tumor cells. For this, cured mice were rechallenged with a subcutaneous 
injection of MC38 cells on their flanks contralateral to their initial tumor challenge. As 
control, naïve mice were transplanted with MC38 tumor cells. Control mice showed 
progressing tumor growth (Figure 21). In contrast, mice that were cured by srVSV 
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treatment rejected the tumors indicating the induction of a long-term antitumor 
immune response by the srVSV tumor therapy.  
 
Figure 21: Mice cured by srVSV treatment were protected from tumor rechallenge. Naïve mice or mice cured 
from MC38 tumors by srVSV treatment were rechallenged with a subcutaneous injection of MC38 cells (2x106 cells) at 
the opposite flank to their original tumor application. Growth curves represent the average tumor volumes. (means ± 
SD)  
To assess whether the srVSV treatment induced a tumor-specific cellular immune 
response, splenocytes of animals were analyzed for antigen-specific IFNγ-secretion by 
ELISpot assay. Mice were sacrificed 14 days after tumor rechallenge and splenocytes 
were isolated. Two different approaches were tested to stimulate isolated splenocytes. 
In a first approach, cells were stimulated with irradiated MC38 tumor cells. In a second 
stimulation variant, cells were stimulated with MC38 tumor lysates. In addition, two 
different stimulants to splenocyte ratios were tested for each approach: 1:10 and 1:5 for 
irradiated tumor cells and 1:6 and 1:2 for MC38 tumor lysates. Thus, IFNγ release by the 
splenocytes was measured in the presence of irradiated MC38 tumor cells or MC38 
tumor lysates as source of in vitro stimulating antigens. As positive control, cells were 
stimulated with ConA and cells incubated with medium only served as negative control.  
The analysis showed that incubation of splenocytes with irradiated MC38 tumor cells 
indeed stimulated immune cells. This was true for both stimulant to splenocyte ratios 
tested (Figure 22). However, almost no IFNγ-secreting immune cells were detectable 
when splenoyctes were stimulated with MC38 tumor lysates. Furthermore, IFNγ-
secreting splenocytes were only clearly detectable in spleens of mice that were cured by 
the srVSV treatment and not in spleens of the control mice. Stimulation of splenocytes 
with ConA revealed IFNγ-secreting cells in the spleens of control mouse and of cured 
mice confirming the reactivity of the splenocytes. Furthermore, the observed amount of 
IFNγ-secreting immune cells after stimulation with MC38 antigen of cured mice was 
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definitely higher as compared to the medium negative control. Altogether, the ELISpot 
assay indicated the induction of a tumor-specific cellular immune response in mice that 
were cured by srVSV treatment and thus further supports the previous data that the 
treatment induced a durable antitumor immune response.  
 
Figure 22: Analyzing IFNγ secretion by splenocytes from srVSV-cured mice after tumor rechallenge. 14 days 
after tumor rechallenge splenocytes were isolated and subjected to ELISpot analysis to assess the amount of tumor-
specific, IFNγ-secreting immune cells. For antigen-specific recall, isolated splenocytes were stimulated either with 
irradiated MC38 tumor cells (ratio of tumor cells to spleen cells: 1:10 or 1:5) or with MC38 tumor lysates (ratio of 
tumor cells to spleen cells: 1:6 or 1:2) before they were tested in IFNγ ELISpot assay for the presence of reactive cells. 
Plain medium served as negative control and Concanavalin A (ConA) served as positive control. Representative wells 
for each mice and stimulant are shown.  
3.1.7 Evaluating viral dose on therapy efficacy 
The previous data described that srVSV armed with immunotherapeutic payload was 
curative for a fraction of treated mice. However, also one mouse treated with 
srVSV(GFP/DsRed) showed complete tumor remission. In the next in vivo experiment it 
was investigated whether a lower viral dose might enhance the antitumoral effect of 
transgene-armed srVSV as compared to srVSV(GFP/DsRed) since lower viral doses 
might diminish the effect of direct viral oncolysis and thereby enhance the influence of 
transgene expression on therapy efficacy. Furthermore, in that context it was 
investigated whether the viral dose has a strong influence on therapeutic efficacy. The 
previous experiment showed a slightly improved treatment response of 
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srVSV(Flt3L/B7) as compared to srVSV(GM-CSF/B7)-injected mice. Therefore, in the 
next in vivo experiment the therapeutic efficacy of srVSV(GFP/DsRed) was compared to 
srVSV(Flt3L/B7). As female mice showed an improved treatment response as compared 
to male mice, only female mice were used in the next in vivo study.  
To this end, increasing doses of srVSV(Flt3L/B7) or srVSV(GFP/DsRed) (104, 105, 
106 TCID50) were injected intratumorally into MC38-bearing C57BL/6 mice and tumor 
growth was followed by caliper measurements.  
 
Figure 23: Tumor growth curves of subcutaneously growing MC38 tumors after intratumoral injections with 
different viral doses of srVSV(GFP/DsRed) or srVSV(Flt3L/B7). 2x106 MC38 tumor cells were subcutaneously 
implanted into the right flank of C57BL/6 mice. At an approximate size of 0.1 cm3, tumors were injected 
intratumorally with escalating doses of 104, 105 and 106 TCID50 srVSV(GFP/DsRed) or srVSV(Flt3L/B7) (5 injections: 
7, 9, 11, 13 and 15 days post tumor implantation). Control mice received the same volume DMEM (Mock). Tumor 
growth curves of individual mice are shown. 
Surprisingly, there was no pronounced difference observable between the different viral 
doses in both srVSV treatment groups (Figure 23). An increasing viral dose was not 
clearly correlated with an improved treatment response. A slight improvement for 
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srVSV(Flt3L/B7) as compared to srVSV(GFP/DsRed) was observable in the 105 TCID50 
cohort. However, this was not applicable to the 104 TCID50 cohort. In conclusion, the data 
showed that there was no pronounced improvement in the therapeutic efficacy for 
srVSV(Flt3L/B7) as compared to srVSV(GFP/DsRed) detectable when a low viral dose 
was injected. Accordingly, injection of lower viral doses did not confirm an increased 
influence of srVSV-encoded Flt3L or B7 on the tumor growth of treated mice.  
Also the overall tumor response to srVSV treatment was not as pronounced as observed 
in the previous in vivo experiment. Only two out of eleven srVSV(Flt3L/B7)-treated mice 
showed complete tumor regression. Treatment with srVSV(GFP/DsRed) was not 
curative at all. In contrast, four out of six female mice were cured by srVSV treatment in 
the previous experiment (srVSV(GFP/DsRed): 1/2; srVSV(GM-CSF/B7): 1/2; 
srVSV(Flt3L/B7): 2/2).  
Thus, it remained to evaluate whether srVSV(Flt3L/B7) treatment induced a superior 
antitumoral effect compared to srVSV(GFP/DsRed) at all. To allow a more 
straightforward comparison, tumor volume and survival of srVSV(Flt3L/B7)- and 
srVSV(GFP/DsRed)-treated mice were compared independently of the viral dose.  
The tumor sizes on day 13, the last day when all mice were alive, were quite comparable 
for both srVSV treatment groups (Figure 24A). The results of the AUC calculation 
showed a slightly increased treatment response for srVSV(Flt3L/B7) as compared to 
srVSV(GFP/DsRed), presumably arising due to the two tumor-free mice in the 
srVSV(Flt3L/B7) group (Figure 24B). However, the difference was not proven to be 
statistically significant. Mice of the srVSV(Flt3L/B7) group showed with an overall 
survival of 29 days a slightly prolonged survival as compared to srVSV(GFP/DsRed)-
treated mice which showed an overall survival of 25 days (Figure 24C). However, the 
difference was again not statistically significant.  
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Figure 24: Comparison of the antitumor efficacy of srVSV(GFP/DsRed) and srVSV(Flt3L/B7). Mice treated with 
srVSV(GFP/DsRed) or srVSV(Flt3L/B7) as described in Figure 23 were compared in regard to tumor size and survival. 
(A) Distribution of tumor volumes of each group on day 13 post tumor implantation. Dots represent tumor volumes of 
each mouse. (means ± SD) (B) Group comparison was performed by calculating the AUC for each animal normalized to 
the day when the respective mouse was sacrificed. (means ± SD) n.s., not significant by unpaired t-test. (C) Kaplan-
Meyer survival analysis. n.s. not significant by log-rank test. AUC: area under the curve  
Overall, the first as well as the latest in vivo experiment indicated only a slightly 
improved treatment response for srVSV encoding immunotherapeutic transgenes as 
compared to srVSV(GFP/DsRed). However, the differences obtained in the present 
preclinical studies were not proven to be statistically significant.    
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3.2 Towards tumor-targeted delivery of immune checkpoint inhibitors by 
receptor-targeted AAV  
One of the most promising approaches in cancer immunotherapy involves the inhibition 
of immune checkpoint receptors by PD-1- or PD-L1-specific mAbs. While the clinical 
response of these antibodies is at least in some cancer patients impressive, therapy is 
associated with a number of irAEs such as colitis and pneumonitis (Hamanishi et al, 
2016; Michot et al, 2016). The toxicities are presumably fostered by the systemic 
administration of these antibodies that does not only promote the activation of immune 
responses at sites of tumor lesions but also in healthy organs. Therefore, this project 
aimed at the specific delivery of immune checkpoint inhibitors precisely to sites of 
tumor growth.  
To this end, a strategy based on receptor-targeted AAV vectors was investigated for the 
tumor-specific delivery of immune checkpoint inhibitors. Her2/neu-targeted AAV 
vectors encoding αPD-1 and αPD-L1 were generated and characterized. After identifying 
a suitable syngeneic tumor mouse model for the in vivo studies, the generated vectors 
were analyzed for their capacity to mediate tumor-targeted delivery of immune 
checkpoint inhibitors.  
3.2.1 Generation and characterization of AAV encoding αPD-1 and αPD-L1 
In order to achieve the aim of tumor-targeted delivery of immune checkpoint inhibitors, 
Her2-AAV vectors packaging the coding sequence of αPD-1 and αPD-L1 were generated. 
For this purpose, the required AAV transfer vector plasmids encoding these inhibitors 
were cloned. The immune checkpoint inhibitors that were investigated in this study are 
composed of a scFv specific for mouse PD-1 or mouse PD-L1 and the Fc-portion of an 
human immunoglobulin IgG1 (Figure 25A). Furthermore, small epitope tags (HA, Myc) 
enabling protein detection are fused to the N- or C-terminal ends. The respective ORFs 
were amplified from the template plasmids pCG-sa-PD-1 or pCG-sa-PD-L1 using the 
primer pair scAAV-αPD-1/αPD-L1_for and scAAV-αPD-1/αPD-L1_rev. Subsequently, the 
amplified sequences were cloned into the AAV2 derived self-complementary transfer 
vector plasmid pscGFP-SFFV_2.0 using the restriction sites NcoI/NotI thereby replacing 
the GFP coding sequence and resulting in pscαPD-1-SFFV or pscαPD-L1-SFFV (Figure 
25B). As control, a similar transfer vector plasmid was cloned that encodes only the 
constant region of immunoglobulin IgG1 (IgG-Fc) as well as the HA- and Myc-tag on the 
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N- and C-terminal ends, respectively. The coding sequence of IgG-Fc was amplified from 
pscαPD-L1-SFFV by the primer pair Fc-only_for and Fc-only_rev and ligated into the 
transfer vector plasmid via the restriction sites Sfi/NotI resulting in pscIgG-Fc-SFFV. The 
inserts of the resulting plasmids were sequenced confirming the absence of mutations. 
Subsequently, the cloned transfer vector plasmids were used for the production of either 
AAV vectors carrying a Her2/neu-specific DARPin or of AAV2 having an unmodified 
capsid.  
 
Figure 25: Cloning of AAV transfer vectors. (A) Schematic representation of the used immune checkpoint 
inhibitors: single-chain variable fragment (scFv) specific for mouse PD-1 or mouse PD-L1 is fused to the constant 
region of an IgG1 (IgG-Fc). IgGκ leader sequence for secretion and an HA- and Myc-tag for detection are fused to the N- 
and C-terminal ends, respectively. HA: hemagglutinin, vH: variable region of the heavy chain, vL: variable region of the 
light chain, cH: constant region of the heavy chain, (G4S)3: Glycine-Serine-linker (B) Schematic representation of the 
cloned AAV transfer vectors. Triangle in the inverted terminal repeat (ITR) indicates the deleted terminal resolution 
site sequence from one ITR (McCarty, 2008). SFFV: spleen focus forming virus, pA: bovine growth hormone 
polyadenylation signal. 
Receptor-targeted AAV vectors were generated by an adenovirus-helper free, four 
plasmid transfection system (Figure 26) (Xiao et al, 1998; Münch et al, 2013). The 
adenoviral helper functions for successful AAV production were provided by the 
plasmid pxx6-80 encoding the required helper genes E2A, E4 and VA RNA, but lacking 
the adenoviral structural and replication genes (Xiao et al, 1998). The AAV transfer 
vector encodes the transgene under the control of the spleen focus forming virus (SFFV) 
promotor and is packaged into the AAV capsid via the ITRs during vector production. 
The rep and cap genes, which are required for the replication of the ITR flanked 
transgene, for the synthesis of the capsid proteins and for the genome packaging, are 
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provided by the plasmid pRC-VP2KO-HSPGmut (Münch et al, 2013). Compared to pRC, 
used for the production of AAV2, the plasmid pRC-VP2KO-HSPGmut carries the two point 
mutations R585A and R588A in order to ablate natural receptor binding to HSPG (Kern 
et al, 2003; Opie et al, 2003; Münch et al, 2013). In addition, incorporation of unmodified 
VP2 was prevented by mutating the start codon required for the expression of VP2 
(Münch et al, 2013). For the incorporation of the Her2/neu-specific DARPin D9.29, the 
plasmid pHer2/neuD9.29-HisXa-VP2KO encoding the DARPin-VP2-fusion protein was 
used. The latter plasmid has the same mutations as described for pRC-VP2KO-HSPGmut 
(Münch et al, 2013). Upon co-transfection of these plasmids into HEK-293T cells, 
recombinant AAV vector particles were produced and purified via iodixanol density 
gradient purification.  
 
Figure 26: Schematic representation of constructs required for the production of recombinant AAV vectors. 
The adenoviral helper plasmid pXX6-80 delivers the adenoviral helper genes E2A, A4 and VA RNA required for AAV 
production. The transfer vector encodes the transgene (αPD-1, αPD-L1, IgG-Fc, GFP, luciferase (luc)) that is flanked by 
two inverted terminal repeats (ITR). The grey triangle in the ITR indicates the deleted terminal resolution site 
sequence from one ITR (McCarty, 2008). The non-structural proteins AAP, Rep78, Rep68, Rep52, Rep40 and the 
capsid proteins VP1, VP2 and VP3 are provided by pRC. For the generation of receptor-targeted AAV vectors pRC-
VP2KO-HSPGmut was used instead. Here the natural receptor binding to HSPG was deleted by introducing the two point 
mutations R585A and R588A (indicated with a black diamond). Furthermore, incorporation of unmodified VP2 is 
prevented by deleting the VP2 start codon (indicated with a black star). The Her2/neu-specific DARPin D9.29 fused to 
the N-terminus of the VP2 capsid protein is delivered by pHer2/neuD9.29-HisXa-VP2KO. SFFV: spleen-focus forming 
virus, CMV: cytomegalovirus. 
In order to characterize AAV preparations, DNA containing vector particles were 
quantified by qPCR using a primer pair specific for the ITRs (D'Costa et al, 2016). 
  Results 
 
85 
 
 
Defined copy numbers of the linearized transfer vector plasmid pscGFP-SFFV were used 
as a standard for quantification.  
 
Figure 27: Genomic titers, capsid titers and packaging efficiency of iodixanol-purified vector stocks. (A) DNA-
containing AAV particles per µl were quantified by qPCR using ITR-specific primers (genomic titer). (n=3, means ± SD) 
(B) The amount of empty and DNA-containing capsids per µl was determined by ELISA using the αAAV2 antibody 
clone A20 that is specific for intact AAV capsids. (n=3, means ± SD) (C) The quotient of capsid to genomic titer 
provides the empty/full capsid ratio and represents the packaging efficiency of the vector. The errors for the 
empty/full capsid ratios were calculated by Gaussian error propagation. (n=3, means ± SD) 
Overall, the genomic titers of the different AAV vector preparations were similar, even 
though the data showed a trend for slightly higher genomic titers for AAV2 (about 2-
fold) as compared to Her2-AAV (Figure 27A). The AAV preparations among the different 
transgenes were proven to be similar in regard to genomic titers, with an exception for 
AAV2GFP.  
The amount of DNA-containing and empty vector particles was analyzed by an ELISA 
using a capsid-specific antibody. The results revealed again similar capsid titers for the 
different AAV vector preparations (Figure 27B). The packaging efficiencies calculated as 
quotient of the capsid and the genomic titer were similar for the different transgenes in 
AAV2 vector preparations (Figure 27C). The best packaging efficiency in Her2-AAV 
preparations was observed for the smallest transfer vector construct IgG-Fc, suggesting 
that the size of the transgene may have influenced the number of empty particles. 
However, the empty/full capsid ratios for the other Her2-AAV vector preparations were 
increased as compared to AAV2. Taken together, these data demonstrate that Her2-AAV 
vectors encoding αPD-1 and αPD-L1 were producible with comparable titers and 
packaging efficiencies to that of the GFP-encoding counterpart. 
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3.2.2 AAV-mediated expression of αPD-1 and αPD-L1 
Renal cell carcinoma (RCC) is considered to be an immunogenic tumor and has been 
subjected to various immunotherapeutic approaches (Itsumi & Tatsugami, 2010). 
Immune checkpoint blockade of the PD-1/PD-L1 axis has shown promising clinical 
results for patients with advanced RCC eventually leading to the marketing 
authorization of nivolumab for the treatment of this malignancy (McDermott et al, 2015; 
Bardhan et al, 2016). Therefore, the newly generated AAV vector particles encoding 
αPD-1 and αPD-L1 were characterized on the mouse RCC cell line RENCA. Furthermore, 
this cell line has been proven to be responsive to PD-1/PD-L1 inhibition (Hirayama et al, 
2016). However, in order to enable the cell entry of Her2/neu-retargeted AAV vectors, 
RENCA cells were used for analysis that had been genetically engineered to express the 
target receptor Her2/neu (RENCA-Her2/neu) (Maurer-Gebhard et al, 1998).   
AAV-mediated transgene expression of αPD-1, αPD-L1 and IgG-Fc was analyzed in cell 
culture supernatants of AAV-transduced RENCA-Her2/neu cells by Western blot 
analysis using an HA-tag-specific antibody. Cell culture supernatants of cells transduced 
with AAV2GFP and Her2-AAVGFP served as negative control.  
 
Figure 28: Transgene expression following AAV transduction of RENCA-Her2/neu cells. RENCA-Her2/neu cells 
were incubated with AAV2 or Her2-AAV encoding αPD-1, αPD-L1, IgG-Fc or GFP (GOI: 450,000). Cell culture 
supernatants were harvested four days post transduction and analyzed by Western blot analysis using a 
HA-tag-specific antibody.  
Specific bands were detected for αPD-1 and αPD-L1 between 55-70 kDa as well as for 
IgG-Fc between 35-55 kDa revealing the successful expression of the respective protein 
following gene transfer by AAV2 and Her2-AAV (Figure 28). The proteins were detected 
at the expected size (Engeland et al, 2014). 
  Results 
 
87 
 
 
3.2.3 Establishing an ELISA for the detection of αPD-1 and αPD-L1  
After showing the successful AAV-mediated expression of αPD-1 and αPD-L1, the next 
step was the quantification of αPD-1 and αPD-L1 protein amounts in cell culture 
supernatants of AAV-transduced cells. For this purpose, an ELISA was established. 
Initially, two different ELISA approaches were compared for their ability to detect αPD-1 
and αPD-L1. In the first approach, commercially available recombinant PD-L1 or PD-1 
were coated on the ELISA plate and protein binding was detected via an HA-tag-specific 
antibody (Approach 1, Figure 29A) (Engeland et al, 2014). In the second approach, an 
HA-tag-specific antibody was used as capture antibody and αPD-1/αPD-L1 binding was 
detected via an Fc-specific antibody (Approach 2, Figure 29B). To compare both 
approaches, RENCA-Her2/neu cells were transduced with AAV vectors encoding αPD-1 
or αPD-L1 and cell culture supernatants were analyzed by the aforementioned ELISA 
approaches. Cell culture supernatants of cells transduced with AAV2 and Her2-AAV 
encoding GFP served as negative control.  
Only for approach 2 a specific detection of both inhibitors was feasible (Figure 29D). 
Approach 1 revealed a lower signal for αPD-L1 or a signal close to the background for 
αPD-1 (Figure 29C). A reason for the variable outcome could be the better accessibility 
of the detection antibody to its antigen in approach 2 as compared to approach 1. 
Another possible reason could be a higher affinity of the αHA antibody to the HA-tag 
(Approach 2) as compared to the affinity of αPD-L1/αPD-1 to their target proteins PD-
L1/PD-1 (Approach 1). Furthermore, it cannot be excluded that the PD-1 and PD-L1 
proteins used for coating of the ELISA plates are not correctly folded. Consequently, in 
the following analysis protein amounts were quantified by sandwich ELISA using Fc- 
and HA-tag-specific antibodies according to approach 2.  
 
  Results 
 
88 
 
 
 
Figure 29: Establishing an ELISA for the detection of αPD-1 and αPD-L1. Schematic representations of two 
different ELISA approaches either using (A) recombinant PD-L1 or PD-1 (Approach 1) or (B) an HA-tag-specific 
antibody (Approach 2) to capture αPD-L1 or αPD-1. To assess both approaches, 8*103 RENCA-Her2/neu cells were 
seeded per well of a 96-well plate and transduced with AAV2αPD-L1, AAV2αPD-1, Her2-AAVαPD-L1 or Her2-AAV2αPD-1 (5 µl) 
on the next day. As mock control, cells were transduced with AAV2GFP or Her2-AAVGFP. Cell culture supernatants were 
collected four days after transduction and subjected to the ELISA either undiluted or diluted 1:10 in PBS. Samples 
were analyzed by (C) approach 1 or (D) approach 2. Arrow indicates that no signal above background was detected.    
The established ELISA was also considered to be a suitable approach to detect in vivo 
delivered immune checkpoint inhibitors in organ lysates after systemic administration 
of AAV vectors into tumor-bearing mice. Since mouse organ lysates will be not only 
prepared with mechanical but also with chemical methods using an appropriate lysis 
buffer, the influence of the used lysis buffer on protein detection in the ELISA was 
investigated. In addition, it was assessed whether a freeze/thaw cycle of the sample 
impaired the detectability of the analyzed proteins. To investigate the influence of the 
lysis buffer, three-fold serial dilutions of cell culture supernatants of AAV2αPD-1-, Her2-
AAVαPD-1-, AAV2αPD-L1- and of Her2-AAVαPD-L1-transduced RENCA-Her2/neu cells were 
prepared using the lysis buffer as diluent and analyzed by ELISA. In addition, cell culture 
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supernatants were stored for one day either at 4°C or frozen at -80°C and diluted in PBS 
for the ELISA.  
 
Figure 30: Influence of sample storage conditions and diluting buffer on protein detectability in the ELISA. 
8*103 RENCA-Her2/neu cells were seeded per well of a 96-well plate and on the following day transduced with 5 µl 
AAV2αPD-1, Her2-AAVαPD-1, AAV2αPD-L1 or Her2-AAVαPD-L1. Cell culture supernatants were collected four days after 
transduction and stored for one day either at 4°C or frozen at -80°C. Serial three-fold dilutions of the supernatants 
were prepared using PBS or lysis buffer as diluent and subsequently subjected to the ELISA.  
The curves obtained under the different conditions were quite similar for all four 
samples tested (Figure 30). This observation indicated that the lysis buffer did not 
impair the detectability of αPD-1 and αPD-L1. Furthermore, a freeze/thaw cycle of the 
sample did not affect protein detection. Accordingly, the used lysis buffer is suitable for 
the preparation of the organ lysates and the subsequent detection of in vivo expressed 
αPD-1 and αPD-L1 by ELISA. 
3.2.4 Quantification of AAV-encoded αPD-1 and αPD-L1  
For quantification of the αPD-1 and αPD-L1 amounts by the established ELISA, protein 
standards were generated. For this purpose, αPD-1 and αPD-L1 were transiently 
expressed in HEK-293T cells and purified out of the cell culture supernatants with high 
purity by Protein A affinity purification. Purified proteins were analyzed by Coomassie-
stained SDS-PAGE (Figure 31A) and Western blot analysis (Figure 31B) revealing signals 
at the expected size.  
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Figure 31: Affinity purification of αPD-1 and αPD-L1. 1.8x107 HEK-293T cells were seeded per 175 cm2 flask and 
transfected with 35 µg of the respective pCG-derived expression plasmids on the next day. Supernatants were 
harvested 24 h, 48 h and 72 h post transfection. Proteins were affinity-purified by Protein A beads. (A) Coomassie-
stained SDS-PAGE and (B) Western blot analysis from affinity-purified αPD-1 and αPD-L1 are shown. 1 µg protein was 
applied for the Coomassie-stained SDS-PAGE and 100 ng for Western blot analysis. In the Western blot analysis a Myc-
tag-specific antibody was used for the specific detection of αPD-1 and αPD-L1.  
To assess the sensitivity of the established ELISA, the assay was performed with serial 
two-fold dilutions of the generated αPD-1 or αPD-L1 standard. Surprisingly, the ELISA 
data showed a higher sensitivity for αPD-1 as compared to αPD-L1 (Figure 32). Since the 
HA-tag is directly fused to the scFv, binding of the HA-tag-specific capture antibody to 
the immune checkpoint inhibitor could be influenced by different biochemical 
properties of the scFv’s, such as folding or stability, probably explaining the difference in 
sensitivity. The lower limits of protein amounts that could be detected in different 
experiments varied from 1.6 ng/ml down to 0.4 ng/ml for αPD-1. For αPD-L1 protein 
amounts ranging from 3.2 ng/ml down to 1.6 ng/ml were detectable by the ELISA. 
 
Figure 32: Sensitivity of the established ELISA. Serial two-fold dilutions of purified αPD-1 and αPD-L1 were 
prepared and applied to the ELISA. Proteins were detected by HA-tag- and Fc-specific antibodies as described 
previously. (n=2; means ± SD) 
Next, the amount of AAV-encoded αPD-1 and αPD-L1 was quantified in cell culture 
supernatants of RENCA-Her2/neu cells that had been transduced with AAV2αPD-1, 
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AAV2αPD-L1, Her2-AAVαPD-1 and Her2-AAVαPD-L1. As negative control, cell culture 
supernatants of AAV2GFP- and Her2-AAVGFP -transduced cells were used.  
 
Figure 33: Quantification of AAV-encoded αPD-1 and αPD-L1 in cell culture supernatants. (A) RENCA-Her2/neu 
cells were incubated with AAV2αPD-1, AAV2αPD-L1, AAV2GFP, Her2-AAVαPD-1, Her2-AAVαPD-L1 or Her2-AAVGFP (GOI 
450,000) and four days later cell culture supernatants were harvested. Serial three-fold dilutions of cell culture 
supernatants were prepared and subjected to the ELISA. (B) For the quantification of αPD-1 and αPD-L1 in cell culture 
supernatants, purified αPD-1 and αPD-L1 were used as standard. (n=3, means ± SD) 
The analysis revealed a higher amount of αPD-1 and αPD-L1 in cell culture supernatants 
of AAV2-transduced cells as compared to Her2-AAV (Figure 33A). Quantification of the 
data using the generated protein standards revealed concentrations of 12.6 ± 0.9 µg/ml 
for AAV2αPD-1 (n=3, mean ± SD), 12.4 ± 1.0 µg/ml for AAV2αPD-L1 (n=3, mean ± SD), 
0.53 ± 0.04 µg/ml for Her2-AAVαPD-1 (n=3, mean ± SD) and 1.2 ± 0.1 µg/ml for Her2-
AAVαPD-L1 (n=3, mean ± SD) (Figure 33B). In summary, the Western blot and ELISA 
analyses proved the AAV-mediated expression of αPD-1 as well as αPD-L1 after 
transduction of RENCA-Her2/neu cells. 
3.2.5 Functionality of AAV-encoded αPD-L1 
In the previous chapters it was shown that AAV-encoded αPD-1 and αPD-L1 were 
expressed after transduction of RENCA-Her2/neu cells. But whether these AAV-
expressed inhibitors recognize their target antigen PD-L1 or PD-1 still needs to be 
answered.  
The melanoma cell line B16-F10 expresses PD-L1 and upregulates the expression of PD-
L1 upon stimulation with IFNγ (Fu et al, 2014; Nagato et al, 2014). Thus, specific binding 
of AAV-encoded αPD-L1 to its antigen was analyzed by incubating IFNγ-stimulated or 
unstimulated B16-F10 tumor cells with cell culture supernatants of AAV-transduced 
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RENCA-Her2/neu cells. In addition, specific binding of AAV-encoded αPD-L1 to PD-L1 
expressed on RENCA-Her2/neu cells was investigated. Binding was analyzed by flow 
cytometry using a fluorophore-labelled Fc-specific antibody. To exclude that the Fc-part 
mediated cell surface binding, cell culture supernatants of cells transduced with AAVs 
encoding IgG-Fc were used as negative controls. Furthermore, tumor cells were 
incubated with purified recombinant αPD-L1. Upregulation of PD-L1 expression on 
IFNγ-stimulated tumor cells was assessed by the commercially available αPD-L1 
antibody MIH5.  
The flow cytometry results showed a higher PD-L1 expression level on unstimulated 
RENCA-Her2/neu cells as compared to unstimulated B16-F10 cells (Figure 34). 
Stimulation with IFNγ induced an upregulation of PD-L1 expression on both tumor cell 
lines. The binding analysis revealed a specific binding of recombinant and AAV-encoded 
αPD-L1 on IFNγ-stimulated tumor cells. For AAV2αPD-L1 and recombinant αPD-L1 a 
comparatively low binding was observed on unstimulated RENCA-Her2/neu cells and 
no binding on unstimulated B16-F10 cells. No binding was detected for Her2-AAVαPD-L1 
on both unstimulated tumor cells. This correlation between the level of PD-L1 on the 
tumor cell surface and the binding efficiency of recombinant and AAV-encoded αPD-L1 
indicates the specificity of the inhibitor for PD-L1. Furthermore, no signals were 
detected for the negative controls AAV2GFP and Her2-AAVGFP as well as for AAV2IgG-Fc and 
Her2-AAVIgG-Fc. Consequently, the flow cytometry analysis demonstrated that AAV-
encoded αPD-L1 specifically recognized its target antigen PD-L1.  
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Figure 34: Specific binding of AAV-encoded αPD-L1 to IFNγ-stimulated tumor cells. B16-F10 and RENCA-
Her2/neu cells were stimulated with 500 U/ml IFNγ for three days and used for the analysis of αPD-L1 binding by 
flow cytometry. 1. Colum: B16-F10 and RENCA-Her2/neu tumor cells were stained with commercially available PE-
labelled αPD-L1 antibody (clone: MIH5) to analyze PD-L1 surface expression on unstimulated and IFNγ-stimulated 
tumor cells. As control, cells were incubated with the respective isotype control (Mock). 2. Colum: Unstimulated or 
IFNγ-stimulated tumor cells were incubated with 5 µg purified recombinant αPD-L1 and binding was detected using a 
FITC-labelled Fc-specific antibody. As control, cells were incubated with the Fc-specific antibody only (Mock). 3. & 4. 
Colum: RENCA-Her2/neu cells were transduced with AAV2αPD-L1, AAV2IgG-Fc, AAV2GFP, Her2-AAVαPD-L1, Her2-AAVIgG-Fc 
or Her2-AAVGFP (GOI 450,000) and cell culture supernatants were harvested four days later. Stimulated or 
unstimulated tumor cells were incubated with 400 µl of the respective cell culture supernatants. Binding to the cell 
surface was detected using a FITC-labelled Fc-specific antibody followed by flow cytometry. Mock-treated cells were 
incubated with the Fc-specific antibody only. Cell counts were normalized to peak value.  
3.2.6 Functionality of AAV-encoded αPD-1 
In order to assess PD-1 recognition of AAV-encoded αPD-1, HT1080 cells were 
genetically engineered to express PD-1. The cDNA sequence of mouse PD-1 (NCBI 
X67914.1) was cloned into a lentiviral transfer vector plasmid via the restriction sites 
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SpeI/BamHI resulting in pS-mPD1-IP-W. The inserts of the resulting plasmid was 
sequenced confirming the absence of mutations. VSV-G pseudotyped lentiviral vectors 
were generated using the cloned transfer vector plasmid. Subsequently, these vectors 
were used for the transduction of HT1080 cells. Successfully transduced cells were 
selected via the antibiotic puromycin for PD-1 positive cells. Surface expression of PD-1 
on the newly generated HT1080-PD-1 cells was proven by flow cytometry using a PD-1-
specific antibody (clone HA2-7B1) (Figure 35A).  
Parental HT1080 and HT1080-PD-1 cells were used to analyze the functionality of 
AAV-encoded αPD-1. For this, HT1080 or HT1080-PD-1 cells were incubated with cell 
culture supernatants of AAV-transduced RENCA-Her2/neu cells. Subsequently, binding 
was analyzed by flow cytometry using a fluorophore-labeled Fc-specific antibody. 
Recombinant αPD-1 was also applied to the assay. As negative control, supernatants of 
cells that had been transduced with AAV vectors encoding IgG-Fc were used. Specific 
binding to PD-1 expressing HT1080 cells was detected for recombinant αPD-1, 
AAV2αPD-1 and Her-AAVαPD-1 (Figure 35B). In contrast, no binding was observed for the 
negative controls AAV2IgG-Fc and Her2-AAVIgG-Fc. 
 
Figure 35: Specific binding of AAV-encoded αPD-1 to HT1080 cells stably expressing PD-1. (A) Generation and 
characterization of transgenic HT1080 cells expressing mouse PD-1. Parental HT1080 cells were transduced with 
VSV-G pseudotyped lentiviral vectors encoding mouse PD-1 as well as a puromycin resistance. After selecting 
puromycin resistant cells, surface expression of mouse PD-1 was proven by flow cytometry using a PE-labelled PD-1-
specific antibody (clone: HA2-7B1). As negative control, parental HT1080 cells were used. (B) Parental HT1080 (grey 
filled curve) or HT1080-PD-1 cells (black empty curve) were either incubated with recombinant, purified αPD-1 
(4 µg) or with 400 µl cell culture supernatants of AAV-transduced RENCA-Her2/neu cells (GOI 450,000). Binding to 
cell surface was detected using a FITC-labelled Fc-specific antibody followed by flow cytometry analysis. 
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PD-1 is physiologically not expressed on HT1080 cells but on immune cells such as 
activated T cells. Accordingly, binding of AAV-encoded αPD-1 was also investigated on 
activated mouse splenocytes. For this, mouse splenocytes were isolated from C57BL/6 
mice, depleted of red blood cells and subsequently activated with PMA and ionomycin 
for two days to induce PD-1 expression. For the binding assay, the stimulated 
splenocytes were incubated with cell culture supernatants of AAV2αPD-1-transduced 
RENCA-Her2/neu cells or purified recombinant αPD-1. As negative controls, 
supernatants of cells transduced with AAV2GFP or AAV2IgG-Fc were used. Binding was 
analyzed by flow cytometry using a fluorophore-labelled Fc-specific antibody. 
 
Figure 36: Binding of AAV2-encoded αPD-1 to stimulated mouse splenocytes. (A) Splenocytes from C57BL/6 
mice were activated for two days with PMA and ionomycin. Subsequently, cells were stained using a PE-labelled PD-1-
specific antibody (clone: HA2-7B1) and analyzed by flow cytometry. As negative control, cells were incubated with an 
appropriate isotype control (Mock). Live/dead staining was performed to exclude dead cells from the analysis. (B) 
RENCA-Her2/neu cells were incubated with AAV2 encoding αPD-1, IgG-Fc or GFP (GOI: 500,000) and cell culture 
supernatants were collected four days later. For analysis, activated mouse splenocytes were incubated either with 
purified recombinant αPD-1 (4 µg) or with 400 µl cell culture supernatants of AAV-transduced RENCA-Her2/neu cells. 
Binding to the cell surface was detected using a FITC-labelled Fc-specific antibody and flow cytometry. As control, 
cells were incubated with the Fc-specific antibody only (Mock). Live/dead staining was performed to exclude dead 
cells from the analysis. For AAV2 two different donors and representative histograms are shown. Cell counts were 
normalized to peak value. 
PD-1 expression of the activated splenocytes was confirmed by flow cytometry using the 
commercially available PD-1-specific-antibody HA2-7B1 (Figure 36A). The binding assay 
revealed binding for recombinant and AAV2-encoded αPD-1 whereas IgG-Fc showed no 
binding on activated splenocytes (Figure 36B). Taken together, these data demonstrate 
that AAV-encoded αPD-1 specifically recognized its target antigen.   
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3.2.7 Detection of in vivo delivered immune checkpoint inhibitors 
The previous chapters proved the generation of Her2-AAV vectors expressing functional 
αPD-1 and αPD-L1. Consequently, the next step was to investigate whether the 
generated vectors enable the delivery of these inhibitors in vivo.  
In previous studies tumor-specific gene transfer by Her2-AAV was shown in xenograft 
tumor mouse models but has not been analyzed in immunocompetent mice so far 
(Münch et al, 2013; Münch et al, 2015). Hence, in a pilot-experiment the AAV-mediated 
in vivo delivery of immune checkpoint inhibitors was assessed in immunodeficient mice 
first. Thereby, it was possible to investigate whether αPD-1 and αPD-L1 are expressed in 
vivo without the aggravating factor of the immune system which possibly reduces the 
efficiency of the in vivo gene transfer.  
RENCA-Her2/neu cells were subcutaneously transplanted into NSG mice and tumor 
growth was monitored until tumors reached a volume of about 70 mm3. Subsequently, 
AAV2αPD-1, AAV2αPD-L1, Her2-AAVαPD-1 or Her2-AAVαPD-L1 were injected intratumorally. 
The local administration route was chosen to evaluate whether AAV2 and Her2-AAV 
mediate the transgene expression in RENCA-Her/neu tumors in vivo at all. To 
additionally investigate whether the transgenes can be delivered into the tumor after 
systemic vector administration, Her2-AAVαPD-1 and Her2-AAVαPD-L1 were injected 
intravenously through the lateral tail vein of tumor-bearing NSG mice. As control, 
AAV2αPD-L1 was also applied intravenously. An untreated RENCA-Her2/neu-bearing NSG 
mouse served as negative control. Seven days post vector application, tumors were 
explanted and tumor lysates were prepared. For the detection of αPD-1 and αPD-L1 the 
prepared tumor lysates were applied to the established ELISA (chapter 3.2.3).  
The ELISA proved the presence of αPD-1 and αPD-L1 in all tumor lysates of mice 
injected intratumorally with AAV showing that both vector types mediated transgene 
expression after local AAV application (Figure 37). Higher signals were detectable for 
AAV2- than for Her2-AAV-mediated gene transfer. This observation is consistent with 
the previous in vitro data that also revealed higher transgene expression for AAV2 than 
for Her2-AAV. Interestingly, when vectors were injected intravenously, αPD-1 and 
αPD-L1 were only detectable in tumor lysates explanted from mice that had received 
Her2-AAV. In contrast, no signal above the background was detectable in the tumor of 
the mouse treated with AAV2αPD-L1. In summary, these data confirm the AAV-mediated 
expression of the immune checkpoint inhibitors in vivo. Furthermore, these results 
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demonstrate that the method chosen for organ disruption and the subsequent ELISA are 
eligible for the detection of αPD-1 and αPD-L1 in tumor lysates.  
 
 
Figure 37: Detection of immune checkpoint inhibitors in tumors explanted from immunodeficient mice 
treated with AAV vectors. The indicated vectors were either injected intratumorally or intravenously into RENCA-
Her2/neu-bearing NSG mice. Seven days after vector administration, mice were sacrificed and tumors isolated. Serial 
two-fold dilutions of the generated tumor lysates were prepared and subjected to the ELISA to analyze αPD-1 and 
αPD-L1 levels. Tumors explanted from RENCA-Her2/neu-bearing NSG mice that had not received AAV vectors served 
as negative control (Mock).  
Since it is well established that AAV2 transduces liver after systemic administration 
(Münch et al, 2013), liver lysates from mice treated intravenously with the AAV vectors 
were prepared and analyzed by ELISA. Signals were detected in the liver lysates of the 
mouse which had received AAV2αPD-L1 but no signals clearly above the background were 
detectable in livers of mice that had received Her2-AAVαPD-1 or Her2-AAVαPD-L1 (Figure 
38A). This observation indicated that AAV2 mediated the transgene expression in liver 
upon systemic vector applications whereas this was not applicable for Her2-AAV. To 
analyze whether the organ lysates can be stored frozen prior they are analyzed in the 
ELISA, liver lysates were also applied to the assay after they had been subjected to a 
single freeze/thaw cycle. The data showed in accordance with the analysis of the cell 
culture supernatants (Figure 30), that a freeze/thaw cycle did not influence the 
detectability of the proteins. The same was observed for tumor lysates (data not shown). 
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Figure 38: Detection of αPD-1 and αPD-L1 in liver and serum from immunodeficient mice systemically 
injected with AAV vectors. Liver and serum from RENCA-Her2/neu-bearing NSG mice that are derived from the 
experiment described in Figure 37 were analyzed by ELISA. Untreated RENCA-Her2/neu-bearing mice served as 
negative control (Mock). (A) αPD-1 and αPD-L1 levels in livers were analyzed by applying serial two-fold dilutions of 
the prepared liver lysates to the ELISA. (B) Analysis of αPD-1 and αPD-L1 levels in sera of mice. Arrow indicates that 
no signal above background was detectable. (n=2, means ± SD)    
These results confirmed that the established ELISA is suitable for the detection of αPD-1 
and αPD-L1 in tumor and liver lysates. In addition, analysis of the sera of mice treated 
intravenously with AAV vectors revealed that the ELISA is also suitable for the detection 
of the inhibitors in blood. The results also showed that only in sera from the mouse that 
had been treated intravenously with AAV2αPD-L1 a signal clearly above the background 
was detectable (Figure 38B). In contrast, for Her2-AAVαPD-1 and Her2-AAVαPD-L1 the 
signals were close to background or even not detectable.  
Overall, the data provide first evidence that the generated AAV vectors can mediate 
expression of αPD-1 and αPD-L1 in vivo and that Her2-AAV is a suitable tool to deliver 
the immune checkpoint inhibitors to the tumor even after systemic vector 
administration. Furthermore, the results show that the applied method for organ 
disruption and the subsequent ELISA can be used to detect the inhibitors in tumor organ 
lysates, in liver organ lysates and in serum.  
3.2.8  Her2-AAV tumor-targeting in immunocompetent mice 
The tumor-targeting capacity of Her2-AAV has been investigated only in 
immunodeficient mouse models so far (Münch et al, 2013; Münch et al, 2015). Since the 
therapeutic effects of the immune checkpoint blockade therapy require the immune 
system, the Her2-AAV tumor-targeting in immunocompetent mice was analyzed in a 
next step. The previous data demonstrate that RENCA-Her2/neu cells were susceptible 
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to AAV transduction in vitro and in vivo and that they expressed functional αPD-1 and 
αPD-L1 upon vector transduction. Accordingly, Her2-AAV tumor-targeting was analyzed 
using a syngeneic tumor mouse model based on immunocompetent BALB/c mice 
carrying subcutaneously growing RENCA-Her2/neu tumors.  
In order to follow tumor-targeting in vivo, Her2-AAV and AAV2 vectors were equipped 
with a luciferase reporter gene. This reporter system enables the non-invasive 
monitoring of the vector biodistribution by measuring the luciferase activity. For the 
experiment, BALB/c mice were subcutaneously injected with RENCA-Her2/neu cells and 
Her2-AAVluc or AAV2luc were administered systemically through the lateral tail vein once 
the tumors had reached an average size of about 80 mm3. Seven days after vector 
application mice were analyzed by in vivo imaging.  
 
Figure 39: Her2-AAV tumor-targeting in immunocompetent mice. BALB/c mice were subcutaneously 
transplanted with 5x106 RENCA-Her2/neu tumor cells (red arrow). Once the tumors had reached a size of about 
80 mm3, mice were intravenously injected with 1x1011 genome copies of AAV2 or Her2-AAV transferring the 
luciferase gene. One week after vector administration, AAV targeting was analyzed by in vivo imaging in (A) living 
mice and (B) isolated organs (L: liver, K: kidney, H: heart, Lu: lung, S: spleen, T: tumor). Luciferase signal intensity is 
expressed as photons/seconds/square centimeter/steradian (p/sec/cm2/sr).  
AAV2-injected mice showed a signal in the upper abdominal region (Figure 39A). In 
contrast, Her2-AAV-injected mice revealed strong luciferase activity in the tumor. 
Immediately after in vivo imaging, mice were sacrificed and luciferase signals of the 
isolated organs were analyzed. Analysis of the organs revealed that the signal in 
AAV2-injected mice originates from the liver (Figure 39B). The strongest signal for 
Her2-AAV-treated mice was observed in the tumor. No luciferase activity was detectable 
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in the liver of these mice showing that Her2-AAV was successfully redirected from liver 
to tumor tissue. However, when mice were imaged in the dorsal position luciferase 
signals were observed for Her2-AAV that presumably did not originate from the tumor 
(Figure 40A). Analysis of the explanted organs indicated that presumably the mammary 
fat pads as well as other fat tissue in the abdomen gave rise to the additional signals 
(Figure 40B). For AAV2-injected mice the expected signal in the upper abdominal region 
was detectable and the mammary fat pad did not show luciferase activity.  
 
Figure 40: Off-targeting after systemic administration of Her2-AAV. Mice that were treated as described in Figure 
39 were imaged in (A) a dorsal position and subsequently, (B) mammary fat pad and fat tissue in the abdomen were 
isolated and analyzed. Luciferase signal intensity is expressed as photons/seconds/square centimeter/steradian 
(p/sec/cm2/sr).  
Taken together, these data demonstrate that also in immunocompetent mice Her2-AAV 
is successfully redirected from liver to tumor tissue when injected intravenously, while 
non-targeted AAV2 retained in liver. Thus, as observed for the immunodeficient mouse 
models the ablation of natural receptor binding to HSPG and the incorporation of a 
Her2/neu-specific DARPin successfully redirected the Her2-AAV-mediated gene transfer 
from liver to tumor lesions.   
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3.2.9 Tumor-targeted delivery of αPD-1 by Her2-AAV 
The successful production of AAV vectors encoding αPD-1 as well as αPD-L1 and the 
identification of a suitable syngeneic tumor mouse model for the investigation of AAV-
mediated tumor-targeted delivery of immune checkpoint inhibitors were described 
above. Finally, the tumor-targeted delivery of immune checkpoint inhibitors by Her2-
AAV in immunocompetent mice was investigated. For the final analysis, αPD-1 was 
chosen as transgene since the ELISA of the pilot-experiment (chapter 3.2.7) revealed 
higher signals for αPD-1 than for αPD-L1. For the experiment, Her2-AAVαPD-1 or 
AAV2αPD-1 were systemically injected through the lateral tail vein into RENCA-Her2/neu-
bearing mice. Mice that were injected with PBS served as negative control and were 
used as blank for the ELISA analysis. One week after vector administration, mice were 
sacrificed and organs isolated as well as blood collected. Tumor lysates, liver lysates and 
serum were analyzed in regard to the αPD-1 level by ELISA. The quantity of αPD-1 in the 
organ extracts was calculated using the αPD-1 protein standard and normalized to the 
total protein yield of the organ lysates.  
The analysis showed tumor-targeted delivery of αPD-1 by systemically administered 
Her2-AAV (Figure 41A). The αPD-1 levels in the tumors were similar for all three mice 
injected. However, AAV2-treated mice showed comparable αPD-1 levels in the tumor. 
Presumably, these signals did not arise from AAV2-mediated expression of αPD-1 in the 
tumor, rather from the transport of liver expressed αPD-1 via the blood stream to other 
organs such as the tumor. On average, the levels of αPD-1 in the tumor of the three 
different mice per group was for Her2-AAV in the range of 1.9 ± 0.11 ng αPD-1/mg 
protein (n=3, mean ± SD) and for AAV2 in the range of 3.28 ± 1.22 ng αPD-1/mg protein 
(n=3, mean ± SD) (Figure 41B). In contrast, αPD-1 levels in the livers were significantly 
higher for AAV2 than for Her2-AAV. The αPD-1 levels in the liver for Her2-AAV were 
quite low. The average αPD-1 amount in the livers for Her2-AAV was 0.17 ± 
0.01 ng αPD-1/mg protein (n=3, mean ± SD) and for AAV2 5.12 ± 1.24 ng αPD-1/mg 
protein (n=3, mean ± SD). Comparing the αPD-1 levels in blood serum, AAV2-injected 
mice showed a fourfold higher level as compared to Her2-AAV-treated mice. The 
average amount of αPD-1 in sera from the different mice treated with Her2-AAV was 
447.3 ± 36.7 ng/ml (n=3, mean ± SD) and for AAV2 1,896.25 ± 378.5 ng/ml (n=3, 
mean ± SD).  
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Figure 41: Analyzing αPD-1 levels in tumor, liver and serum of mice after systemic administration of Her2-
AAV or AAV2. RENCA-Her2/neu-bearing BALB/c mice received a single intravenous injection of Her2-AAV or AAV2 
encoding αPD-1 (1.1x1010 genome copies) or PBS as mock control. One week after vector administration, organs were 
isolated and blood taken. αPD-1 levels were analyzed by the previously described sandwich ELISA using Fc- and HA-
tag-specific antibodies. (A) Raw data obtained by ELISA. (tumor: n=1, liver: n=3; serum: n=3-4; means ± SD) (B) αPD-1 
levels in tumor and liver were quantified using the generated αPD-1 protein standard and normalized to the total 
protein yields. The amount of αPD-1 in serum was calculated as ng/ml. (tumor: n=3; liver: n=9; serum: n=5-7; means 
± SD);  **, p<0.01; ns, not significant by unpaired t-test (n=3)  
Overall, these results confirmed the tumor-targeted delivery of the immune checkpoint 
inhibitor αPD-1 in a syngeneic tumor mouse model by Her2-AAV. This model will pave 
the way for further investigations addressing toxicity and efficacy of vector-mediated 
immune checkpoint modulation. 
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4 Discussion 
Treatment strategies in cancer therapy are currently shifting from targeting exclusively 
tumor cells towards stimulating the host immune system to attack the malignancy. 
Indeed, one of America’s leading scientific journals - Science - deemed cancer 
immunotherapy as ‘Breakthrough of the Year 2013’ due to substantial benefit observed 
in clinical trials (Couzin-Frankel, 2013). Improving this type of therapy will likely 
require the combination with other treatment modalities and possibly the application of 
viral based systems may contribute to further increase efficacy and safety of cancer 
immunotherapeutic approaches. In fact, recent advances in oncolytic virotherapy as well 
as viral gene therapy have proven that viral systems can be a powerful tool for medical 
applications, including the treatment of cancer (Rehman et al, 2016; Büning, 2013). In 
this thesis, oncolytic srVSV as well as receptor-targeted AAV were developed as novel 
systems for applications in cancer immunotherapy. To this end, oncolytic srVSV was 
armed with immunotherapeutic cargo to enhance its capacity to induce an antitumor 
immune response. Moreover, receptor-targeted AAV vectors were equipped with the 
coding sequence of αPD-1 as well as αPD-L1 in order to enable tumor-directed delivery 
of immune checkpoint inhibitors upon systemic vector administration.  
4.1  Arming VSV with immunotherapeutic transgenes 
Oncolytic VSV is currently developed as biological anticancer therapeutic and different 
strategies have been investigated to further improve its antitumoral efficacy. This 
involves a variety of approaches to increase the potential of VSV to induce a long-lasting 
antitumor immune response (Hastie & Grdzelishvili, 2012). In this context, VSV has been 
designed to encode TAAs or cytokines such as IL-4, IL-12, Ftl3L or GM-CSF (Pulido et al, 
2012; Fernandez et al, 2002; Shin et al, 2007; Leveille et al, 2011; Bergman et al, 2007).  
One aim of this thesis included arming of srVSV with immunotherapeutic transgenes. 
The srVSV system was developed by Muik et al. and was proven to be genetically stable, 
exhibited no neurotoxicity and showed potent antitumor activity (Muik et al, 2012). 
Furthermore, a key benefit of srVSV is the increased coding capacity for therapeutic 
transgenes making the system attractive for oncolytic immunotherapy. Accordingly, 
both viral vectors, the VSVΔG and VSVΔL vector, can be armed to enhance srVSV-
mediated antitumor immune responses. Also other oncolytic viruses were already 
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equipped with more than one immunotherapeutic transgene in order to enhance their 
antitumor efficacy. For instance, oncolytic adenovirus or HSV armed with the T cell 
costimulatory molecule B7-1 together with GM-CSF, IL-12 or IL-18 were shown to 
improve the efficacy of virotherapy (Choi et al, 2006; Lee et al, 2006; Fukuhara et al, 
2005). 
In this thesis, srVSV was armed with the immunostimulatory transgenes GM-CSF, Flt3L, 
B7 as well as with the TAA Her2/neu and CTLA4-Her2/neu. The different 
immunostimulatory transgenes were cloned into the VSVΔG and VSVΔL vector genomes, 
all VSV vectors were successfully generated de novo and functional analyses revealed 
srVSV-mediated transgene expression in vitro. Transgenes inserted into the G-position 
were expressed at higher levels as those inserted into the L-position of the VSV vector 
genome. This observation is in perfect agreement with the transcriptional gradient 
described for VSV leading to a decrease in mRNA and thus protein abundance from the 
3’ to the 5’ located genes (Villarreal et al, 1976; Barr et al, 2002). 
4.1.1 Mechanisms of action of the incorporated immunotherapeutic transgenes 
The mechanisms of inducing antitumor immunity by the used immunostimulatory 
transgenes have been studied before in the context of virotherapy and cancer 
immunotherapy. Especially, GM-CSF is highly promising as a variety of advanced 
oncolytic viruses code for GM-CSF including T-Vec, an approved oncolytic virus for the 
treatment of metastatic melanoma (Rehman et al, 2016; Lichty et al, 2014). GM-CSF is 
considered to improve antitumor effects due to the stimulation of the development and 
maturation of APCs such as DCs (Kaufman et al, 2014; Pan et al, 2004). These DCs in turn 
are recruited to the tumor microenvironment, process tumor antigens and promote 
antigen presentation that finally stimulates T cell responses augmenting antitumor 
immune responses (Figure 42) (Pan et al, 2004).  
Flt3L is also a cytokine stimulating maturation and proliferation of DCs that has shown 
promising antitumor efficacy and the induction of an immunological memory in various 
tumor models (Maraskovsky et al, 1996; Shurin et al, 1997; Chen et al, 1997; Wang et al, 
2000; King et al, 2008; Lynch et al, 1997). However, even if both cytokines have the 
capability to increase the amount of tumor-infiltrating DCs, studies directly comparing 
the efficiency of GM-CSF and Flt3L to mount an antitumor immunity revealed either an 
superior efficacy for Flt3L over GM-CSF or vice versa (Braun et al, 1999; Mach et al, 
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2000). Several differences exist between the DCs elicited by GM-CSF and Flt3L. GM-CSF 
stimulates exclusively the generation of myeloid-type DCs, whereas Flt3L drives the 
generation of both, lymphoid- and myeloid-type DCs. Moreover, GM-CSF induces the 
upregulation of the costimulatory molecule B7 on DCs and has the capability to induce a 
broad T cell cytokine response, whereas Flt3L only shows a Th1 response (Mach et al, 
2000). Furthermore, Flt3L is not only known to stimulate DCs but also to stimulate NK 
cell generation in vivo (Shaw et al, 1998). Accordingly, Flt3L-induced antitumoral effects 
were described to also depend on NK cells (Péron et al, 1998; Braun et al, 1999). In the 
present study, both cytokines were incorporated into srVSV. A pilot-experiment 
indicated a superior performance for srVSV(Flt3L/B7) treatment resulting in two 
tumor-free mice out of four over srVSV(GM-CSF/B7) treatment resulting in one tumor-
free mouse out of three. However, this was only a pilot-experiment and further studies 
with more animals will be required to confirm this tendency. 
Furthermore, srVSV was equipped with the coding sequence of soluble B7, which was 
composed of the extracellular domain of mouse B7-1 and the constant region of an IgG1, 
in order to promote antitumor T cell activity (Figure 42). B7-1-IgG fusion proteins 
demonstrated antitumor effects in multiple murine tumor models in the context of 
tumor cell vaccines as well as oncolytic virotherapy (Todo et al, 2001; Zhou et al, 2003; 
Sturmhoefel et al, 1999; Ino et al, 2006). Several hypotheses are discussed for the 
underlying mechanism by which B7-1-IgG fusion proteins assist the induction of 
antitumor immune responses since B7-1 is described to bind to CD28, CTLA-4 and PD-
L1 (Sturmhoefel et al, 1999; Zhou et al, 2003; Chen, 2004; Butte et al, 2007). Thus, B7-1-
IgG molecules probably enhance T cell co-stimulation by engaging CD28. This might be 
relevant for naïve T cells that express CD28 but no CTLA-4 on their surface. 
Furthermore, it is feasible that soluble B7-1-IgG functions like an immune checkpoint 
inhibitor. Accordingly, B7-1-IgG probably binds to CTLA-4 on activated T cells or to PD-
L1 and thereby, might antagonize T cell inhibition (Zhou et al, 2003; Sturmhoefel et al, 
1999). 
The third followed strategy to enhance tumor-specific immune responses was the 
equipment of srVSV with the TAA Her2/neu. Since the presentation of TAAs by DCs is 
critical for the induction of tumor-specific T cell responses, srVSV was also armed with 
the fusion protein CTLA4-Her2/neu. This construct is supposed to facilitate tumor-
antigen uptake by mediating the binding to B7 molecules on DCs via CTLA-4. In the 
context of other cancer vaccination studies, the CTLA4-Her2/neu fusion construct was 
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already shown to be internalized upon specific binding to B7-expressing cells eventually 
leading to intracellular protein degradation (Rohrbach et al, 2005). Comparing 
Her2/neu and CTLA4-Her2/neu in tumor mouse models revealed a superior capability 
of the fusion protein to protect mice from tumor challenge and to induce a potent 
antitumor response in terms of tumor growth and survival (Rohrbach et al, 2005; Sloots 
et al, 2008).  
4.1.2 Therapeutic efficacy of srVSV armed with immunotherapeutic cargo 
Taken together, srVSV is considered to be a promising oncolytic virotherapeutic due to 
its potent antitumor efficacy in xenograft tumor mouse models and its increased safety 
profile (Muik et al, 2012). Furthermore, the immunotherapeutic transgenes that were 
incorporated into srVSV in the present study are capable to enhance antitumor 
immunity as well as to increase the efficacy of virotherapy as demonstrated in the 
context of other cancer immunotherapy studies. Thus, combining srVSV with 
immunotherapeutic transgene expression was expected to improve srVSV cancer 
therapy. However, the present study could not confirm a clearly improved therapeutic 
efficacy of srVSV armed with immunostimulatory transgenes as compared to 
srVSV(GFP/DsRed) in an immunocompetent tumor mouse model. The in vivo pilot-
experiment compared srVSV(GM-CSF/B7), srVSV(Flt3L/B7) and srVSV(GFP/DsRed). 
Indeed, some srVSV-treated mice showed complete tumor regression. However, this was 
true for all three srVSV variants tested. Remarkably, all mice showing complete tumor 
regression were female with one tumor-free out of two treated female mice for 
srVSV(GM-CSF/B7), two tumor-free out of two treated female mice for srVSV(Flt3L/B7) 
and one tumor-free out of two treated female mice for srVSV(GFP/DsRed). This 
observation might be explained by the growth inhibition of MC38 cells by female sex 
steroids that possibly supported the antitumor effects in female mice (Motylewska & 
Melen-Mucha, 2009). Cured mice were protected against tumor rechallenge and showed 
tumor-specific immune cells in isolated splenocytes as determined by IFNγ ELISpot 
showing that the mice exhibited protective immunity against tumor cells. However, even 
though cured mice were observed in all srVSV cohorts, the tumor growth and the 
median survival indicated an improved treatment response for srVSV(GM-CSF/B7) and 
srVSV(Flt3L/B7) as compared to srVSV(GFP/DsRed), whereby srVSV(Flt3L/B7) 
indicated the best therapeutic effect. Thus, the in vivo experiment was repeated with 
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female mice only to confirm the improved efficacy of srVSV(Flt3L/B7) versus 
srVSV(GFP/DsRed). In addition, it was evaluated whether a lower viral dosage might 
improve the antitumoral effect of srVSV(Flt3L/B7) compared to srVSV(GFP/DsRed) as 
this set-up might enhance the influence of transgene expression and diminish the effect 
of direct viral oncolysis. However, when the same viral dosage was applied as in the first 
in vivo experiment the therapeutic effect of srVSV-treated mice in both cohorts was not 
as pronounced as observed in the previous in vivo experiment. Only one out of four 
female mice showed complete tumor regression in the srVSV(Flt3L/B7) cohort and no 
mouse was cured by srVSV(GFP/DsRed) treatment. Furthermore, an increased 
therapeutic efficacy of srVSV(Flt3L/B7) compared to srVSV(GFP/DsRed) with lower 
viral doses was not observed. After all, srVSV(Flt3L/B7) treatment showed again a 
slightly improved treatment response as compared to srVSV(GFP/DsRed). However, the 
results did not reveal a statistically significant superior therapeutic efficacy of 
srVSV(Flt3L/B7) as compared to srVSV(GFP/DsRed). Consequently, the therapeutic 
efficacy of srVSV armed with immunotherapeutic cargo was not clearly improved as 
compared to srVSV(GFP/DsRed) treatment as initially assumed. Thus, much larger 
cohort sizes will be required to clarify whether arming of srVSV with 
immunostimulatory transgenes improves srVSV therapy efficacy.   
4.2 Oncolytic immunotherapy requires a balance between antitumor and 
antiviral immune responses 
The host immune response is critical for the efficacy of oncolytic virotherapy. On the one 
hand, viral oncolysis potentially elicits beneficial antitumor immunity and on the other 
hand, provokes detrimental antiviral immune responses. For example, induced antiviral 
immune responses might eliminate virus-infected tumor cells and thereby enhance 
therapy efficacy due to tumor regression and otherwise also dampen efficacy due to 
early viral clearance. Thus, a fine balance between viral and tumor elimination is 
required for successful oncolytic immunotherapy (Prestwich et al, 2008).  
Even VSV that was not armed with additional immunotherapeutic transgenes was 
capable to elicit antitumor immune responses. Diaz and colleagues showed that the 
efficacy of VSV in an immunocompetent melanoma mouse model did not only depend on 
its oncolytic activity but also on host-derived immune cells, in particular on CD8+ T cells. 
In this study, not only tumor-specific but also VSV-specific T cells were induced during 
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therapy. Arming VSV with a tumor-antigen induced a similar number of antiviral T cells, 
while the number of tumor-antigen-specific T cells were increased eventually leading to 
an improved therapy efficacy (Diaz et al, 2007). Thus, equipping srVSV with the TAA 
Her2/neu or CTLA4-Her2/neu might also be able to increase the amount of tumor-
specific T cells and to improve efficacy as compared to parental srVSV. However, since 
no suitable Her2/neu-positive tumor model was available, these srVSV constructs have 
not been investigated in vivo so far.  
4.2.1 Type I IFN-induced antiviral immune responses 
A major barrier for successful VSV oncolytic immunotherapy is the innate immune 
response as VSV is particularly sensitive to type I IFN-induced antiviral responses. Thus, 
defective IFN pathways in cancer cells are described to be the key determinant of VSV 
oncoselectivity and are decisive for effective VSV therapy (Stojdl et al, 2000; Stojdl et al, 
2003; Liu et al, 2013; Hastie & Grdzelishvili, 2012). Even though many tumor cells have 
acquired deregulated IFN-responsiveness, the extent of the defects are highly variable 
between different cancers (Liu et al, 2013; Stojdl et al, 2003; Dold et al, 2016). 
Therefore, in the present study different murine cancer cell lines were analyzed 
concerning their IFN sensitivity to identify a suitable mouse model to investigate the 
therapeutic efficacy of srVSV in vivo. Analyses revealed that the murine colon cancer cell 
line MC38 could be an appropriate tumor model since MC38 cells were infectable even 
when pretreated with high doses of IFNα. However, albeit MC38 cells remained 
susceptible to VSV infection after pretreatment with the highest tested IFNα doses of 
100 U/ml and 1000 U/ml, cell viability was increased compared to untreated control 
cells showing that even MC38 cells were not totally unresponsive to the antiviral effects 
of IFNα. Accordingly, partially intact antiviral mechanisms in MC38 tumor cells probably 
limited the efficacy of the srVSV treatment in the MC38 tumor model (Figure 42). To 
investigate in future experiments whether MC38 cells are resistant to srVSV infection in 
vivo, immunohistochemical staining of VSV proteins in isolated tumors would be feasible 
for example.  
It was shown that even if cancer cells have functional IFN response pathways, they are 
permissive to VSV infection in vitro due to the absence of accessory cells which produce 
IFN. In contrast, those cancer cells are protected from VSV infection in vivo due to 
stromal cells of the tumor microenvironment such as tumor-associated macrophages 
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that produce IFN (Liu et al, 2013). Accordingly, one strategy of Lemay and colleagues to 
harness VSV-mediated antitumor immunity was the usage of an infected cell vaccine. 
Here, B16-F10 cells, which are not VSV-permissive in vivo, were infected in vitro with 
VSV to bypass the requirement for in vivo replication to elicit an antitumor immune 
response. Those VSV-infected cell vaccines were used to immunize mice and were 
shown to protect some animals against a subsequent tumor challenge in a prophylactic 
setting. Using B16-F10 cells infected with VSV encoding GM-CSF (VSV-GMCSF) protected 
even more mice against future tumor challenge and also showed antitumor efficacy in 
therapeutic models of subcutaneously or metastatically growing B16-F10 tumors. In 
contrast, B16-F10-tumor-bearing mice that were solely treated with VSV or VSV-GMCSF, 
the same approach as used in the present study, did not respond to VSV treatment most 
likely due to the lack of intratumoral viral replication (Lemay et al, 2012).  
Other studies aimed at suppressing IFN signaling in the tumor microenvironment in 
order to support VSV spread and oncolysis. In that context, localized expression of B18R, 
a type I IFN antagonist that is originally derived from vaccinia virus, was shown to 
enhance viral spread and tumor destruction of tumor cells exhibiting low VSV-
susceptibility (Alcami et al, 2000; Le Boeuf et al, 2010; Cronin et al, 2014). In another 
study the IFN sensitivity of ovarian cancer cells was overcome by inhibiting the Janus 
kinase/signal transducer and activator of transcription (JAK/STAT) pathway, which is 
involved in the induction of IFN responsive antiviral genes, using the drug ruxolitinib. 
The combination of VSV treatment and ruxolitinib administration showed an improved 
therapeutic efficacy in a subcutaneous as well as in an orthotopic tumor mouse model 
(Dold et al, 2016). Thus, if the srVSV treatment failed to elicit a pronounced antitumor 
effect due to the partial sensitivity of MC38 cells to the antiviral effects of IFN, 
combination of srVSV with B18R or ruxolitinib probably might improve srVSV treatment 
outcome.  
However, tumor selectivity of VSV is mainly mediated via intact IFN pathways of healthy 
cells. Accordingly, combination therapy of B18R or ruxolitinib might lead to VSV 
replication in healthy tissue resulting in damage of nontumor cells. Anyway, so far no 
signs of toxicity have been reported for the combination therapy of VSV with one of 
these IFN modulators (Dold et al, 2016; Cronin et al, 2014; Le Boeuf et al, 2010). 
Moreover, the risk of toxicity for srVSV might be even lower as compared to fully 
replication-competent VSV, due to its mode of co-propagation. Furthermore, it must be 
considered that inhibition of type I IFN responses in the tumor microenvironment might 
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not only support viral oncolysis but might also dampen antitumoral immune responses 
(Sikora et al, 2009; Hiroishi et al, 2000; Smyth et al, 2004).  
4.2.2 Humoral immune responses 
A further factor of the immune system potentially limiting efficacy of oncolytic 
virotherapy is the humoral adaptive immunity. VSV was shown to trigger a rapid and 
robust neutralizing antibody (nAb) response beginning at day 3 post intravenous VSV 
administration (Muik et al, 2014; Pinschewer et al, 2004). Single intratumoral 
application of srVSV also resulted in a nAb response beginning at day 5 post application 
and was increased until the end of the observation period on day 14 (data not shown). 
Thus, it has to be expected that the induction of nAbs probably will also limit the therapy 
efficiency of srVSV (Figure 42). One promising strategy to prevent the induction of a nAb 
response against srVSV could be the exchange of the VSV glycoprotein (VSV-G) with the 
glycoprotein of LCMV (LCMV-GP) (WE strain). Replication-competent VSV pseudotyped 
with LCMV-GP (rVSV(GP)) was already shown to escape nAb response after a single 
intravenous injection and was efficiently delivered to subcutaneous growing tumors in 
preimmunized mice (Muik et al, 2014). Thus, in the present study srVSV was also 
pseudotyped with the glycoprotein of LCMV (srVSV(GP)) to investigate whether this 
construct also evades humoral immune responses and indeed, srVSV(GP) did not elicit a 
nAb response after a single intratumoral injection (data not shown). Furthermore, 
previous work by Muik et al. demonstrated that immune cells were less susceptible to 
VSVΔG pseudotyped with LCMV-GP (VSVΔG-GP) as compared to VSV-G complemented 
VSVΔG vectors (VSVΔG-G). In particular, VSVΔG-GP was shown to spare stimulated 
T cells and DCs that were in contrast infected by the VSVΔG-G vector (Muik et al, 2011). 
Thus, pseudotyping srVSV with LCMV-GP may not only avoid the induction of nAbs but 
also prevent the infection of immune cells that are recruited into the tumor 
microenvironment. Leveille et al. showed that tumor-associated DCs were infected by 
VSV in vivo reducing their viability as well as preventing their migration to the draining 
lymph nodes to prime a tumor-specific T cell response (Leveille et al, 2011). 
Accordingly, infection of DCs by VSV potentially interferes with tumor-antigen 
presentation being crucial to induce an antitumor immune response and on the 
contrary, might enhance VSV-specific immune responses. Possibly, infection of recruited 
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DCs, T cells or other immune cells by srVSV also hampered therapy efficacy in the 
present study (Figure 42).  
 
Figure 42: Schematic drawing of possible mechanisms promoting or limiting srVSV therapy efficiency. Possible 
mechanisms promoting therapy efficiency: Infection of tumor cells by srVSV causes direct virus-mediated cell lysis 
and the recruitment of conventional dendritic cells (cDCs) as a result of srVSV-mediated GM-CSF or FLt3L expression 
(①) as well as by release of PAMPs and DAMPs. Released tumor-associated antigens (TAAs) are captured and 
processed by the recruited cDCs that migrate to lymphatic organs in order to stimulate tumor-specific T cells (②). 
Tumor-specific T cells migrate into the tumor microenvironment (TME) where B7, expressed by srVSV-infected tumor 
cells, support their activity (③). Finally, T cells potentially directly attack tumor cells leading to tumor debulking. In 
addition to increasing the amount of cDCs, Flt3L potentially also triggers the generation of plasmacytoid DCs (pDCs) 
and natural killer (NK) cells (Shortman et al, 2013; Shaw et al, 1998). pDCs are the major interferon (IFN)-producing 
cell type and thus, intratumoral production of type I IFN by pDCs might also contribute to antitumor immunity 
through the upregulation of MHC molecules on tumor cells or via stimulating TAA-specific T cells for instance (Smyth 
et al, 2004). Recruited NK cells potentially also trigger tumor cell killing (Marcus et al, 2014). Possible mechanisms 
limiting therapy efficiency: srVSV possibly infects recruited DCs and thereby prevents the migration of DCs into 
lymphatic organs. This event interferes with tumor-antigen presentation and activation of tumor-specific T cells. 
Secreted type I IFN might affect srVSV spread within tumor cells that exhibit at least partial sensitivity to type I IFN 
induced antiviral responses. The induction of neutralizing antibody (nAb) response might further hamper viral 
spread. Altogether, antiviral immune responses also shorten the duration of srVSV-mediated transgene expression.  
4.2.3 Antiviral immune responses may interfere with srVSV-mediated expression 
of immunomodulatory proteins 
Innate and adaptive antiviral immune responses also shorten the duration of viral-
mediated transgene expression. However, some immunotherapeutic proteins might 
need a certain time to fulfill their immunostimulatory function. For example, Flt3L has 
been shown to trigger the increase of DCs in mice after 8 to 10 days following daily 
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administration (Maraskovsky et al, 1996). Accordingly, srVSV-mediated Flt3L 
expression might not be sustained for a sufficient time to augment the DC numbers in 
the tumor-microenvironment. Similarly, it was demonstrated that the combination 
therapy of VSV and of recombinant Flt3L (daily administration over 10 days) exhibited a 
pronounced survival advantage as compared to parental VSV, whereas VSV engineered 
to encode Flt3L could only provide modest or even no survival improvement in the 
different tumor mouse models tested (Leveille et al, 2011). Consequently, srVSV 
engineered to encode immunotherapeutic transgenes probably did not elicit a 
pronounced superior therapeutic effect as compared to srVSV(GFP/DsRed) in the 
present study, since the duration of srVSV-mediated transgene expression was not 
sufficient to benefit from the immunostimulatory properties of the viral-encoded cargo.  
In order to examine the aforementioned assumptions the analysis of srVSV replication in 
MC38 tumor cells in vivo, the investigation of antiviral immune responses as well as of 
the duration of srVSV-mediated transgene expression in MC38 tumors would be 
necessary. 
4.2.4 Possible strategies to improve srVSV therapy 
Taken together, srVSV treatment probably failed to induce a potent antitumor effect due 
to induced innate and adaptive antiviral immune responses. To avoid antiviral innate 
immune responses, the usage of tumor mouse models that are totally unresponsive to 
type I IFN antiviral responses, such as 5TGM1 or MPC-11, would be reasonable in future 
experiments (Liu et al, 2013). Alternatively, combining IFN modulators with srVSV 
therapy would be a further feasible strategy to overcome IFN sensitivity of tumor cells. 
Furthermore, using srVSV pseudotyped with the glycoprotein of LCMV could also 
enhance the outcome of srVSV oncolytic immunotherapy by evading humoral immunity 
and preventing the infection of recruited immune cells. In conclusion, combining these 
strategies might prolong the duration of srVSV-mediated transgene expression and thus, 
potentially also enhance the therapeutic efficacy of srVSV armed with 
immunostimulatory transgenes as compared to srVSV(GFP/DsRed). 
4.3 Local delivery of immune checkpoint inhibitors 
Monoclonal antibodies directed against immune checkpoints, such as PD-1 and PD-L1, 
have revolutionized cancer therapy with now several products on the market that 
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substantially prolong survival of end stage cancer patients (Bardhan et al, 2016). Despite 
the exciting clinical results obtained for the treatment of several malignancies using 
αPD-1 and αPD-L1 mAbs, there is an urgent need of further improving immune 
checkpoint blockade therapy. First, not all cancer patients respond to PD-1/PD-L1 
blockade therapy whereas the objective response rates range between 15 % up to 40 % 
for the approved antibodies (Weber et al, 2015; Robert et al, 2015a; Topalian et al, 2014; 
Robert et al, 2015b; Robert et al, 2014; Rosenberg et al, 2016). Second, PD-1/PD-L1 
immune checkpoint blockade therapy is associated with a number of immune-related 
toxicities. Grade 3 – 4 adverse events are observed in about 5 % up to 16 % of treated 
patients (Weber et al, 2015; Robert et al, 2015a; Robert et al, 2015b; Rosenberg et al, 
2016). Third, the treatment entails high costs due to the amount of inhibitors needed. 
Generally, patients are treated with the respective mAbs in regular intervals until 
disease progression or unacceptable toxic effects are observed (Weber et al, 2015; 
Robert et al, 2014).  
Local delivery of immune checkpoint inhibitors is a promising approach potentially 
addressing the aforementioned drawbacks. Toxicities elicited through autoimmune or 
inflammatory side effects might be limited by local mAbs delivery due to lower systemic 
exposure (Aznar et al, 2017). Furthermore, off-target binding of immune checkpoint 
inhibitors to healthy tissue might not only promote toxicity but also reduce the efficacy 
of the treatment. Local administration may circumvent low tumor tissue penetration by 
systemically injected mAbs (Aznar et al, 2017). It was shown by immuno-positron 
emission tomography (PET) imaging that only around 5 % to 10 % of systemically 
injected αPD-1 was accumulated in tumor tissue of treated mice (Natarajan et al, 2015).  
Various approaches were investigated to achieve local delivery of immune checkpoint 
inhibitors. This included generation of tumor cell lines stably expressing the respective 
mAbs or novel delivery systems such as polymeric microparticles or Montanide 
emulsions that are loaded with mAbs (e.g. αCTLA-4) (Simmons et al, 2008; Rahimian et 
al, 2015; Fransen et al, 2013). A further strategy to increase the safety of checkpoint 
blockade therapy was based on dual-targeting bispecific antibodies that targeted a TAA 
as well as a checkpoint receptor (Dheilly et al, 2017). In the present thesis, Her2-AAV 
vectors were investigated as potential vehicles for the tumor-targeted delivery of the 
immune checkpoint inhibitors αPD-1 and αPD-L1. 
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4.3.1 Delivery of antibodies and antibody-like molecules by AAV vectors 
AAV vectors are currently under investigations as platform for the delivery of 
antibodies. In contrast to passive immunization where neutralizing antibodies are 
directly administered into the patient, viral vector-mediated antibody gene transfer 
delivers the respective gene to the target cell being subsequently expressed in vivo 
(Schnepp & Johnson, 2014).  
AAV vectors exhibit a limited packaging capacity that ranges about 4.7 kb for ssAAV and 
is even reduced for scAAV packaging a double-stranded DNA (McCarty, 2008). Wu et al. 
suggested a maximum packaging capacity of scAAV vectors of around 3.3 kb (Wu et al, 
2007). Thus, scAAVs are not able to accommodate the heavy and the light chain required 
for a full-length immunoglobulin G (IgG) antibody. Nevertheless, scAAV vectors achieve 
considerably higher levels of transgene expression in vitro as well as in vivo and 
therefore, different approaches were investigated to enable scAAV-mediated expression 
of antibodies or antibody-like molecules (McCarty et al, 2001; McCarty et al, 2003; Fuchs 
et al, 2016). AAV vectors are under intense development especially for the delivery of 
anti-human immunodeficiency virus (HIV) antibodies in order to prevent or treat the 
disease and various strategies for antibody delivery by AAV vectors were investigated in 
that context (Schnepp & Johnson, 2014; Fuchs & Desrosiers, 2016; Deal & Balazs, 2015). 
One approach relied on the usage of antibody-like molecules composed of a simian 
immunodeficiency virus (SIV)-specific scFv attached to a rhesus IgG2-derived Fc-part. 
Upon expression the scFv-Fc dimerizes and forms the so-called ‘immunoadhesins’. The 
respective coding sequence was packaged into an AAV serotype 1 (AAV1)-derived 
vector and resulting AAVs were administered intramuscularly into rhesus macaques. 
Using this approach, SIV-specific immunoadhesins were expressed in vivo and were 
detectable in sera of some treated animals up to 12 months that were furthermore 
protected against SIV infection. Additionally, transgene expression levels of 
immunoadhesins that were packaged into scAAV vectors were higher as compared to 
ssAAV vectors (Johnson et al, 2009). 
One aim of this thesis was the generation of AAV vectors encoding immune checkpoint 
inhibitors targeting PD-1 or PD-L1. The molecular architecture of the inhibitors used in 
the present study was comparable to that of the above described SIV-specific 
immunoadhesins that were successfully delivered by AAV vectors in vivo and exhibited 
biological function (Johnson et al, 2009). The αPD-1 and αPD-L1 constructs used in this 
thesis were composed of a scFv specific for mouse PD-1 or PD-L1 and a constant region 
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of a human IgG1. Immune checkpoint inhibitors exhibiting the same molecular 
architecture were already proven to show antitumoral efficacy in preclinical mouse 
models when encoded by an oncolytic virus (Engeland et al, 2014).  
The ORFs of αPD-1 or αPD-L1 were cloned into AAV2-derived self-complementary 
transfer vectors and together with both ITRs as well as the SFFV promotor, the transfer 
vector constructs finally exhibited a size of about 2.6 kb. Thus, the generated AAV 
transfer vectors encoding αPD-1 and αPD-L1 matched to the packaging capacity 
required for scAAV vectors (Wu et al, 2007). Successful encapsidation of the AAV 
transfer vectors by scAAV particles was proven by determining the genomic titers by 
qPCR. The genomic titers were mainly comparable among the different transgenes GFP 
(size transfer vector: 2,217 bp), αPD-1 (size transfer vector: 2,594 bp), αPD-L1 (size of 
transfer vector 2,588 bp) and IgG-Fc (size transfer vector 1,862 bp) ranging between 
5x108 and 1x109 gc/µl and thus, demonstrated that the vectors were producible to 
similar yields. Only AAV2GFP exhibited a slightly higher titer of about 1x1010 gc/µl. 
Calculating the ratio of capsid to genomic titer revealed a slightly decreased packaging 
efficiency of Her2-AAV vectors having the larger constructs encapsidated (GFP, αPD-1, 
αPD-L1) as compared to non-targeted AAV2. However, it has been described previously 
that the fusion of a DARPin to the N-terminus of VP2 and even small alterations in the 
AAV capsid can influence the packaging efficiency of AAV vectors (Münch et al, 2013; Wu 
et al, 2000). Furthermore, the empty-full capsid ratio of Her2-AAV encoding IgG-Fc was 
improved as compared to the other Her2-AAV vectors indicating that the size of the 
transfer vector construct can influence the packaging efficiency.  
The AAV2 and Her2-AAV vectors were proven to successfully mediate the expression of 
αPD-1 and αPD-L1 after transduction of the mouse RCC cell line RENCA-Her2/neu and 
the expressed immune checkpoint inhibitors specifically recognized their target protein 
PD-1 or PD-L1. However, the analyses revealed higher levels of transgene expression for 
AAV2 as compared to Her2-AAV vectors even though the same GOI was applied for 
transduction. This result can probably be explained by previous observations showing 
that Her2-AAV vector preparations are not only composed of DARPin-displaying AAVs 
but also of vector particles that had not incorporated the DARPin-VP2 fusion protein and 
are build up by VP1 and VP3 proteins only (Münch et al, 2015). Those VP1/VP3 particles 
have also packaged the vector genome but they can neither bind to Her2/neu nor to 
HSPG and thus do not contribute to gene transfer. Therefore, the transduction of AAV2 is 
probably more efficient than for Her2-AAV even though the same GOI was applied 
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resulting in different protein yields in cell culture supernatants of transduced cells. 
However, this could be obviated including a further purification step during AAV 
production. Münch and colleagues showed that affinity purification can be used to 
separate DARPin-displaying from DARPin-deficient AAV particles enabling the 
generation of vector preparations solely composed of DARPin-displaying AAV vectors 
(Münch et al, 2015). 
To study antitumoral effects by immune checkpoint blockade therapy, 
immunocompetent models are mandatory. Therefore, RENCA cells that are syngeneic to 
fully immunocompetent BALB/c mice were investigated as a potential mouse model. In 
order to enable the cell entry of Her2-AAV, RENCA cells were used that had been 
genetically engineered to express the target receptor Her2/neu (Maurer-Gebhard et al, 
1998). The results of the present study showed that RENCA-Her2/neu cells were 
transducable by Her2-AAV vectors and expressed functional αPD-1 and αPD-L1 upon 
AAV transduction. In addition, Hirayama et al. demonstrated that RENCA derived tumors 
are responsive to the inhibition of the PD-1/PD-L1 axis (Hirayama et al, 2016). 
Furthermore, immune checkpoint blockade therapy was successfully used for the 
treatment of RCC in clinics (McDermott et al, 2015). Taken together, these observations 
demonstrate that RENCA-Her2/neu is a reasonable syngeneic tumor mouse model to 
investigate immune checkpoint blockade therapy after systemic AAV vector 
administration. Therefore, the tumor-targeting capacity of Her2-AAV was analyzed in an 
immunocompetent BALB/c mouse model bearing subcutaneous growing RENCA-
Her2/neu tumor cells after intravenous vector administration. Her2-AAVluc vectors 
showed a high luciferase signal in the tumor tissue, whereas the highest signal of non-
targeted AAV2luc was detectable in the liver. This is in accordance with the previously 
performed AAV-targeting experiments in immunodeficient mice in which also successful 
redirection of Her2-AAVluc from liver to tumor tissue was shown (Münch et al, 2013; 
Münch et al, 2015). The residual off-target signals observed for Her2-AAVluc vectors are 
likely elicited by VP1/VP3 vector particles that had not incorporated the DARPin-VP2 
fusion protein (Münch et al, 2015). Finally, tumor-targeted delivery of αPD-1 by Her2-
AAVαPD-1 vectors was shown. Upon systemic administration of Her2-AAVαPD-1 into the 
aforementioned tumor mouse model, higher αPD-1 levels were detectable in the tumor 
as compared to the liver. In contrast, mice injected with non-targeted AAV2αPD-1 revealed 
the highest level of αPD-1 in the liver.   
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Approved immune checkpoint inhibitors that are used for the treatment of end-stage 
cancer patients are full-length IgG mAbs. Thus, to translate the AAV vector technology 
from pre-clinical models to clinical studies, it would be preferably to equip the vectors 
with the sequence encoding for one of the approved mAbs. This would require the 
incorporation of the heavy and the light chain of an IgG into AAV vectors. Different 
studies already attempted to use AAV vectors for the delivery of full-length IgG 
molecules in order to treat or prevent infectious diseases as well as to treat Alzheimer’s 
disease or methamphetamine addiction (Fuchs et al, 2015; Skaricic et al, 2008; Shimada 
et al, 2013; Chen et al, 2017). One approach enabling the expression of a full-length 
antibody specific for HIV by ssAAV vectors is the dual promotor approach. Here, the 
vector encodes a CMV promotor for the heavy chain and an EF1α promotor for the light 
chain (Lewis et al, 2002).  
Another study by Fuchs et al. used scAAV as well as ssAAV vectors for the in vivo 
delivery of full-length versions of IgG antibodies specific for SIV. Due to the limited 
packaging capacity of scAAV vectors, those vectors were generated by placing the heavy 
and the light chain on two separate scAAV vectors (two vector approach). For the 
generation of ssAAV vectors, the heavy and the light chain sequences were placed onto 
one single ssAAV vector separated by the 2A self-cleaving sequence from foot-and-
mouth disease virus (F2A) (one vector approach). The respective AAV transfer vectors 
were packaged into rAAV1 capsids and injected intramuscularly into rhesus macaques. 
SIV-specific antibodies were measured in the serum through 44 weeks with 
concentrations ranging from 1 to 270 µg/ml that seemed to be dependent on the 
presence of anti-antibody responses. In one animal high antibody levels persisted for 
more than two years. The presence of AAV-delivered SIV-specific antibodies showed 
significant antiviral effects (Fuchs et al, 2015). Remarkably, the efficiencies of scAAV and 
ssAAV vectors were similar in the study of Fuchs et al., in contrast to numerous other 
studies exhibiting a superior efficiency of scAAV vectors (McCarty, 2008; McCarty et al, 
2001; Gao et al, 2006; Wang et al, 2003; Natkunarajah et al, 2008). This can probably be 
explained by the principle of the two vector approach that is based on the idea that high 
concentrations of scAAV particles are injected into localized areas of tissue leading to a 
high likelihood that a majority of the cells will take up many particles. This is crucial 
since the heavy and the light chains encoded of the respective scAAV vector must come 
together to form the full length IgG (Fuchs et al, 2015; Fuchs et al, 2016). Therefore, the 
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two vector approach using scAAV is probably even less suitable for receptor-targeted 
AAV that are administered systemically.  
Finally, different studies have shown that AAV vectors can be used for the delivery of 
full-length antibodies making their application for the tumor-targeted delivery of 
immune checkpoint inhibitors that are used in clinics also feasible. However, due to the 
potential limitations of the two vector approach using scAAV vectors, ssAAV vectors 
should probably be preferred for the delivery of full-length antibodies especially when 
receptor-targeted vectors are used.   
4.3.1.1 Duration of AAV-mediated antibody expression 
An often mentioned advantage of AAV vectors for the delivery of antibodies is their 
capability to mediate a long-term transgene expression making re-administration of 
antibodies not necessary that, in contrast, is generally required for passive 
immunization due to the short half-life of antibodies (Deal & Balazs, 2015). Even though 
AAV genomes persist predominantly episomally in the cells, the protein will be 
expressed for the lifetime of the cell and as long as the transgene product is not 
recognized as foreign by the immune system (Schnepp et al, 2003; Schnepp et al, 2016; 
Johnson et al, 2009; Fuchs et al, 2015; Rivera et al, 2005; Mueller et al, 2017; Fuchs & 
Desrosiers, 2016). When long-term delivery of the transgene product is desired, AAV 
vectors are generally delivered to post-mitotic organs such as muscle, brain or liver 
resulting in a sustained transgene expression that can continue up to years (Mueller et 
al, 2017; Fuchs et al, 2015; Korbelin et al, 2016; Nakai et al, 1998). Intramuscular 
injection of AAV vectors delivering antibodies for cancer therapy resulted in a stable 
antibody expression for at least 70 to 85 days in mice. The serum concentrations 
strongly varied between the studies and were found to be in the range of 1 µg/ml up to 
1,000 µg/ml (Lv et al, 2011; Ho et al, 2009; Principe et al, 2015). Intraperitoneal 
injections of AAV vectors into mice also enabled long-term transgene expression 
including one study by Xie et al. that used an AAV vector encoding an antibody for the 
treatment of ovarian cancer (Chen et al, 2017; Xie et al, 2014). Xie et al. observed 
persistent and high levels of AAV-delivered antibodies in intraperitoneal organs (lavage, 
omentum, mesentery and diaphragm) with concentrations between 200 ng/mg total 
protein up to 1,000 ng/mg total protein in the different organs 9 weeks after vector 
administration. Thus, their concentrations were around 100- up to 500-times higher as 
compared to the αPD-1 amounts in tumor tissue of Her2-AAVαPD-1-treated mice 
measured in the present study (2 ng/mg total protein). However, this can probably be 
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explained due to differences in the study design such as different time points of analysis 
(Xie et al.: 9 weeks; this thesis: 7 days after vector administration), different tissues 
encoding the antibody (Xie et al.: intraperitoneal organs; this thesis: tumor) or design of 
the AAV vector (Xie et al.: rhesus serotype 10 AAV (AAVrh10); this thesis: receptor-
targeted Her2-AAV).  
Also for immune checkpoint blockade in cancer therapy a sustained transgene 
expression might be advantageous since multiple administrations of immune checkpoint 
inhibitors are performed in pre-clinical models as well as for the treatment of patients in 
clinics (Kim et al, 2014; Duraiswamy et al, 2013; Larkin et al, 2015; Robert et al, 2015b). 
The present study aimed at the AAV-mediated delivery of immune checkpoint inhibitors 
to cancer cells that belong to mitotically active tissue. Accordingly, as long as the tumor 
cell is alive the transgene can probably be expressed by the cell enabling a sustained 
AAV-mediated expression of immune checkpoint inhibitors. But as soon as the tumor 
cell dies due to necrosis for instance this particular cell cannot further contribute to 
transgene expression. Thus, expression of the immune checkpoint inhibitors might 
decline over time. So far, the current study provided evidence for AAV-mediated 
expression of αPD-1 and αPD-L1 in the tumor 7 days after vector administration. It 
remains to be evaluated in more detail which amounts of immune checkpoint inhibitors 
are present in the tumor over time.  
4.3.2 Further strategies to achieve local delivery of immune checkpoint 
inhibitors 
As discussed in the previous chapter AAV vectors are a promising tool for the delivery of 
antibodies in order to treat different diseases. Furthermore, the current study provided 
first evidence that receptor-targeted Her2-AAV vectors are suitable for the tumor-
specific delivery of immune checkpoint inhibitors. However, at present it is not exactly 
known to what extent the immune checkpoint inhibitors αPD-1 and αPD-L1 solely 
provoke their antitumor activity locally in the tumor microenvironment or whether 
immune checkpoint modulation in lymphoid organs might also play a decisive role for 
their efficacy. Nevertheless, as discussed in the following section other studies already 
investigated the therapeutic efficacy of locally administered αPD-1 as well as αPD-L1 
immune checkpoint inhibitors showing a superior antitumor response for locally 
compared to systemically delivered inhibitors.  
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Li et al. used an alginate hydrogel system to locally deliver PD-1 specific mAbs (Table 
20). A single local injection of hydrogels encapsulated with αPD-1 (100 µg/mouse) into 
the region adjacent to subcutaneous growing tumors showed an improved therapeutic 
efficacy as compared to a single systemic injection (intraperitoneal) of free αPD-1 
(100 µg/mouse) in a syngeneic melanoma mouse model. The hydrogel-mediated local 
delivery resulted in sustained high levels of αPD-1 in serum and in tumor as compared 
to systemically applied αPD-1. In the serum, αPD-1 delivered from the hydrogel system 
achieved a stable αPD-1 serum concentration of about 10 µg/ml over a period of two 
weeks after treatment, whereas the αPD-1 levels of animals that were systemically 
injected with free αPD-1 started to decline on day 7 post medication achieving a level of 
about 2 µg/ml on day 14. In the tumor, the hydrogel delivery system achieved up to 
50 µg αPD-1 per gram tumor tissue on day 1 post treatment and declined to a value of 
about 10 µg αPD-1 per gram tumor tissue two weeks later. In contrast, systemically 
injected αPD-1 resulted in comparatively lower antibody concentrations in the tumor 
with about 10 µg per gram tumor tissue on day 1 and no detectable levels on day 14 (Li 
et al, 2015). As in the present AAV study, Li et al. determined the αPD-1 levels in serum 
and in the tumor by ELISA and achieved higher levels as compared to the AAV-targeting 
approach. Using Her2-AAV vectors, an αPD-1 level of about 0.5 µg/ml was detected in 
the serum of mice and of about 0.13 µg αPD-1 per gram tumor tissue was measured in 
the tumor 7 days after vector administration. Thus, the measured αPD-1 concentrations 
in the present AAV study was around 20-times lower in the serum and about 80- to 400-
times lower in the tumor. However, when comparing these two approaches it must be 
considered that Li et al. directly injected 100 µg αPD-1 encapsulated into hydrogels. In 
contrast, in the present AAV-targeting approach the αPD-1 protein is not directly 
injected into the mice rather an AAV vector encoding the immune checkpoint inhibitor. 
Moreover, it is possible that 7 days after vector administration is not sufficient to reach 
the peak of AAV-mediated transgene expression. Accordingly, higher expression levels 
might be achieved at later time points after vector application. 
It remains to be investigated whether the amount of Her2-AAV-delivered αPD-1 is 
sufficient to mediate a therapeutic effect. If not, it would be possible to increase the AAV 
vector dose used for treatment and thereby potentially increase the intratumoral level of 
αPD-1. The high serum levels of αPD-1 in the study of Li et al. could be problematic in 
regard to treatment-induced toxicity mediated by αPD-1 but otherwise could be also 
required for the induction of the observed antitumoral effect. Further investigations are 
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necessary to evaluate in detail which αPD-1 levels are required in tumor, serum or other 
organs in order to induce an antitumoral response.    
Table 20: Different strategies for the local delivery of PD-1- and PD-L1-specific immune checkpoint inhibitors  
 
1Immune checkpoint inhibitor 
 
A further approach for the sustained local delivery of αPD-1 mAbs involved self-
degradable microneedle (MN) patches investigated by Wang et al. (Table 20). The used 
MN patches were loaded with dextran nanoparticles that encapsulate αPD-1 mAbs and 
were implanted into the skin of the mice at the site of the subcutaneous growing 
melanoma tumor. MN patches enabled a sustained release of αPD-1 for at least 3 days 
after implantation as determined by immunostaining of tumor sections. In contrast, 
intratumoral injection of free αPD-1 resulted in a strong antibody signal on the 
administration day, but signals diminished in the following 3 days. In accordance to that 
observation, αPD-1 delivered by MN patches exhibited a superior antitumor effect as 
compared to intratumorally injected αPD-1 in tumor-bearing mice and furthermore, 
showed an increased number of CD8+ TILs. Wang and colleagues attributed this 
improved antitumor efficacy to the sustained release of αPD-1 into the tumor by MN 
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patches (Wang et al, 2016). Probably, AAV vectors might also facilitate a sustained 
delivery of immune checkpoint inhibitors as the vectors enable expression of their 
transgene for the life-time of the transduced cell (more details discussed in 4.3.1.1). 
Moreover, it is probable that the duration of antibody delivery might be even prolonged 
for AAV vectors as compared to the hydrogel system of Li et al. or the MN patch system 
of Wang et al., since the respective gene that continuously expresses the immune 
checkpoint inhibitor is transferred. In addition, continuous delivery of immune 
checkpoint inhibitors by AAV vectors may counterbalance the lower antibody levels that 
are delivered into the tumor tissue by the vectors as compared to direct administration 
of mAbs. Furthermore, Wang et al. revealed an improved therapeutic efficacy of αPD-1 
delivered locally by MN patches as compared to systemically administered 
(intravenous) free αPD-1 (Wang et al, 2016). This again indicates that local application 
of immune checkpoint inhibitors is not only beneficial as it might minimize the risk of 
toxicity but also as it can enhance the therapeutic effect of cancer immunotherapy. 
However, in contrast to the receptor-targeted AAV vectors specifically delivering 
immune checkpoint inhibitors directly into the tumor tissue, the hydrogel delivery and 
the MN patch system deliver αPD-1 mAbs in the region of the tumor and thus possibly 
also to local lymph nodes. Accordingly, delivery of αPD-1 mAbs in lymphatic tissue 
might have supported the observed antitumoral efficacy. Nevertheless, the clinical 
applicability of the hydrogel and the MN patch system is limited for the treatment of 
patients exhibiting accessible tumor sites. In contrast, Her2-AAV vectors would also 
enable the local delivery of immune checkpoint inhibitors to inaccessible or metastatic 
tumors (Münch et al, 2015).  
Another strategy also investigated by Wang and colleagues that enabled the treatment of 
metastases used αPD-L1 conjugated to the surface of platelets (Table 20). They showed 
that upon intravenous injection of αPD-L1-conjugated platelets into tumor-bearing mice, 
platelets facilitated αPD-L1 accumulation in the tumor. Due to the enhanced local 
antibody concentration around the tumor cells, αPD-L1-conjugated platelets showed an 
improved therapeutic effect as compared to the systemic injection of free αPD-L1 (Wang 
et al, 2017).  
 
In order to achieve the local delivery of PD-1- and PD-L1-specific inhibitors, other 
groups also examined the applicability of viral systems, especially in the context of 
oncolytic immunotherapy (Table 20). In contrast to the previous described strategies, 
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the gene rather than the protein is locally delivered to the tumor, as in the present AAV 
study.  
Engeland et al. compared the therapeutic efficacy of intratumorally injected oncolytic 
measles virus encoding a PD-L1-specific inhibitor (MV-αPD-L1) with the combination 
therapy composed of systemically administered αPD-L1 mAb and intratumoral measles 
virus infection in a melanoma mouse model. The same PD-L1-specific inhibitor that was 
encoded by the measles virus in their study was also used in the present AAV study. 
However, Engeland and colleagues could not observe an improved treatment response 
for local measles virus-mediated checkpoint blockade compared to the combination 
treatment of measles virus with systemic αPD-L1 therapy. Therapy efficacy was similar 
for both approaches (Engeland et al, 2014). 
Another study by Bartee and colleagues equipped oncolytic myxoma virus with the 
coding sequence of the soluble form of PD-1 (vPD-1) that was also proven to block the 
PD-1/PD-L1 checkpoints. They showed that intratumorally injected vPD-1 exhibited less 
toxicity and was more effective than the combination therapy using intratumoral 
injection of unmodified myxoma virus and systemic application of αPD-1 mAbs. 
However, since they used different immune checkpoint inhibitor constructs (soluble 
PD-1 vs αPD-1 mAb) for their comparison, the results should be considered carefully. 
Nevertheless, vPD-1 treatment exhibited significantly less symptoms of an autoimmune-
like toxicity that was characterized by progressive alopecia as compared to the 
combination therapy of systemically administered αPD-1 and local myxoma virus 
treatment. Thus, their study is an example that locally delivered immune checkpoint 
inhibitors might decrease treatment-related toxicity. Furthermore, the study 
demonstrated an increased therapeutic efficacy of local virus-delivered immune 
checkpoint inhibitors as compared to systemic mAb administration. Accordingly, their 
investigations provide evidence that tumor-expressed immune checkpoint inhibitors 
may improve therapy outcome as compared to systemically applied mAbs (Bartee et al, 
2017).  
 
Taken together, immune checkpoint blockade therapy is most likely improved by 
strategies enabling a sustained and local delivery of the inhibitors. Thus, receptor-
targeted AAV vectors are a promising vehicle for the in vivo delivery of immune 
checkpoint inhibitors as they potentially have the capability to mediate a local as well as 
a continuous expression of antibodies in vivo and are also applicable for the treatment of 
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inaccessible tumors. Further investigations are required to evaluate whether tumor-
targeted delivery of PD-1- or PD-L1-specific inhibitors by Her2-AAV indeed reduces 
toxicity compared to systemic antibody administration and whether this strategy elicits 
a potent antitumor response. 
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6 Abbreviations 
°C degree celsius 
µ micro 
µl microliter 
µm micrometer 
A ampere 
AAP assembly-activating protein 
AAV adeno-associated virus 
ACT adoptive cell transfer 
APC antigen-presenting cell 
APS ammonium persulfate 
ATCC American Type Culture Collection 
ATP adenosine triphosphate 
AUC area under the curve 
BGH bovine growth hormone 
bp base pair 
cap capsid protein 
CAR chimeric antigen receptor 
CD cluster of differentiation 
cDC conventional dendritic cell 
cDNA complementary DNA  
cH constant region of the heavy chain 
cm centimeter 
cm2 square centimeter 
cm3 cubic centimeter 
CMV cytomegalovirus 
ConA Concanavalin A 
CTLA-4 cytotoxic T-lymphocyte-associated antigen 
CV column volumes 
DAMP danger-associated molecular pattern 
DARPin designed ankyrin repeat protein 
DC dendritic cell 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dNTP deoxyribonucleotide triphosphate 
dsRed Discosoma red fluorescent protein 
E. coli Escherichia coli 
EDTA ethylenediaminetetraacetic acid 
EF1α elongation factor-1α 
ELISA enzyme-linked immunosorbent assay 
ELISpot enzyme-linked immune spot assay 
EMCV Encephalomyocarditis virus 
EpCAM epithelial cell adhesion molecule 
et al.  and others 
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F2A 2A self-cleaving sequence from foot-and-mouth disease virus 
Fc fragment crystallizable 
FCS fetal calf serum 
FDA Food and Drug Administration 
FITC fluorescein isothiocyanate  
Flt3L FMS-like tyrosine kinase 3 ligand 
for forward 
G glycoprotein 
g gram or gravity force 
GFP green fluorescent protein  
GM-CSF granulocyte-macrophage colony-stimulating factor 
GOI genome containing particles per cell 
Gy gray 
h hour 
HA hemagglutinin  
HDV Hepatitis Delta Virus 
Her2/neu human epidermal growth factor 2 
His6 hexa-histidine motif 
HIV human immunodeficiency virus 
HLA human leukocyte antigen 
HRP horseradish peroxidase 
HSPG heparin sulfate proteoglycan 
HSV herpes simplex virus 
HSV-1 herpes simplex virus-1 
ICD immunogenic cell death 
IEE integration efficiency element 
IFN interferon 
IFN receptor IFNAR 
IgG immunoglobulin G 
IL interleukin 
irAE immune-related adverse events 
IRES internal ribosomal entry site 
ITR inverted terminal repeat 
JAK/STAT Janus kinase/signal transducer and activator of transcription 
kb kilobase  
kDa kilo Dalton 
L large polymerase 
l liter 
LB Luria-Bertani 
LCMV lymphocytic choriomeningitis virus 
LDL low density lipoprotein 
LPL lipoprotein lipase 
luc luciferase 
LV lentiviral vector 
M matrix protein or molar 
m meter 
mAb monoclonal antibody 
MHC major histocompatibility complex 
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min minutes 
ml milliliter 
mM millimolar 
mm3 cubic millimeter 
MCC Merkel cell carcinoma 
MN microneedle 
MOI multiplicity of infection 
mRNA messenger RNA 
MVA modified vaccinia virus Ankara 
N nucleoprotein 
n.s. not significant 
nAb neutralizing antibody 
NCBI National Center for Biotechnology Information  
ng nanogram 
NK cell natural killer cell 
NSCLC non-small cell lung cancer 
NSG NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ 
ORF open reading frame 
P phosphoprotein 
p/sec/cm2/sr photons/seconds/square centimeter/steradian 
PAMP pathogen-associated molecular pattern 
PAP prostatic acid phosphatase 
PBMC peripheral blood mononuclear cells 
PBS phosphate-buffered saline 
pBSII pBluescriptII 
PCR polymerase chain reaction 
PD-1 programmed cell death protein-1 
PDB Protein Data Bank 
pDC plasmacytoid DC 
PDGFR platelet-derived growth factor receptor 
PD-L1 programmed cell death ligand-1 
PE phycoerythrin 
PEI polyethleneimine 
PET positron emission tomography 
PMA phorbol 12-myristate 13-acetate  
poly A polyadenylation signal 
qPCR quantitative PCR 
RCC renal cell carcinoma 
rep viral regulatory proteins 
rev reverse 
RNA ribonucleic acid 
RNP ribonucleoprotein 
rpm rounds per minute 
RPMI Roswell Park Memorial Institute 
rVSV recombinant vesicular stomatitis virus 
s seconds 
scAAV self-complementary AAV 
scFv single chain Fragment variable 
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SD standard deviation 
SDS sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SFFV spleen focus forming virus 
SIV simian immunodeficiency virus 
srVSV semireplication-competent vesicular stomatitis virus 
ss single-stranded 
ssAAV single-stranded AAV 
SV40 simian virus 40 
TAA tumor-associated antigen 
TCID50 50 % tissue culture infective dose 
TCR T cell receptor 
TEMED tetramethylethylenediamine 
TGF-β transforming growth factor β 
TILs tumor infiltrating lymphocytes 
TMB 3,3′,5,5′-Tetramethylbenzidine 
TME tumor microenvironment 
Treg cells regulatory T cells 
Tris  tris(hydroxymethyl)aminomethane 
U unit 
UV ultraviolet 
V volt  
v/v volume per volume 
vH variable region of the heavy chain 
vL variable region of the light chain 
VP viral protein 
VSV vesicular stomatitis virus 
w/v weight per volume 
α alpha or anti 
β beta  
γ gamma 
Δ delta 
κ kappa 
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